

## 2023 Utah Medical Licensure Program

- 3.5 Hours  
Approved Controlled  
Substance Course\*



**\*Mandatory CME Requirement Met by  
Approved Course Only: 3.5 Credit Hours on  
Controlled Substances for all Prescribers**

**CME FOR:**

AMA PRA CATEGORY 1 CREDITS™

MIPS

MOC

STATE LICENSURE

**UT.CME.EDU**

# 2023 UTAH

- 01** **EFFECTIVE MANAGEMENT OF ACUTE AND CHRONIC PAIN WITH OPIOID ANALGESICS**  
COURSE ONE | 3.5 CREDITS\*
- 38** **GUIDANCE ON PROFESSIONAL BOUNDARIES AND SEXUAL MISCONDUCT**  
COURSE TWO | 2 CREDITS
- 56** **LEARNER RECORDS: ANSWER SHEET AND EVALUATION**  
REQUIRED TO RECEIVE CREDIT

\*This course is approved by the Utah Division of Professional and Occupational Licensing to satisfy the mandatory 3.5 credit hour controlled substance requirement for all prescribers.



## CME that counts for MOC

Participants can earn MOC points equivalent to the amount of CME credits claimed for designated activities (see page iii for further details). InforMed currently reports to the following specialty boards: the American Board of Internal Medicine (ABIM), the American Board of Anesthesiology (ABA), the American Board of Pediatrics (ABP), the American Board of Ophthalmology (ABO), the American Board of Otolaryngology–Head and Neck Surgery (ABOHNS), and the American Board of Pathology (ABPath). To be awarded MOC points, you must obtain a passing score, complete the corresponding activity evaluation, and provide required information necessary for reporting.

**\$55.00**

ENTIRE PROGRAM

**\$50.00**

COURSE 1

**DATA REPORTING:** Federal, State, and Regulatory Agencies require disclosure of data reporting to all course participants. InforMed abides by each entity's requirements for data reporting to attest compliance on your behalf. Reported data is governed by each entity's confidentiality policy. To report compliance on your behalf, it's mandatory that you must achieve a passing score and accurately fill out the learner information, activity and program evaluation, and the 90-day follow up survey. Failure to accurately provide this information may result in your data being non-reportable and subject to actions by these entities.

# InforMed has joined the Elite Learning family

Two of the nation's top healthcare education providers have joined forces with one goal in mind: to offer physicians a state-of-the-art learning experience that fulfills your state requirements and empowers you with the knowledge you need to provide the best patient care.

Here's what you can expect from our new partnership:

- **COURSES:** In addition to the mandatory courses you need to renew your state license, you'll now have access to dozens of hours of elective courses and an expanded content library.
- **ACCOUNTS:** You'll also have access to a personalized learner account. In your account you can add, organize, and track your ongoing and completed courses. For instructions on how to set up your account, email us at [office@elitelearning.com](mailto:office@elitelearning.com).
- **BOOK CODES:** You may notice a book code on the back cover of the latest InforMed program you've received in the mail. When entered on our new site, this code will take you directly to the corresponding self-assessment. See more information below.



## How to complete


Please read these instructions before proceeding.

Read and study the enclosed courses and answer the self-assessment questions. To receive credit for your courses, you must provide your customer information and complete the mandatory evaluation. We offer three ways for you to complete. Choose an option below to receive credit and your certificate of completion.

### Fastest way to receive your certificate of completion

#### Online

- Go to **BOOK.CME.EDU**. Locate the book code **UT23CME** found on the back of your book and enter it in the box then click **GO**. If you would like to choose a different program option, use the table below and enter the corresponding code in the box.
- If you already have an account created, sign in to your account with your username and password. If you do not have an account already created, you will need to create one now.
- Follow the online instructions to complete your self-assessment. Complete the purchase process to receive course credit and your certificate of completion. Please remember to complete the online evaluation.



Program Options	Code	Credits	Price
Entire Program	UT23CME	5.5	\$55.00
Course 1	UT23CME-50	3.5	\$50.00


#### By mail

- Fill out the answer sheet and evaluation found in the back of this booklet. Please include a check or credit card information and e-mail address. Mail to **InforMed, PO Box 2595, Ormond Beach, FL 32175-2595**.
- Completions will be processed within 2 business days from the date it is received and certificates will be e-mailed to the address provided.
- Submissions without a valid e-mail will be mailed to the address provided.

#### By fax

- Fill out the answer sheet and evaluation found in the back of this booklet. Please include credit card information and e-mail address. Fax to **1-800-647-1356**.
- All completions will be processed within 2 business days of receipt and certificates will be e-mailed to the address provided.
- Submissions without a valid e-mail will be mailed to the address provided.

# INFORMED TRACKS WHAT YOU NEED, WHEN YOU NEED IT



## Utah Professional License Requirements

### MANDATORY CONTINUING MEDICAL EDUCATION FOR LICENSE RENEWAL

The Utah Division of Occupational and Professional Licensing (DOPL) requires the following professions to complete approved continuing medical education/equivalent during each two (2) year license period:

40 credit hours for MDs, DOs, PAs and DPMs.  
30 credit hours for DDSs, ARNPs and ODs.

### **MANDATORY CME ON CONTROLLED SUBSTANCE PRESCRIBING**

DOPL requires that all licensees, with a current DEA registration to prescribe controlled substances shall complete at least three and one-half (3.5) credit hours of continuing education in one or more approved controlled substance prescribing courses, except dentists who shall complete at least two (2) such hours.

This does not increase the total number of state-required continuing professional education credit hours required for a licensed prescriber. A controlled substance prescribing course shall be delivered by an accredited or approved continuing education provider recognized by DOPL as offering continuing education appropriate for the controlled substance prescriber's respective license type; and include a post-course knowledge assessment (<https://dopl.utah.gov/wp-content/uploads/2022/06/approved-cs-courses.pdf>).

### What This Means for You:

If you are licensed by the DOPL and have a current DEA registration to prescribe controlled substances during the current license period, you must complete a DOPL approved course on controlled substance prescribing for three and one-half (3.5) credit hours.

*We are a nationally accredited CME provider.  
For all board-related inquiries please contact:*

**Utah Department of Commerce,  
Division of Occupational and  
Professional Licensing**  
160 East 300 South  
Salt Lake City, UT 84111  
P : (801) 530-6628  
F : (801) 530-6511

#### **COMPLETION DEADLINE:**

**MD/APRN: 1/31/2024  
DO/PA/DDS: 5/31/2024  
DPM/OD: 9/30/2024**

#### **LICENSE TYPES:**

**MD, DO, DDS, DPM,  
OD, PA, APRN**

**Disclaimer:** The above information is provided by InforMed and is intended to summarize state CE/CME license requirements for informational purposes only. This is not intended as a comprehensive statement of the law on this topic, nor to be relied upon as authoritative. All information should be verified independently.

## MOC/MIPS CREDIT INFORMATION

In addition to awarding *AMA PRA Category 1 Credits™*, the successful completion of enclosed activities may award the following MOC points and credit types. To be awarded MOC points, you must obtain a passing score and complete the corresponding activity evaluation.

**Table 1. MOC Recognition Statements**

Successful completion of certain enclosed CME activities, which includes participation in the evaluation component, enables the participant to earn up to the amounts and credit types shown in Table 2 below. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.

**Board Programs**

	<b>ABA</b>	American Board of Anesthesiology's redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®
	<b>ABIM</b>	American Board of Internal Medicine's Maintenance of Certification (MOC) program
	<b>ABO</b>	American Board of Ophthalmology's Maintenance of Certification (MOC) program
	<b>ABOHNS</b>	American Board of Otolaryngology – Head and Neck Surgery's Continuing Certification program (formerly known as MOC)
	<b>ABPath</b>	American Board of Pathology's Continuing Certification Program
	<b>ABP</b>	American Board of Pediatrics' Maintenance of Certification (MOC) program.

**Table 2. Credits and Type Awarded**

Activity Title	AMA PRA Category 1 Credits™	ABA	ABIM	ABO	ABOHNS	ABPath	ABP
Effective Management of Acute and Chronic Pain with Opioid Analgesics	3 AMA PRA Category 1 Credits™	3 Credits LL	3 Credits MK	3 Credits LL & SA	3 Credits SA	3 Credits LL	3 Credits LL+SA
Guidance on Professional Boundaries and Sexual Misconduct	2 AMA PRA Category 1 Credits™	2 Credits LL	2 Credits MK	2 Credits LL & SA	2 Credits SA	2 Credits LL	2 Credits LL+SA

**Legend:** LL = Lifelong Learning, MK = Medical Knowledge, SA = Self-Assessment, LL+SA = Lifelong Learning & Self-Assessment, PS = Patient Safety

**Table 3. CME for MIPS Statement**

Completion of each accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA PSPA\_28) for the Merit-based Incentive Payment Program (MIPS). Participation in this Clinical Practice Improvement Activity (CPIA) is optional for eligible providers.

# EFFECTIVE MANAGEMENT OF ACUTE AND CHRONIC PAIN WITH OPIOID ANALGESICS

COURSE DATES:	MAXIMUM CREDITS:	FORMAT:
Release Date:10/2021 Exp. Date: 9/2024	3.5 <i>AMA PRA</i> <i>Category 1 Credits™</i>	Enduring Material (Self Study)

## TARGET AUDIENCE

This course is designed for all physicians and other health care professionals involved in the management of patients with pain.

## COURSE OBJECTIVE

This CME learning activity is designed to increase physician knowledge and skills about guideline-recommended principles of pain management, the range of opioid and non-opioid analgesic treatment options, and specific strategies for minimizing opioid analgesic prescription, diversion, and abuse.

## **HOW TO RECEIVE CREDIT:**

- Read the course materials.
- Complete the self-assessment questions at the end. A score of 70% is required.
- Return your customer information/ answer sheet, evaluation, and payment to InforMed by mail, phone, fax or complete online at program website.

## LEARNING OBJECTIVES

Completion of this course will better enable the course participant to:

1. Identify the range of therapeutic options for managing acute and chronic pain, including non-pharmacologic approaches and pharmacologic therapies.
2. Explain how to integrate opioid analgesics into a function-based pain treatment plan individualized to the needs of the patient, including counseling patients and caregivers about the safe use of opioid analgesics.
3. Discuss recommendations and rationale for incorporating emergency opioid antagonists into prescribing practice for training patients and family members on the use of naloxone.
4. Identify medications currently approved for the treatment of opioid use disorder and the ways these medications differ in terms of mechanisms of action, regulatory requirements, and modes of administration.

## ACCREDITATION STATEMENT

InforMed is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

## DESIGNATION STATEMENT

InforMed designates this enduring material for a maximum of 3.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **FACULTY**

### **Paul J. Christo, MD, MBA**

Associate Professor, The Johns Hopkins University School of Medicine  
Director, Multidisciplinary Pain Fellowship Program (2003-2011)  
Director, Blaustein Pain Treatment Center (2003-2008)  
Division of Pain Medicine

### **Annette Skopura, PHD**

Medical Writer  
EnlightenMed

## **ACTIVITY PLANNER**

### **Michael Brooks**

CME Director  
InforMed

## **DISCLOSURE OF INTEREST**

In accordance with the ACCME Standards for Commercial Support of CME, InforMed implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.

## **FACULTY/PLANNING COMMITTEE DISCLOSURE**

The following faculty and/or planning committee members have indicated they have no relationship(s) with industry to disclose relative to the content of this CME activity:

- Annette Skopura, PHD
- Michael Brooks

The following faculty and/or planning committee members have indicated they have relationship(s) with industry to disclose:

- Paul J. Christo, MD, MBA has received honoraria from GlaxoSmithKline and Eli Lilly.


## **STAFF AND CONTENT REVIEWERS**

InforMed staff, input committee and all content validation reviewers involved with this activity have reported no relevant financial relationships with commercial interests.

## **DISCLAIMER**

\*2023. All rights reserved. These materials, except those in the public domain, may not be reproduced without permission from InforMed. This publication is designed to provide general information prepared by professionals in regard to the subject matter covered. It is provided with the understanding that InforMed, Inc is not engaged in rendering legal, medical or other professional services. Although prepared by professionals, this publication should not be utilized as a substitute for professional services in specific situations. If legal advice, medical advice or other expert assistance is required, the service of a professional should be sought.

## **COURSE SATISFIES**



### **UTAH SPECIAL APPROVAL**

This course is approved by the Utah Division of Occupational and Professional Licensing to satisfy the mandatory three and one-half (3.5) credit hours on controlled substance prescribing for all licensees with a current DEA registration to prescribe controlled substances.

The Utah Division of Occupational and Professional Licensing requires all prescribers of controlled substances to complete three and one-half (3.5) credit hours on controlled substance prescribing through approved courses.

## The challenge of pain management

Physicians caring for patients in pain face an unusually daunting set of challenges. As with many other chronic conditions, clinicians must carefully balance expected benefits of treatment with the potential for harm from such treatments. Treating pain, however, involves an additional level of complexity because one of the most commonly-used classes of pain medications—opioids—are at the center of national efforts to stem the epidemic of opioid-related abuse, addiction, and overdose.<sup>1</sup>

The United States has seen three successive waves of opioid overdose deaths related to both legal and illegal opioids (Figure 1).<sup>2</sup> The first began in the 1990s and was associated with steadily rising rates of prescription opioids. In 2010, deaths from heroin increased sharply, and by 2011 opioid overdose deaths reached “epidemic” levels as described by the Centers for Disease Control and Prevention (CDC).<sup>3</sup> The third wave began in 2013 with a sharp rise in overdose deaths attributed to synthetic opioids, particularly those involving illicitly-manufactured fentanyl.

In late 2020, the CDC announced that 81,230 drug overdose deaths occurred in the 12 months ending in May, 2020, which was the highest level of overdose deaths ever reported.<sup>4</sup> The surge was primarily driven by a 34% increase in overdose deaths related to synthetic opioids, primarily fentanyl.<sup>4</sup> Overdose rates appear to have accelerated during the COVID-19 pandemic.<sup>5</sup> Between 1999 and 2019, the CDC estimates that nearly 500,000 people in the United States died from such overdoses.<sup>6</sup>

Coupled with rising rates of overdose death are equally dramatic increases in the number of people misusing or abusing opioids. As many as 1 in 4 patients on long-term opioid therapy in a primary care setting are estimated to be struggling with opioid use disorder (OUD), also called opioid addiction.<sup>7-9</sup> In 2016 approximately 11.5 million Americans reported misusing prescription opioids in the previous year.<sup>10</sup> According to the federal Substance Abuse and Mental Health Services Administration (SAMSHA), approximately 80% of heroin users started on their path to addiction after using oral opioid analgesics (either prescribed to them or illicitly).<sup>11</sup>

Although the rates of opioid prescriptions have leveled off or declined slightly in recent years, the average days of supply per opioid prescription has continued to rise.<sup>10</sup>

It is against this background that providers must make daily decisions about how best to treat their patients in pain. Unfortunately, many providers are unfamiliar with the growing evidence base suggesting that opioids are actually not very effective for relieving chronic non-cancer pain in the long-term and, in fact, may be associated with harms such as increased pain, reduced functioning, and physical opioid dependence.<sup>12,13</sup> Providers may also not be aware of the expanding range of both non-opioid medications and non-pharmacological therapies shown to be effective in reducing many common chronic pain conditions.

This CME learning activity discusses the management of chronic and acute pain in a variety of patient populations and is structured to conform

to the latest Food and Drug Administration (FDA) Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain (2018). It reviews evidence for non-opioid therapies, including non-drug and non-opioid drug options, as well as current evidence regarding opioid efficacy, harms, and overdose prevention with naloxone, and how to slowly and safely taper opioid doses.

### Key opioid-related terms

**Opioid:** any psychoactive chemical resembling morphine, including opiates, and binding to opioid receptors in the brain. This term describes opioid and opiates.

**Opiate:** “natural” opioids derived from the opium poppy (e.g., opium, morphine, heroin).


**Semi-synthetic opioids:** analgesics containing both natural and manufactured compounds (e.g., oxycodone, hydrocodone, hydromorphone, oxymorphone).

**Synthetic opioids:** fully-human-made compounds (e.g., methadone, tramadol, and fentanyl).

### Types of Pain

Differentiating between nociceptive and neuropathic pain is critical because the two respond differently to pain treatments. Neuropathic pain, for example, may respond poorly to both opioid analgesics and non-steroidal anti-inflammatory (NSAID) agents.<sup>14</sup> Other classes of medications, such as anti-epileptics, antidepressants, or local anesthetics, may provide more effective relief for neuropathic pain.<sup>15</sup>

Figure 1. Opioid-related overdose deaths by type in the United States<sup>6</sup>





Another important dimension of pain is its effects beyond strictly physiological functioning. Pain is currently viewed as a multi-dimensional, multi-level process similar in many ways to other disease processes which may start with a specific injury but which can lead to a cascade of events that can include physical deconditioning, psychological and emotional burdens, and dysfunctional behavior patterns that affect not just the sufferer, but their entire social milieu (illustrated in Figure 2).<sup>16</sup>

Although pain is expected after injury or surgery, the patient pain experience can vary markedly. The intensity of pain can be influenced by psychological distress (e.g., depression or anxiety), heightened illness concern, or ineffective coping strategies regarding the ability to control pain and function despite it.<sup>17</sup> It may also be shaped by personality, culture, attitudes, and beliefs.

## Evaluating pain

### Take a history

The patient's self-report is the most reliable indicator of pain.<sup>18</sup> Physiological and behavioral signs of pain (e.g., tachycardia, grimacing) are neither sensitive nor specific for pain and should not replace patient self-report unless the patient is unable to communicate. Therefore, talking to patients and asking them about their pain (i.e., obtaining a "pain history") is integral to pain assessment.

The pain history usually is obtained as part of the patient history, which includes the patient's past medical history, medications, habits (e.g., smoking, alcohol intake), family history, and psychosocial history. Obtaining a comprehensive history provides many potential benefits, including improved management, fewer treatment side effects, improved function and quality of life, and better use of health care resources.

Assessing the impact of pain on functional status and sleep and screening for mental health conditions potentially related to pain or treatment adherence (e.g., depression, anxiety, and memory issues) may provide useful information for pain management.<sup>19</sup> Depression in older patients, for example, sometimes presents with somatic complaints of pain. Pain complaints may resolve when the underlying depression is treated. Patients can also be screened for known risk factors for OUD (see below).

### Tools

Many tools have been developed to document and assess pain. Initial approaches to assessing pain severity use a numerical rating scale (NRS) rating pain from 0 (no pain) to 10 (worst pain you can imagine) (some scales use a 0 to 100 scale). Such scales are often used in clinical trials of pain therapies, and the minimal clinically important difference using these scales is generally considered a 20%-30% change from baseline (i.e., 2-3 points on a 0-10 scale or 20-30 points on a 0-100 scale).<sup>20</sup>


Multidimensional tools, such as those described below, include questions relating to quality of life and participation in daily activities. Such tools can provide a more comprehensive approach to assessing pain and response to treatment. The selection of a pain assessment tool must balance the comprehensiveness of the assessment obtained with the time and energy required to use the tool in a real-world practice setting.

### Brief pain inventory

The Brief Pain Inventory (BPI) is used frequently in clinical trials to assess pain. Specifically developed for patients with chronic pain, the BPI more fully captures the impact of pain on patient function and quality of life than simple VAS scales.<sup>21</sup> By including a pain map, the BPI allows tracking of the location of pain through the course of management. The BPI is self-administered but somewhat time-consuming, which may limit its role in a busy clinical practice.

### PEG scale

The PEG scale (Pain average, interference with Enjoyment of life, and interference with General activity) is a three-item tool based on the BPI and is practical for clinical practice (Figure 3).



**Figure 3: PEG scale<sup>22</sup>**

What number best describes your pain on average in the past week?

0      1      2      3      4      5      6      7      8      9      10

No pain Pain as bad as you can imagine

Zero-to-10 scales are used to assess pain, enjoyment of life, and general activity. PEG can be self-administered or done by the clinician and is relatively brief.<sup>22</sup>

### Assessing acute pain

Acute pain intensity can be assessed with unidimensional tools such as the VAS and the Wong-Baker FACES Pain Rating Scale (faces depicting increasing levels of pain). While useful for a quick assessment, these scales alone may not appropriately identify patients with pain-related suffering driven by functional limitations, worry, or other factors, and may not detect some patients with clinically significant pain.<sup>23</sup>

Although developed for patients with chronic pain, the BPI is also applicable to patients with acute pain. Completed by the patient, the BPI captures ways that pain impacts function and quality of life, although, like most multidimensional

questionnaires, it requires more time (about 10 minutes) and concentration to complete, which may limit its utility in some elderly patients.<sup>21</sup>

### Pain in patients with dementia

Although patients with mild-to-moderate dementia can report their pain and its location, those with severe dementia are often unable to communicate their pain experience or request medication. In these patients, physicians need to observe pain behaviors, including facial expressions, verbal cues, body movements, changes in interpersonal interactions, activity patterns, and mental status. Caregiver observations and reports are critical to appropriate assessment and management of chronic pain conditions.<sup>24</sup>

**BEFORE MOVING ON TO THE NEXT SECTION, PLEASE COMPLETE CASE STUDY 1.**

### Chronic pain that develops after acute pain

A number of factors have been associated with an increased risk for chronic pain following acute pain or surgery including older age, psychological problems, higher levels of pre-procedural pain or pain sensitivity, type and duration of surgery, severity and number of comorbidities, and use of post-procedural radiation or chemotherapy.<sup>25</sup>

Some tools have been developed to help clinicians predict the likelihood that a patient will experience chronic pain following acute injury or procedures. The 5-item PICKUP model, for example, showed moderate prognostic performance in a derivation study using data from 2,758 patients with acute low back pain.<sup>26</sup> And Sipila and colleagues developed a 6-item screening instrument for risk factors of persistent pain after breast cancer surgery based on a cohort of 489 women.<sup>27</sup>

## Case Study 1

**Instructions: Spend 5-10 minutes reviewing the case below and considering the questions that follow.**

*Maurianne is an 85-year-old woman living in a residence facility for people with Alzheimer disease. Her cognition has deteriorated slowly in the seven years she has lived at the facility and now her speech is often a rambling, incoherent stream-of-consciousness, that she only seldom recognizes as such. Maurianne fell and sustained a right femur fracture requiring internal fixation. On the second day after surgery, the hospital nurse noted that Maurianne had an order for acetaminophen every 6 hours as needed. Although Maurianne was lying still and did not appear to be in distress, the nurse contacted the nursing home nurse who reported that Maurianne rarely lies still. The nursing home nurse explained that they assess pain using the Pain Assessment in Advanced Dementia (PAINAD) tool and emailed a copy to the hospital nurse. A review of the medical chart indicated that Maurianne slept intermittently the previous night, and when she conducted a physical examination, Maurianne seemed rigid and exhibited shallow breathing at a rate of about 20 breaths per minute. The nurse used the PAINAD behavioral tool to assess Maurianne's pain and the result suggested a positive score for possible pain. The nurse immediately called the surgeon and received an order for 1-2 mg morphine every 8 hours over the next 3 days. After the first dose, Maurianne's body relaxed, and her breathing became regular at a rate of 14 per minute. Later that evening, Maurianne slept 7 hours.*

- 1. Do you think the initial script for acetaminophen was appropriate for this patient? If now, what would you have prescribed?**

---

---

- 2. How might Maurianne's cognitive impairments affect her pain management plan?**

---

---

- 3. What other tools or techniques might be used to characterize Maurianne's level of pain or her response to prescribed analgesics?**

---

---

## Screen for opioid abuse risk factors

Screening and monitoring in pain management seeks to identify patients at risk of substance misuse and overdose as well as improve overall patient care. Evaluations of patient physical and psychological history can screen for risk factors and help characterize pain to inform treatment decisions. Screening approaches include efforts to assess for concurrent substance use and mental health disorders that may place patients at higher risk for OUD and overdose. This includes screening for drug and alcohol use and the use of urine drug testing, when clinically indicated. These approaches enable providers to identify high-risk patients so that they can consider whether to prescribe opioids, engage substance misuse and mental health interventions, and education materials to mitigate opioid misuse.<sup>16</sup>

Many tools have been developed for the formal assessment of a patient’s risk of having a substance misuse problem, some of which are appropriate for routine clinical use because they are relatively brief and easily implemented. Table 1 lists the tools that appear to have good content and construct validity for assessing patient risks related to chronic opioid therapy, although to date, no single tool has been widely endorsed or thoroughly validated.<sup>28</sup>

The Screening, Brief Intervention and Referral to Treatment (SBIRT) is an evidence-based tool used to facilitate screening patients for OUD, which typically takes 5-10 minutes to administer.<sup>29</sup> SBIRT has been endorsed by the Substance Abuse and Mental Health Services Administration (SAMHSA), but should always be paired with referral to treatment.<sup>30</sup> SAMHSA recommends universal screening with oral or writing-based tools because of the high prevalence of substance use disorders in patients visiting primary care settings. In contrast, universal screening with urine, blood, or oral fluid tests are not recommended.<sup>30</sup> In the context of pain care, however, the 2016 CDC guidelines recommend urine drug testing before initiating opioid therapy and probably at least annually when prescribing opioids for chronic pain.<sup>31</sup>

Other tools for universal substance abuse screening include:

- Single screening question screening tool for drug use.
- Drug Abuse Screening Test (DAST) 10
- Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST).
- Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS).
- the CAGE questionnaire adapted to include drugs (CAGE-AID).

## Use drug monitoring programs

As of March, 2020, all U.S. states (except Missouri) and the District of Columbia have operational prescription drug monitoring programs (PDMPs).<sup>32,33</sup> Information available through PDMPs varies based on reporting requirements and restrictions, but may include DEA schedules reported, timeliness of pharmacy dispensing information, access, and required reviews.

Recommendations for using a PDMP include:

- Check the PDMP before starting anyone on opioid therapy.
- Review the PDMP periodically throughout opioid therapy (at least every 3 months).
- Look for prescriptions for other controlled substances, like benzodiazepines, that can increase risk of overdose death.
- Review the total MMED (Morphine Milligram Equivalent Dose).

## Urine drug testing

Urine drug testing (UDT) is recommended before prescribing any opioid and at least annually thereafter.<sup>31</sup> Providers using urine drug screens should be familiar with the metabolites and expected positive results based on the opioid prescribed. For example, a patient taking oxycodone may test positive for both oxycodone and oxymorphone (a metabolite).<sup>34</sup>

UDT often involves both presumptive (screen) testing, and definitive (quantitative) testing because many synthetic and semisynthetic opioids cannot be detected by presumptive testing alone.<sup>35,36</sup>

If the prescribed opioid is not detected, discuss the finding with the patient and, if diversion is confirmed or suspected, re-evaluate the pain management strategy or taper the opioid. If the patient tests positive for unprescribed drugs, schedule more frequent follow-up visits, consider opioid discontinuation, offer naloxone, or refer for treatment for substance use disorder. Decision tools and help with interpreting urine drug testing results are available at: <http://mytopcare.org/udt-calculator/interpret-opiates-test-result>.

## Pain management overview

Many pharmacologic and non-pharmacologic approaches to treating pain are available to primary care providers.

These options should be employed using the following general principles:

- Identify and treat the source of the pain, if possible, although pain treatment can begin before the source of the pain is determined
- Select the simplest approach to pain management first. This generally means using non-pharmacologic approaches as much as possible and/or trying medications with the least severe potential side effects, and at the lowest effective doses
- Establish a function-based, individualized treatment plan if therapy is expected to be long-term

## Non-drug approaches

Many nonpharmacologic and self-management treatment options have been found to be effective alone or as part of a comprehensive pain management plan, particularly for musculoskeletal pain and chronic pain.<sup>37</sup> Examples include, but are not limited to, psychological, physical rehabilitative and surgical approaches, procedural therapies (e.g., injections, nerve blocks), complementary therapies, and use of approved/cleared medical devices for pain management.

**Table 1. Tools for patient risk assessment**

Tool	Use	Who Administers?	Length
Current Opioid Misuse Measure (COMM)	Monitor for misuse by patients currently on long-term opioid therapy	Patient self-report	17 items
Diagnosis, Intractability, Risk, Efficacy (DIRE)	Screen for risk of opioid addiction	Clinician	7 items
Opioid Risk Tool (ORT)	Screen for risk of opioid addiction	Clinician or patient self-report	5 yes/no questions
Screener and Opioid Assessment for Patients with Pain, Version 1 and Revised (SOAPP, and SOAPP-R)	Screen for risk of opioid addiction	Patient self-report	24 items

Primary care clinicians should know about the range of treatment options available, the types of pain that may be responsive to those options, and when they should be used as part of a multidisciplinary approach to pain management.<sup>37</sup> Clinicians should also be aware that not all nonpharmacologic options have the same strength of evidence to support their utility in the management of pain, and some may be more applicable for some conditions than others.

### **Movement-based options**

Movement therapies that may be helpful in patients with chronic pain include muscle-strengthening, stretching, and aerobic exercise (e.g., walking, aquatics). Recommended exercise programs typically occur one to three times a week for a total of 60-180 minutes per week, but any regimen must be carefully tailored to a patient's existing level of physical conditioning, comorbidities, and cognitive status.<sup>38-40</sup>

Additional movement-based options include:

- **Physical therapy** supervised by a licensed physical therapist, which can include resistance, aerobic, balance, and flexibility exercises as well as elements of massage, manipulation, or transcutaneous electrical nerve stimulation.
- **Tai chi**, a mind-body practice that combines controlled movements, meditation, and deep breathing. "Chair tai chi" can be an option for patients with limited mobility.
- **Yoga**, exercises or a series of postures designed to align muscle and bones, and increase strength and flexibility. It can also relax mind and body through breathing exercises and meditation. Gentler forms of yoga that may be more appropriate for older patients include Iyengar, Hatha, or Viniyoga.

Although these interventions may cause muscle soreness, increased back pain, or falls, movement-based options are generally considered safe.<sup>40</sup>

### **Weight loss**

Some pain syndromes, such as knee osteoarthritis, are worsened by obesity. For some patients, pain due to this condition is improved by reducing body weight because of reduced loads and physical stresses on the affected joints. The goal of body weight reduction is a baseline weight loss of 7%-10% by calorie reduction and increased activity using a balanced diet with less than 30% of calories from fat, 15%-20% from protein, and 45%-60% from carbohydrates.<sup>41</sup>

### **Passive options**

Acupuncture involves the stimulation of specific points on the body, most often involving skin penetration with fine metallic needles manipulated by hand but sometimes also including electrical stimulation or low intensity laser therapy. Potential adverse events include minor bruising and bleeding at needle insertion sites.<sup>42</sup>

Massage is the manual manipulation of the body to promote relaxation, reduce stress and improve well-being. Handheld devices may also provide relief for some patients. Some patients may report muscle soreness.<sup>43</sup>

Transcutaneous electrical nerve stimulation (TENS) is a machine that generates mild electrical pulses which are applied cutaneously. The electrical stimulation from TENS may block or disrupt pain signals to the brain, reducing pain perception. TENS machines can be used at home or in conjunction with other interventions like physical therapy.

### **Cognitive and behavioral options**

Cognitive behavioral therapy (CBT) is a structured, time-limited (typically 3-10 weeks) intervention focused on how thoughts, beliefs, attitudes, and emotions influence pain and can help patients use their minds to control and adapt to pain. This therapy includes setting goals, often with recommendations to increase activity to reduce feelings of helplessness.<sup>44</sup>

### **Meditation**

Mindfulness meditation programs typically include a time-limited (8 weeks; range 3-12 weeks) trainings with group classes and home meditation. The objective is to inculcate a long-term practice that helps patients refocus their minds on the present, increase awareness of self and surroundings, and reframe experiences.<sup>45,46</sup>

### **Non-opioid drug approaches**

A wide range of medications can be used to treat pain, including:

- Acetaminophen
- NSAIDs (oral or topical)
- Antidepressants
  - serotonin and/or norepinephrine reuptake inhibitors
  - tricyclic antidepressants (TCAs)
  - selective serotonin reuptake inhibitors (SSRIs)
- Anticonvulsants
- Topical lidocaine or capsaicin
- Cannabinoid-based therapies
- Ketamine

### **Acetaminophen**

Lower doses of acetaminophen are recommended to decrease risk of side effects. Patients should not exceed 1000 mg in a single dose. The maximum recommended dose for healthy adults is 4000 mg/day.<sup>47</sup>

The most severe potential side effect of acetaminophen is liver toxicity. Acetaminophen is the most common cause of acute liver failure, accounting for 46% of all cases.<sup>48</sup> Patients should stay within recommended doses to help prevent side effects and should only be prescribed one acetaminophen-containing product at a time.

### **NSAIDs**

Chronic use of NSAIDs may be limited by gastrointestinal (GI) toxicity, including GI bleeding, upper GI symptoms, ulcers, and related complications. For high-risk patients, including the elderly, patients on warfarin or aspirin, and those with coagulopathies, adding a proton pump inhibitor (PPI) may help reduce the risk.<sup>49,50</sup> In addition to GI side effects, NSAIDs have been associated with an increased risk of renal and cardiac complications. Side effects with NSAIDs are typically lower with topical formulations.

Some early trials suggested that COX-2 inhibitors, as a class, were associated with higher risks for myocardial infarction and stroke compared to other NSAIDs, and the COX-2 inhibitor rofecoxib (Vioxx) was removed from the market in 2004 because of such concerns.<sup>51</sup> More recent trials and meta-analyses, however, provide strong evidence that the risks of CV events with celecoxib are no greater than those of other NSAIDs, and in 2018 two FDA advisory panels recommended that the FDA change its advice to physicians regarding celecoxib's safety.<sup>52</sup>

### **Selective serotonin norepinephrine reuptake inhibitors**

SNRIs such as duloxetine, venlafaxine, and milnacipran are characterized by a mixed action on norepinephrine and serotonin, though their exact mechanism of action for pain reduction is unknown. These agents affect the descending pain pathways to facilitate pain relief. Side effects (e.g., nausea, dizziness, and somnolence) may limit treatment. Monitoring is suggested for blood pressure (duloxetine and venlafaxine), heart rate (venlafaxine), and drug interactions (duloxetine). SNRIs can be very helpful in patients who have central sensitization.

### **TCAs**

TCAs inhibit reuptake of norepinephrine and serotonin. These agents act on descending pain pathways, but their mechanism of action for pain relief is unknown.

Examples of TCAs studied for the management of chronic pain include amitriptyline, desipramine, and nortriptyline. Side effects, such as anticholinergic effects (e.g., dry mouth, constipation, dizziness) and QTc prolongation limit the use of TCAs in elderly patients. The majority of side effects occur at the typically higher doses used to treat depression.

### **SSRIs**

SSRIs, such as citalopram, fluoxetine, and paroxetine, block the reuptake of serotonin in the brain, making more serotonin available in the synapse. The mechanism of SSRIs for pain remains unknown. Compared to SNRIs and TCAs, there is relatively little evidence to support the use of SSRIs in treating chronic pain conditions.<sup>28</sup> Potential side effects of SSRIs include weight gain, sexual dysfunction, and QTc prolongation, especially with citalopram.

### **Anticonvulsants**

Anticonvulsants, such as gabapentin, pregabalin, oxcarbazepine, and carbamazepine, are often prescribed for neuropathic pain and are thought to exert their analgesic effect by inhibiting neuronal calcium channels. Potential side effects include sedation, dizziness, and peripheral edema. Pregabalin and gabapentin have low abuse potential in the general population, are currently classified as Schedule V by the DEA, and prescriptions for these drugs are tracked by some state Prescription Drug Monitoring Programs (PDMPs). Anticonvulsants can be very helpful in patients who have central sensitization and neuropathic pain.

### **Topical lidocaine and capsaicin**

Topical lidocaine inhibits the conduction of nociceptive nerve impulses. Irritation at the application site is the most common side effect. The most common products for chronic pain management are lidocaine 5% patches, available by prescription, and lidocaine 4% patches available OTC. Capsaicin is an active component of chili peppers and has moderate analgesic properties at 8% concentrations for neuropathic pain, specifically postherpetic neuralgia and diabetic neuropathic pain of the feet.<sup>53</sup> The most common side effect is a mild-to-severe burning sensation at the application site.

### **Cannabinoid preparations**

With medical cannabis now legal in 36 states and recreational use legal in at least 10 states and the District of Columbia (as of 2020)<sup>54</sup>, there has been increased interest among patients for the use of cannabis or cannabis derivatives (e.g., cannabidiol [CBD]) for pain relief. The CB1 and CB2 receptors have been shown to mediate the analgesic effects of cannabinoids<sup>55</sup> and some evidence suggests a potential benefit for chronic pain.

A 2017 National Academies of Science report, for example, concluded that “conclusive or substantial evidence” supports a beneficial role for cannabis or cannabinoids for treating chronic pain,<sup>56</sup> and a 2018 Cochrane review of the existing literature evaluating cannabinoids (cannabis, CBD, or combinations) suggests that these agents are moderately effective for neuropathic pain with adverse effects that are less than, or comparable to, existing non-opioid analgesics.<sup>57</sup>

But the evidence for a benefit of cannabinoids on acute pain, is extremely limited and mixed. A small double-blind, cross-over study in 18 females and experimentally-induced mild acute pain found no significant analgesic effect of oral cannabis extract.<sup>58</sup> Another randomized, double-blind study with 15 healthy volunteers using smoked cannabis found no analgesic effect with low doses of cannabis, a modest effect with moderate doses, and enhanced pain responses with high doses.<sup>59</sup> The authors of a 2017 review on cannabis and pain conclude that cannabis may have a narrow therapeutic window as a pharmacotherapy for chronic pain but that much more research is needed to inform physician recommendations to patients regarding the analgesic efficacy of cannabis.<sup>60</sup>

A systematic review of both randomized trials (47) and observational studies (57) in patients with chronic noncancer pain published through July 2017 found moderate evidence that cannabinoids can exert analgesia.<sup>61</sup> Cannabis preparations, however, may pose both short-term and long-term risks. Short-term effects include impaired memory, motor coordination, and judgment. Paranoid ideation and psychotic symptoms, while rare, may occur with high doses of THC. Possible long-term effects include impaired brain development in young adults, potential for habituation, and increased risk of anxiety or depression. Abrupt cessation of marijuana in long-term users may cause withdrawal symptoms such as anxiety, irritability, craving, dysphoria, and insomnia. There is an increased risk of chronic bronchitis, respiratory infections, and pneumonia with inhaled products.<sup>62</sup>

Nonetheless, the use of cannabis may have an opioid-sparing effect at a population level. The use of medical cannabis has been associated with a 25% reduction in opioid overdose mortality in states that legalized medical use.<sup>63</sup> However, a more recent study showed that states legalizing medical cannabis actually experienced a 22.7% increase in opioid overdose deaths.<sup>64</sup>

FDA-approved cannabinoids include dronabinol (Marinol), indicated for second-line treatment of chemotherapy-induced nausea and vomiting, and anorexia-associated weight loss in patients with HIV.

Nabilone (Cesamet) is indicated for chemotherapy-induced nausea and vomiting. Common side effects include dizziness/vertigo and euphoria. Dronabinol may cause nausea/vomiting, abdominal pain, and abnormal thinking. Nabilone may cause ataxia and dry mouth.<sup>62,65,66</sup> None of these are indicated for the treatment of pain. When recommending cannabis for patients with chronic pain, clinicians may inform patients that the analgesic properties are due to both the CBD and THC components, which act on different pain pathways.<sup>67</sup>

### **Ketamine**

Ketamine has been used as a general anesthetic since the 1960s, but its use in subanesthetic concentrations for analgesia has grown rapidly in recent years, due, in part, to efforts to reduce the risks of chronic opioid use.<sup>68</sup> Ketamine has been successfully used to treat such acute pain conditions as sickle cell crises, renal colic, and trauma.<sup>68</sup> Recently the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists released the first joint recommendations for subanesthetic ketamine (including transdermal ketamine) for acute pain.<sup>68</sup> Ketamine infusions are used for the treatment of complex regional pain syndrome based on placebo-controlled trials, and topical ketamine may also be beneficial for the cutaneous hypersensitivity associated with this condition.<sup>69</sup>

### **Opioids**

#### **Mechanism of Action**

Opioids exert their analgesic effects by acting on the mu, kappa, and delta opioid receptors. Individual agents may be classified as agonists or partial agonists of those receptors:<sup>70</sup>

- Agonists (e.g., morphine, codeine, hydromorphone, hydrocodone) stimulate at least one of the opioid receptors and provide continued analgesia with increasing doses.
- Partial agonists (e.g., buprenorphine) have high affinity at mu-receptors, have a ceiling for analgesic effect, and are less likely to cause respiratory depression.

Opioids are classified by the Drug Enforcement Agency (DEA) according to their presumed abuse and addiction potential, although the evidence base for making these differentiations continues to evolve. Tramadol, for example, is now known to have as much potential for abuse as opioids in more restrictive classes, although its DEA classification has not changed.<sup>71</sup>

### **Relative effectiveness**

The analgesic efficacy of opioids for treating acute pain has been known for centuries and they continue to be reliable agents for moderate-to-severe acute pain, although they are not without risks. But the evidence for opioid efficacy for acute pain cannot be extended to chronic pain with a few exceptions that are discussed below. Neuronal and physiologic adaptations to long-term opioid use can result in reduced analgesic effectiveness, or even, paradoxically, increased pain or sensitivity to pain.<sup>72</sup> Opioid-induced hyperalgesia is different pharmacologically from the phenomenon of opioid tolerance, although both can lead to an increased need for opioids and disentangling the two, clinically, can be difficult.<sup>73</sup>

For chronic pain, the evidence that opioids reduce pain and improve function more than placebo is relatively weak. A 2018 systematic review and meta-analysis of 96 trials comparing various opioids vs. placebo or non-opioid analgesics in 26,169 patients with chronic noncancer pain found that opioids may slightly reduce pain and increase physical functioning compared to placebo, but not compared to non-opioids.<sup>12</sup> In 76 trials comparing opioids vs. placebo with follow-up ranging from 1 to 6 months, the reduction in pain scores with opioids (on a 10-point scale) was only 0.69 points, which is below the generally-accepted 2-point minimum clinically important difference for pain. Physical function scores (on a 100-point scale) improved with opioids by 2.04 points, which, again, may not be clinically important. The risk of vomiting with opioids, however, was more than 4 times higher than with placebo.<sup>12</sup>

The same meta-analysis compared opioids to non-opioid analgesics including NSAIDs, TCAs, anticonvulsants, and synthetic cannabinoids. No significant differences were found in physical functioning scores for any of the comparisons, and no significant differences were found in pain scores for comparisons with NSAIDs, TCAs, or cannabinoids.<sup>12</sup>

### **Exceptions: chronic opioid use in limited patient subsets**

Sickle cell disease as an example for which chronic opioid therapy may be appropriate in some patients. The risk for opioid death in patients with sickle cell disease comprises a small fraction of the total number of opioid-related deaths.

From 1999 through 2013, there were 174,959 documents deaths attributed to opioid use. Of these 174, 959 deaths, 95 were patients with sickle cell disease (0.05%).<sup>74</sup> The pain experienced by patients includes both acute and chronic aspects through multiple mechanisms that are not completely understood. The American Society of Hematology 2020 guidelines endorses the use of

chronic opioid therapy for patients with sickle cell disease with pain that is refractory to multiple other treatments using the lowest effective dose and with regular monitoring.<sup>75,76</sup>

### **Opioid formulations**

Prescription opioids are available in immediate-release and extended-release/long-acting (ER/LA) formulations. Immediate-release agents are recommended in opioid-naïve patients and for all acute pain conditions, with ER/LA agents reserved for patients or conditions in which the longer duration of action and smoother pharmacodynamics are preferred.<sup>31</sup> A trial comparing immediate release to an ER/LA opioid did not find evidence that the continuous, time-scheduled use of ER/LA opioids was more effective or safer than intermittent use of the immediate-release opioid.<sup>71</sup>

According to the FDA, ER/LA opioids should only be used for patients who tolerate 60 morphine milligram equivalents per day (MME) for at least one week.<sup>78</sup>

Efforts to create formulations with lower risks of abuse have met with limited success. For example, ER Oxycodone was removed from the market after reports of intravenous abuse of the oral formulation.<sup>79</sup> Abuse-deterrent or tamper-resistant formulations do not prevent patients from developing opioid dependence, opioid use disorder, or simply taking too much of an opioid by mouth.<sup>80,81</sup>

### **BEFORE MOVING ON TO THE NEXT SECTION, PLEASE COMPLETE CASE STUDY 2 ON THE NEXT PAGE.**

### **Atypical opioids: tramadol and tapentadol**

Tramadol and tapentadol are mu receptor agonists and norepinephrine reuptake inhibitors. Their mechanisms of action are unknown, but their analgesic effects are similar to morphine. Patients taking tramadol should be monitored for nausea, vomiting, constipation, and drowsiness, all of which are similar to side effects with opioids.<sup>82</sup> There is potential risk of serotonin syndrome when tramadol is combined with SSRIs, SNRIs, or tricyclic antidepressants.<sup>83</sup>

As noted above, tramadol is classified as Schedule IV, which has led some to view it as less potent or safer than other opioids. The 2016 National Survey on Drug Use and Health, however, found that 1.7 million people in the U.S. aged > 12 years reported misusing tramadol products (e.g., Ultram, Ultram ER, Ultracet) in the previous year.<sup>71</sup> In addition, a 2019 cohort study of 88,902 patients with osteoarthritis showed increased risks of death at one year compared to NSAIDs naproxen, diclofenac, and celecoxib.<sup>84</sup>

Abrupt cessation of tramadol is associated with opioid withdrawal, restlessness, and drug cravings (similar to those associated with other opioids) as well as hallucinations, paranoia, extreme anxiety, panic attacks, confusion, and numbness/tingling in extremities (which are less typical of other opioids).<sup>85</sup>

Tapentadol is FDA-approved for treating neuropathic pain associated with diabetic peripheral neuropathy, although it is also used for musculoskeletal pain. A 2015 Cochrane review of 4 randomized trials with 4,094 patients with osteoarthritis or back pain found modest reductions in pain with tapentadol vs. placebo.<sup>86</sup>

### **Problematic opioid use**

Although evidence for the long-term effectiveness of opioids for chronic pain is weak, evidence for opioid-related harms is abundant and strong. In a 2007 study assessing behaviors indicative of opioid misuse, many patients in primary care practices reported having engaged in aberrant behaviors with opioids one or more times (Table 2).<sup>9</sup> It is important to recognize and differentiate problematic use from adverse side effects of opioids. For instance, tolerance and opioid withdrawal occur with long term use of prescribed opioids. Clinicians should be able to differentiate this from problematic use.

Among adults without a prescription, 41% obtained prescription opioids from friends or relatives for their most recent episodes of misuse.<sup>87</sup>

For prescription opioids, long-term therapy is associated with an increased risk in accidental overdose and death. A retrospective study including 9,940 patients who received three or more opioid prescriptions within 90 days for chronic pain between 1997 and 2005 found that annual overdose rates rose significantly as doses exceeded 50 MME (Figure 4).<sup>88</sup>

Combining opioids with sedating drugs such as benzodiazepines or alcohol increases the risk of respiratory depression and overdose death.<sup>34</sup> Benzodiazepines have been linked with overdose fatalities in 50-80% of heroin overdoses, and 40-80% in methadone-related deaths.<sup>34,89</sup> Patients prescribed benzodiazepines who are being initiated on opioids should have their benzodiazepine tapered and discontinued whenever possible. For patients being co-managed by mental health professionals, coordinate a plan regarding continuing or tapering benzodiazepines in the setting of opioid co-prescribing.

## Case Study 2

Instructions: Spend 5-10 minutes reviewing the case below and considering the questions that follow.

Wayne is an 86-year-old who lives at home with his wife. He was diagnosed with ALS 6 months ago, with deterioration occurring first in his diaphragm. He has been experiencing increasing muscle weakness in his legs and uses a walker or a wheelchair to get around in his home. He uses a bilevel positive airway pressure device except when eating or bathing and finds it helpful. He takes the following medications: fish oil, a statin, a thiazide diuretic, and a non-benzodiazepine sedative to help him sleep. Lately he has been complaining of pain and stiffness in both of his knees and hips, which interferes with his sleep. He is physically deconditioned due to a lack of exercise, and has become increasingly withdrawn socially, which worries his wife and family members. He asks if you can prescribe something to ease his pain.

1. Is Wayne a good candidate for an ER/LA opioid? Why, or why not?

---



---

2. Is he a better candidate for an immediate-release opioid? Why or why not?

---



---

3. Would Wayne's current medication need to be adjusted if he were to be prescribed an ER/LA opioid?

---



---

4. What kinds of non-opioid treatments might be tried to help Wayne with his pain?

---



---


Table 2. Behaviors indicative of opioid misuse<sup>9</sup>

Behavior	Frequency in patients with opioid misuse
Requested early refills	47%
Increased dose on own	39%
Felt intoxicated from pain medication	35%
Purposely over sedated oneself	26%
Used opioids for purpose other than pain	18%

### Other adverse events

In addition to risks of misuse, addiction, respiratory depression, and overdose death, there are many well-known side effects associated with chronic opioid use that can significantly compromise quality of life, including constipation, nausea or vomiting, sedation, pruritus, erectile dysfunction, menstrual changes, fracture, immunosuppression, hallucinations, and hyperalgesia.

Figure 4. Risk of overdose rises with daily milligram morphine-equivalent dose.<sup>88</sup>



### Gastrointestinal side effects

Constipation is one of the most common opioid-related adverse events, affecting most patients to at least some degree, and which usually does not resolve with continued exposure.<sup>28</sup> To mitigate this side effect, patients should use a mild stimulant laxative such as senna or bisacodyl and increase the dosage in 48 hours if no bowel movement occurs. Physicians should perform a rectal examination if no bowel movement occurs in 72 hours. If there is no impaction, consider other therapies such as an enema, suppository, or magnesium citrate.<sup>90</sup>

Medications for refractory, opioid-induced constipation include naloxone derivatives: naloxegol (Movantik), methylnaltrexone (Relistor), or naldemedine (Symproic). Naloxegol is an oral tablet that is used daily while methylnaltrexone is a subcutaneous injection or oral tablet used daily. Naldemedine is taken by mouth daily (0.2 mg) and may cause side effects such as abdominal pain or discomfort, diarrhea, and nausea.<sup>88</sup> In the COMPOSE-1 trial, patients on naldemedine had significantly more spontaneous bowel movements (defined as  $\geq 3$  per week) than those on placebo (47.6% vs. 34.6%,  $P=0.002$ ).<sup>91</sup>

For nausea or vomiting, physicians should consider a prophylactic antiemetic, add or increase non-opioid pain control agents (e.g., acetaminophen as an opioid-sparing drug), and decrease opioid dose by 25% if analgesic is satisfactory.

### Sedation

Sedation is the first warning sign of a patient being at risk for opioid overdose. Take this symptom very seriously. If a patient complains of sedation, determine whether sedation is related to the opioid, eliminate nonessential depressants (such as benzodiazepines or alcohol), reduce dose by 10%-15% if analgesia is satisfactory, add or increase non-opioid or non-sedating adjuvant for additional pain to reduce opioid dose. There is insufficient evidence to recommend opioid rotation as a possible means of reducing sedation.<sup>31</sup> Patients should also be co-prescribed naloxone for opioid overdose reversal.

### Fracture

A retrospective cohort study over seven years compared the risk of fracture associated with starting opioids vs. NSAIDs (2,436 older adults initiated on opioids and 4,874 older adults initiated on NSAIDs). Opioids significantly increased the risk of fracture in a dose-dependent fashion. The opioid formulation mattered with much of the risk in the first month after drug initiation for short-acting opioids, though fracture increased for both long- and short-acting opioids over time.<sup>92</sup>

### Infection

Opioids may increase risk of infection in older adults. A case-control study of 3,061 older community dwelling adults ages 64-95 years evaluated the association between pneumonia and opioid use. Current prescription opioid users had a 38% increased risk of pneumonia compared with nonusers. The risk was highest for opioid users categorized as being immunosuppressed, such as those with cancer, recent cancer treatment, or chronic kidney disease, or those receiving immunosuppressive medications or medications for HIV.<sup>93</sup>

### Myocardial Infarction (MI)

A case-control study assessed the risk of MI among adults on opioids for chronic pain in the UK General Practice Research Database (11,693 cases with up to four matched controls). Current opioid use was associated with a 28% increased risk of MI compared to non-use.<sup>94</sup>

### Erectile Dysfunction (ED)

In a cross-sectional analysis of 11,327 men with back pain, 909 (8%) were receiving ED medications or testosterone (documented between 6 months before and 6 months after the study index visit). Prescriptions for an ED drug or testosterone were 54% greater for men using doses  $\geq 120$  MMEDs compared with those using doses of 1 to  $<20$  MMED. In addition, the proportion of men receiving either of types of medications was 95% greater for those with chronic opioid use compared with those with no opioid use. These findings suggest that dose and duration of opioid use are associated with ED.<sup>95</sup>

### ***Tamper-resistant/abuse-deterrent opioids***

One strategy to mitigate the risk of opioid abuse has been the development of “abuse-deterrent” formulations of opioids that make it more difficult to alter for non-oral consumption (e.g., injecting, snorting, or smoking).<sup>96</sup> However, these opioids are more aptly named as “tamper-resistant” formulations instead of “abuse-deterrent” since they are no less potentially addictive than regular opioids when taken by mouth.

Tamper-resistant formulations often contain a higher opioid dose than immediate-release preparations. Furthermore, most are extended-release and also considerably more expensive than generic, off-patent opioids.<sup>96</sup> As of this writing, only one immediate-release opioid is available in an abuse deterrent formulation (oxycodone hydrochloride [RoxyBond]).<sup>96</sup>

### ***Patient education***

Before prescribing an opioid for pain, clinicians should discuss with patients the risks and benefits of such therapy. An important consideration in framing treatment, and a key message to communicate to patients, is that the goal is not “zero pain” but, rather, a level of analgesia that maximizes a patient’s physical and mental functioning.<sup>97</sup> A multimodal approach, using both drug and non-drug treatments, should be encouraged.

In addition, patients should be educated about the safe storage and disposal of opioid medications. Safe use means following clinician instructions about dosing, avoiding potentially dangerous drug interactions (e.g., alcohol), and assuring full understanding of how the medication should be consumed or applied. Remind patients that opioid

pain medications are sought after by many people, and, therefore, opioids should be stored in a locked cabinet or, if a locked unit is not available a place that is not obvious or easily accessed by others.

Proper disposal methods should be explained:

- Follow any specific disposal instructions on the prescription drug labeling or patient information that accompanies the medication
- Do not flush medicines down the sink or toilet unless the prescribing information specifically instructs to do so.
- Return medications to a pharmacy, health center, or other organization with a take-back program.
- Mix the medication with an undesirable substance (e.g., used coffee grounds or kitty litter) and put it in the trash, or use special drug deactivation pouches that your health care provider may recommend.

### Managing acute pain

It is now becoming clear that many of the problems and risks associated with managing chronic pain with opioids are also at work in the management of acute pain with opioids. For example, a number of studies demonstrate increased risk of new persistent opioid use in opioid-naïve patients after having been prescribed opioids for acute pain.<sup>98-101</sup> Although the risk of opioid misuse in patients prescribed opioids for acute post-surgical or post-procedural pain is relatively small (roughly 0.6% per year)<sup>102</sup>, the volume of such procedures (approximately 48 million ambulatory surgeries or procedures in 2010)<sup>103</sup> translates into large numbers of patients (i.e., approximately 160,000) who may develop dependence, abuse, or overdose every year.

A central tenet of pain management, whether acute or chronic, is that the goal of treatment is a tolerable level of pain that allows the patient maximum physical and emotional functioning with the lowest risk of side effects, progression to chronic pain, or misuse or abuse.<sup>104</sup> This requires an adroit balancing of patient-related factors (e.g., comorbidities, medical history, risk of abuse) and drug-related factors (e.g., potency, mechanism of action, expected side effects). A commonly-recommended way to achieve this balance is with multimodal analgesia, in which several therapeutic approaches are used, each acting at different sites of the pain pathway, which can reduce dependence on a single medication and may reduce or eliminate the need for opioids and attendant risks/side effects.<sup>105</sup>



Multimodal analgesia (e.g., using drugs from two or more classes, or a drug plus a non-drug treatment) can produce synergistic effects, reduce side effects, or both. One example of multimodal analgesia is the use of both an NSAID and acetaminophen, plus physical approaches (e.g., cold, compression, or elevation) to manage postoperative pain. Demonstrated benefits of multimodal analgesia include earlier ambulation, earlier oral intake, and earlier hospital discharge for postoperative patients, as well as higher levels of participation in activities necessary for recovery (e.g., physical therapy).<sup>105</sup>

### **Non-pharmacological treatments for acute pain**

When possible, non-pharmacologic methods should be used, alone or in combination with analgesics, to manage acute pain.<sup>106</sup> The degree to which this is possible depends on the severity, type, and origin of the pain, but many non-pharmacological approaches can be very effective and their use avoids the potential side effects and risks associated with pharmacological interventions.

Physical methods of pain management can be helpful in all phases of care, including immediately after tissue trauma (e.g., rest, application of cold, compression, elevation) and later in the healing period (e.g., exercises to regain strength and range of motion).

Physical therapy may be useful for a range of musculoskeletal issues and can be helpful in recovering from acute pain-producing traumas initially treated with other methods. A 2018 study reported that patients with low back pain who first consulted a physical therapist were less likely to receive an opioid prescription compared to those who first saw their primary care physician.<sup>107</sup>

Exercise therapy can take many forms, including walking, swimming or in-water exercise, weight training, or use of aerobic or strength-training equipment. According to a CDC review, conditions that may improve with exercise therapy include low back pain, neck pain, hip and knee osteoarthritis pain, fibromyalgia, and migraine.<sup>108</sup>

**BEFORE MOVING ON TO THE NEXT SECTION, PLEASE COMPLETE CASE STUDY 3.**

### **Case Study 3**

**Instructions: Spend 5-10 minutes reviewing the case below and considering the questions that follow.**

*Hannah, a 64-year-old female presents with severe pain in both anterior-lateral thighs and lateral shoulders, rated at 7/10 on the VAS. She reports that the pain is constant and that she gets only mild relief from NSAIDs. She cannot walk without a cane or walker. She had been diagnosed six years ago with severe peripheral neuropathy in her legs for which she was prescribed gabapentin. She reports that gabapentin gives her intense “brain fog” and forgetfulness, however, and that she has stopped taking it because of these side effects. The patient also has type 2 diabetes, initially treated with metformin but lately also with 50 units of insulin per day.*

*The patient was given a treatment plan that included chiropractic adjustments and exercise rehabilitation exercises. She also adopted a “Paleo” diet, which she followed strictly for three months, although it did not significantly lower her hemoglobin A1c levels. She has come to you because the pain is eroding her quality of life, interrupting her sleep, and contributing to tensions with her partner.*

**1. Given the subjective nature of pain, how can a clinician more objectively assess the kind of pain reported by patients such as this?**

---

---

**2. Is it reasonable to believe that the gabapentin was responsible for her reported side effects?**

---

---

**3. Would Hannah be a good candidate for an opioid analgesic? Why or why not?**

---

---

**4. What non-pharmacological treatments might be tried for reducing this patient’s pain?**

---

---

## Non-opioid pharmacologic treatments for acute pain

### Acetaminophen and NSAIDs

In general, mild-to-moderate acute pain responds well to oral non-opioids (e.g., acetaminophen, NSAIDs, and topical agents). Although they are weaker analgesics than opioids, acetaminophen and NSAIDs do not produce tolerance, physical dependence, or addiction and they do not induce respiratory depression or constipation. Acetaminophen and NSAIDs are often added to an opioid regimen for their opioid-sparing effect. Since non-opioids relieve pain via different mechanisms than opioids, combination therapy can provide improved relief with fewer side effects.

The choice of medication may be driven by patient risk factors for drug-related adverse effects (e.g., NSAIDs increase the rate of gastrointestinal, renal, and cardiovascular events). If acetaminophen or NSAIDs are contraindicated or have not sufficiently eased the patient's pain or improved function despite maximal or combination therapy, other drug classes (e.g., opioids) are sometimes used.

Non-opioid analgesics are not without risk, particularly in older patients. Potential adverse effects of NSAIDs include gastrointestinal problems (e.g., stomach upset, ulcers, perforation, bleeding, liver dysfunction), bleeding (i.e., antiplatelet effects), kidney dysfunction, hypersensitivity reactions, and cardiovascular concerns, particularly in the elderly.<sup>109</sup> The threshold dose for acetaminophen liver toxicity has not been established; however, the Food and Drug Administration (FDA) recommends that the total adult daily dose not exceed 4,000 mg in patients without liver disease (with a lower ceiling for older adults with certain conditions).<sup>110</sup>

The FDA currently sets a maximum limit of 325 mg of acetaminophen in prescription combination products (e.g., hydrocodone and acetaminophen) in an attempt to limit liver damage and other potential ill effects of these products.<sup>32</sup>

### Topical agents

Topical capsaicin and salicylates can both be effective for short term cutaneous pain relief and generally have fewer side effects than oral analgesics, but their long-term efficacy is not well studied.<sup>111,112</sup> Topical aspirin, for example, can help reduce pain from acute herpes zoster infection.<sup>107</sup> Topical NSAIDs and lidocaine may also be effective for short-term relief of superficial pain with minimal side effects. Topical agents can be simple and effective for reducing pain associated with wound dressing changes, debridement of leg ulcers, and other sources of superficial pain.<sup>103</sup>

### Anticonvulsants

Anticonvulsants, such as gabapentin, pregabalin, oxcarbazepine, and carbamazepine, are often prescribed for chronic neuropathic pain (e.g., post-herpetic neuralgia and diabetic neuropathy) although evidence for efficacy in acute pain conditions is weak.<sup>114</sup> A 2017 trial, for example, randomized 209 patients with sciatica pain to pregabalin 150 mg/day titrated to a maximum of 600 mg/day vs. placebo for 8 weeks.<sup>115</sup> At 8 weeks there was no significant difference in pain between groups (mean leg pain intensity on a 0-10 scale 3.7 with pregabalin vs. 3.1 with placebo,  $P=0.19$ ).

### Opioids for acute pain: use caution

Opioids are commonly prescribed for pain, with nearly two thirds (64%) of the public reporting being prescribed an opioid for pain at some point in their lives.<sup>116</sup> However, this approach is not as safe and effective as once thought, and high-dose prescriptions or prolonged use not only increase the risk of misuse, addiction, or overdose, they may actually *increase* pain and pain sensitivity.<sup>117,118</sup>

Recent evidence suggests that opioids may not be more effective for moderate to severe acute pain than non-opioid pain regimens.<sup>119,120</sup> A randomized trial of 416 patients with acute extremity pain found no clinically important differences in pain reduction at two hours after single-dose treatment with ibuprofen and acetaminophen vs. three different opioid and acetaminophen combination analgesics.<sup>113</sup>

Physical dependence can readily occur after use of opioids at a sufficient dose (e.g., 30mg of oxycodone) for just a few days. In addition, side effects of opioid use can include constipation, confusion/gait instability, respiratory depression, pruritus, erectile dysfunction, and fractures, all of which may be more problematic in older patients and occur at higher rates than with non-opioid analgesics.

A cross-sectional study compared common side effects experienced during the first week of treatment with opioid analgesics vs. non-opioid analgesics in patients over age 65 with acute musculoskeletal pain.<sup>121</sup> The intensity of six common opioid-related side effects were significantly higher with opioids. (A limitation of this study is that it could not assess severe but less common adverse events associated with NSAIDs and acetaminophen, including the risk for gastrointestinal bleeding, acute kidney injury, and hepatotoxicity.)

In a retrospective study of 12,840 elderly patients with arthritis, opioid use was associated with an increased risk relative to non-opioids for cardiovascular events, fracture, events requiring hospitalization, and all-cause mortality.<sup>122</sup>

The risk of prolonged opioid use is particularly high after arthroscopic joint procedures. In a 2019 case-control study of 104,154 opioid-naïve adults, 8,686 (8.3%) developed new prolonged opioid use (continued opioid use between 91 and 180 days after shoulder arthroscopy).<sup>123</sup>

Subgroups at higher risk for long-term use included women, those with a history of alcohol use disorder, those with a mood disorder, and those with an anxiety disorder.

### Opioid choices for acute pain

If an opioid is deemed necessary to treat moderate-to-severe acute pain, the following general principles are recommended when starting an opioid:

- Avoid extended-release and long-acting opioids such as methadone, fentanyl patches, and ER/LA versions of opioids such as oxycodone or oxymorphone.
- Avoid co-prescribing opioids with other drugs known to depress central nervous system function (e.g., benzodiazepines)
- Limit the dose and quantity of opioids to address the expected duration and severity of pain (usually less than 7 days).
- Combine opioids with other treatments (e.g., non-pharmacologic options such as exercise or cognitive behavioral therapy, NSAIDs, or acetaminophen).
- Closely monitor patients with impaired hepatic or kidney function if they are prescribed opioids, and adjust the dose or duration accordingly

Immediate-release agents are strongly preferred because of the higher risk of overdose associated with ER/LA agents. A cohort study of 840,000 opioid-naïve patients over a 10-year span found that unintentional overdose was 5 times more likely in patients prescribed ER/LA agents compared to immediate-release opioids.<sup>124</sup>

### Opioid dosing for acute pain

The amount of opioid prescribed should relate to the level of pain expected from the injury or procedure. Injuries or procedures involving bones and joints tend to be more painful than those involving soft tissues.<sup>125</sup> Table 3 illustrates the wide range of expected pain and associated recommended opioid doses for some common surgeries or procedures.

**Table 3. Opioid dose recommendations for post-procedural pain<sup>126</sup>**

Procedure	Number of oxycodone 5 mg tablets (or equivalent)
Dental extraction	0
Thyroidectomy	5
Breast biopsy or lumpectomy	5
Lumpectomy plus sentinel lymph node biopsy	5
Hernia repair (minor or major)	10
Sleeve gastrectomy	10
Prostatectomy	10
Open cholecystectomy	15
Cesarean delivery	15
Hysterectomy (all types)	15
Cardiac surgery via median sternotomy	15
Open small bowel resection	20
Simple mastectomy with or without sentinel lymph node biopsy	20
Total hip arthroplasty	30
Total knee arthroplasty	50

**Managing chronic non-cancer pain**

Management of chronic non-cancer pain begins by establishing individualized treatment goals, exploring non-opioid treatment options, and addressing comorbid depression and anxiety, if present. Pain management goals may include both pain and functional targets, with the understanding that being 100% pain free is not realistic. Functional goals should focus on activities that are meaningful to the patient and attainable based on the severity of the painful condition. Multi-modal approaches that include non-drug (procedures, integrative treatments) and drug interventions are recommended.<sup>28</sup>

Be aware that comorbid conditions such as depression and anxiety can impact pain management. (In a study of 250 patients with chronic pain and moderate depression, using antidepressant therapy reduced pain levels before analgesic interventions were added.<sup>127</sup>)

For patients with intractable, moderate-to-severe chronic noncancer pain unresponsive to non-opioid treatment options, a trial of opioids may be indicated guided by the following principles (each detailed below):

- Discuss risks and benefits of opioid use
- Establish a written treatment agreement
- Check or monitor opioid use with the prescription drug monitoring program
- Use caution with dose escalation
- Prescribe naloxone if at risk for overdose
- Screen for opioid misuse or abuse using history and, ideally, a validated questionnaire, as well as urine drug testing
- Taper or discontinue opioids when possible

**Establishing a written treatment agreement**

Written documentation of all aspects of a patient's care, including assessments, informed consent, treatment plans, and provider/patient agreements, are a vital part of opioid prescription "best practices." Such documentation provides a transparent and enduring record of a clinician's rationale for a particular treatment and provides a basis for ongoing monitoring and, if needed, modifications of a treatment plan.<sup>104</sup>

Many computerized systems are now available for the acquisition, storage, integration, and presentation of medical information. Most offer advantages that will benefit both patients and prescribers, such as maintaining up-to-date records, and providing instant availability of information relevant to prescribing or treatment. Although automation can help, clear documentation is not dependent on electronic record-keeping; it merely requires a commitment to creating clear and enduring communication in a systematic fashion. Good documentation can be achieved with the most elaborate electronic medical record systems, with paper and pen, or with dictated notes. Clinicians must decide for themselves how thoroughly, and how frequently, their documentation of a patient's treatment should be.

**Informed Consent**

Informed consent is a fundamental part of planning for any treatment, but it is particularly important in long-term opioid therapy, given the potential risks of such therapy. At its best, consent also fortifies the clinician/patient relationship.

Prescribers must be able to answer with confidence four key questions when obtaining informed consent in the context of treatment with opioids:<sup>122</sup>

1. Does the patient understand the various options for treatment?
2. Has the patient been reasonably informed of the potential benefits and risks associated with each of those options?
3. Is the patient free to choose among those options, free from coercion by the healthcare professional, the patient's family, or others?
4. Does the patient have the capacity to communicate his or her preferences—verbally or in other ways (e.g., if the patient is deaf or mute)?
5. Is there a proxy available if the patient cannot provide consent due to cognitive impairment?

Documentation related to these key areas can be accomplished by creating a separate paper or electronic informed consent form or by incorporating informed consent language into a larger treatment plan or patient/provider agreement.

**Patient-Provider Agreements**

A written agreement between a clinician and a patient about the specifics of their pain treatment with opioids can help clarify the plan with the patient, the patient's family, and other clinicians who may become involved in the patient's care.<sup>104</sup>

Such agreements can also reinforce expectations about the appropriate and safe use of opioids. Caution must be exercised, however, to ensure that patient/provider agreements are not used in a coercive way to unethically place patients in the position of having to agree to its terms or else lose an important component of their treatment (or even lose *all* treatment).<sup>128</sup>

Although evidence is lacking about the most effective methods to convey the information included in most patient-provider agreements, such agreements have been widely used and are recommended by regulators and many experts on treatment guidelines for long-term opioid therapy.<sup>28</sup> The Veterans Administration and U.S. Department of Defense chartered an expert panel to undertake a systematic review of existing medical literature on this subject. In the clinical practice guidelines resulting from that work, the panel concluded that opioid treatment agreements are a standard of care when prescribing long-term opioid therapy.<sup>128</sup>

Clinicians should strive to craft agreements that serve their patients' best interests and avoid coercive or punitive language. Thus, agreements should avoid:

1. Putting all burden on the patient rather than sharing it between patient and clinician
2. Framing the agreement in terms of punishments for possible future crimes or difficulties

3. Using language that is stigmatizing, dominating, or pejorative
4. Using coercion in any way
5. Imposing limitations for the clinician's convenience without clear and substantial benefit for the patient.
6. Insisting on behaviors unrelated to actual use of medications Using the term "fired" to describe termination of treatment.
7. Threatening abandonment or suggesting that patients will not have continued access to non-opioid pain-relieving treatments if opioids are terminated

To be effective, written agreements must be clearly understood by the patient. This may require the provision of agreements in multiple languages. All agreements should be written at the sixth- to seventh-grade level or even lower.<sup>129</sup> Translators may need to be provided for speakers of other languages to ensure patient understanding and effective informed consent. A patient who does not fully understand the potential risks and benefits of a treatment cannot be truly "informed" as required by the legal and ethical guidelines for medical practice. Time must be allowed for patients to ask questions, and for prescribers to ensure patients understand what they are being told. Some, or all, of these tasks may be handled by trained personnel (or staff members) rather than clinicians.

Although the term "agreement" is generally perceived as being more patient-friendly than the word "contract," clinicians should understand that, from a legal standpoint, any written or oral agreement between a prescriber and a patient may be considered a binding "contract."<sup>130</sup> Clinicians should ensure that the terms in any agreement are understood by the patient, and are acceptable, attainable, and consistent with high-quality practice.

**BEFORE MOVING ON THE NEXT SECTION, PLEASE COMPLETE CASE STUDY 4 ON THE NEXT PAGE.**

***Creating individualized function-based pain treatment plans***

Once a patient has been assessed and accepted as a candidate for chronic opioid therapy, and after informed consent has been obtained for such treatment, a written plan for implementing the treatment should be drafted. Such plans typically include a statement of the goals of therapy. These goals should be written carefully in light of the inherent subjectivity of pain. Since pain itself cannot be measured objectively, framing treatment goals solely in terms of pain relief means that such goals cannot be objectively confirmed.

Although a patient's subjective pain and suffering are obviously important factors, only the functional impact of the pain can be measured

and used to create objective treatment goals. This impact takes many forms, but typically chronic pain erodes foundations of daily life, such as physical activity, concentration, emotional stability, interpersonal relationships, and sleep. This can, in turn, degrade functioning at work or in the home, which can lead to depression, anxiety, insomnia, and even suicide. Clinicians should know that even relatively modest reductions in pain can translate into significant functional improvements as pain rating declines.<sup>104</sup> A 20% reduction in a pain score (i.e., roughly two points on the standard 0-10 pain scale) may be acceptable if it produces significant functional benefits for a patient.

Framing treatment goals in terms of improved patient functioning, rather than merely pain relief, offers two primary advantages to clinicians:

- Prescribing decisions (or decisions to terminate treatment) are based on outcomes that can be objectively demonstrated to both clinician and patient (and, possibly, to the patient's family)
- Individual differences in pain tolerance become secondary to the setting and monitoring of treatment goals, since subjectively perceived levels of pain are not the primary focus in determining functionality.

Basing treatment plans on functional goals is especially valuable in the context of prescribing opioid pain medications, because such goals may help determine whether a patient has an opioid use disorder because patients with OUD often have decreased functioning, while effective pain relief typically improves functioning.

Functional decline itself may result from a range of problems, including inadequate pain relief, non-adherence to a regimen, function-limiting side effects, or untreated affective disorders. Sometimes impaired functioning is the result of OUD, and these objective results may shed valuable light on an otherwise confusing presentation of a patient's pain symptoms.

Functional treatment goals should be realistic. Progress in restoring function is usually slow and gains are typically incremental. Chronic non-cancer pain is often marked by long-standing physical and psychological deconditioning, and recovery may require reconditioning that may take weeks, months, or years. It is much better to set goals that are slightly too low than slightly too high. Raising goals after a patient has "succeeded" in achieving them is far more motivational and encouraging than lowering goals after a patient has "failed." Table 4 illustrates some simple functional goals and ways they might be verified.

The responsibility for obtaining evidence of success in meeting a functional goal lies with the patient and should be made explicit in the prescribing agreement. If a patient is unable to document or achieve the progress outlined in a treatment plan, this may suggest a need for goal readjustment.

**Initiating therapy**

When initiating a trial of opioids, start with immediate-release formulations because their shorter half-life reduces the risk of inadvertent overdose. Prescribe low doses on an intermittent, as-needed basis. For elderly patients who have comorbidities, start at an even lower dose (25-50% of usual adult dose).

Long-term opioid use often begins with treatment for acute pain, and research shows that opioids are often over-prescribed for acute pain. For example, a study of 1,416 patients in a 6-month period found that surgeons prescribed a mean of 24 pills (standardized to 5 mg oxycodone) but patients reported using a mean of only 8.1 pills (utilization rate 34%).<sup>125</sup> For acute pain, only enough opioids should be prescribed to address the expected duration and severity of pain from an injury or procedure (or to cover pain relief until a follow-up appointment). Several guidelines about opioid prescribing for acute pain from emergency departments<sup>131,132</sup> and other settings<sup>133,134</sup> have recommended prescribing  $\leq 3$  days of opioids in most cases, whereas others have recommended  $\leq 7$  days,<sup>135</sup> or  $\leq 14$  days.<sup>136</sup> CDC guidelines suggest that for most painful conditions (barring major surgery or trauma) a 3-day supply should be enough, although many factors must be taken into account (for example, some patients might live so far away from a health care facility or pharmacy that somewhat larger supplies might be justified) and clinician judgment is an important factor in determining the supply.<sup>31</sup>

**Monitoring opioid use**

Follow-up appointments should occur one to four weeks after initiation of opioids or with dose changes; maintenance therapy visits should occur at least every three months. Each visit should include an assessment using a pain and function tool, questions about side effects, evaluation of overdose risk, and discussions about how the medication is being used.<sup>34</sup>

Many strategies to monitor opioid use and ensure patient safety have been recommended. However, simply asking patients how they are using the medication, how often they take it, how many pills they take at one time, and what triggers them to take the medication, can identify patients who may be misusing opioids or need changes to their pain management plan.

### Case Study 4

**Instructions: Spend 5-10 minutes reviewing the case below and considering the questions that follow.**

*Inessa is 72 and lives in an urban area, having immigrated from Russia as a young woman. She grew up on a farm and worked in the fields or tending animals starting as a child. She blames these early labors for the arthritis she now has in her hands and wrists, and for the pain she feels in her lower back. Although Inessa lives alone, following the death of her husband from a heart attack 5 years ago, she relies on a young man who lives in a small apartment attached to her house for help with activities of daily living and simply for company.*

*According to Inessa, the pain medication she was prescribed for her arthritis (short-acting hydrocodone/acetaminophen) is no longer working and she has come to you asking for either a different medication or a higher dose of the existing medication. Despite her reported pain, Inessa is ambulatory and appears cognitively intact. She takes a range of herbal supplements including St. John's wort, turmeric, and a "joint support" supplement, the ingredients of which she is unsure. She has a very insistent, demanding personality and is convinced she needs the new, or higher-dose, opioid medication.*

**1. How would you respond to Inessa's request?**

---

---

**2. What alternatives to an opioid analgesic could you offer to Inessa?**

---

---

**3. If you end up prescribing an opioid analgesic for Inessa, would you require that she sign a patient-provider agreement? If so, what specific caveats would you include in the agreement?**

---

---

**4. Would it be prudent to include the young man who cares for her in discussions about treatment?**

---

---

**Table 4: Example of functional goals and evidence used to assess progress<sup>104</sup>**

Functional Goal	Evidence
Begin physical therapy	Letter from physical therapist
Sleeping in bed as opposed to lounge chair	Report by family member or friend (either in-person or in writing)*
Participation in pain support group	Letter from group leader
Increased activities of daily living	Report by family member or friend
Walk around the block	Pedometer recordings or written log of activity
Increased social activities	Report by family member or friend
Resumed sexual relations	Report by partner
Returned to work	Pay stubs from employer or letter confirming the patient is off of disability leave
Daily exercise	Gym attendance records or report from family member or friend

\* Involving other persons requires explicit permission from the patient, and this permission should be documented.

Other ways to objectively monitor opioid use are checking prescription drug monitoring programs, completing urine drug tests/oral fluid tests, or random pill counts.

Relatively infrequent urine monitoring may be appropriate for low-risk patients on a stable dose of opioids (i.e., 1-2 times a year). More frequent or intense monitoring is appropriate for patients during the initiation of therapy or if the dose, formulation, or opioid medication is changed. Patients who may need more frequent or intense monitoring (i.e., 4-6 times a year) include:<sup>104</sup>

- Those with a prior history of an addictive disorder, past abuse, or other aberrant use
- Those in an occupation demanding mental acuity
- Older adults
- Patients with an unstable or dysfunctional social environment
- Those with comorbid psychiatric or medical conditions

It is important to recognize that urine drug testing is expensive and not all insurance companies will pay for frequent testing. Discuss the cost of testing with patients. Also, only order the test that is necessary. It is not necessary to order quantitative (definitive test) testing on all patients as this test can be very expensive. For low-risk patients urine drug screening (presumptive test), even done as a point of care test, may be sufficient. However, if the urine drug screen will not detect the drug of interest, then a quantitative test will be needed.

Trust is a necessary part of any patient/clinician relationship, but studies suggest that in the context of controlled substances, it is unwise to rely on a patient's word that medications are being consumed as prescribed. Although the use of more objective ways to monitor adherence to medication regimens is an imperfect science, such methods remain an essential component of periodic review. Multiple objective methods to assess adherence exist, but there is no single "best" approach and all such methods have both advantages and potential drawbacks.

In the context of family practice settings (and even pain specialist settings) unobserved urine collection is usually an acceptable procedure for drug testing. Prescribers, however, should be aware of the many ways in which urine specimens can be adulterated. Specimens should be shaken to determine if soap products have been added, for example. The urine color should be noted on any documentation that accompanies the specimen for evaluation, since unusually colored urine could indicate adulteration. Urine temperature and pH should be measured immediately after collection when possible.<sup>131</sup>

Prescribers should be familiar with the metabolites associated with each opioid that may be detected in urine, since the appearance of a metabolite can be misleading. A patient prescribed codeine, for example, may test positive for morphine because morphine is a metabolite of codeine. Similar misunderstandings may occur for patients prescribed hydrocodone who appear positive for hydromorphone or oxycodone and oxymorphone.

### **Opioid rotation and equianalgesic dosing**

"Opioid rotation" means switching from one opioid to another in order to better balance analgesia and side effects. Rotation may be needed because of a lack of efficacy (often related to tolerance), bothersome or unacceptable side effects, increased dosing that exceeds the recommended limits of the current opioid (e.g., dose limitations of co-compounded acetaminophen), or inability to absorb the medication in its present form (i.e., if there is a change in the patient's ability to swallow, switch to a formulation that can be absorbed by a different route such as transdermal.)

Because of the large number of variables involved in how any given opioid will affect any given patient, opioid rotation must be approached cautiously, particularly when converting from an immediate-release formulation to an ER/LA product. As noted previously, equianalgesic charts must be used carefully, and titration must be done carefully and with appropriate monitoring. In some cases, because of the risk of potential harm during the time of rotating from one chronic opioid regimen to another, it may be wise to initially use lower doses of an ER/LA opioid than might be suggested by equianalgesic charts, while temporarily liberalizing, as needed, the use of a short-acting opioid.<sup>138</sup> This would then be followed by gradual titration of the LA opioid to the point where the as-needed short-acting opioid is incrementally reduced, until no longer necessary.

Equianalgesic dosing charts help clinicians determine the appropriate starting dose of an opioid when changing routes of administration or when changing from one opioid drug to another. Such charts must be used carefully, however. A high degree of variation has been found across the various charts and online calculator tools, and may account for some overdoses and fatalities.<sup>132</sup> The optimal dose for a specific patient must be determined by careful titration and appropriate monitoring, and clinicians must be mindful that patients may exhibit incomplete cross-tolerance to different types of opioids because of differences in the receptors or receptor sub-types to which different opioids bind.<sup>138</sup> In addition, the patient's existing level of opioid tolerance as well as concurrent medications that depress the central

nervous system must be taken into account. Printed equianalgesic charts are common, and online calculators are also freely available (a common one can be accessed at [clincalc.com/Opioids](http://clincalc.com/Opioids)). Always work with a clinical pharmacist if you do not have a lot of experience with opioid rotation as this can be a risk factor for unintentional opioid overdose.

### **Recognizing patients with opioid use disorder**

Whenever a clinician considers treating pain with a controlled substance, such as an opioid, risk of misuse or diversion is always a possibility, no matter how remote, and must be assessed. Some patient characteristics are predictive of a potential for drug abuse, misuse, or other aberrant behaviors. The factor that appears to be most strongly predictive in this regard is a personal or family history of alcohol or drug abuse.<sup>28</sup> Some studies have also shown that younger age and the presence of psychiatric conditions are also associated with aberrant drug-related behaviors.<sup>28</sup>

In evaluating patients with chronic pain for risk of addiction or signs that they may be abusing a controlled substance, it may be helpful to consider the sets of characteristics listed in Table 5.

Signs of physical dependence include the appearance of an abstinence syndrome with abrupt cessation or diminution of chronic drug administration and is not the same as OUD, a condition where patients lose control of their opioid use or compulsively use opioids. The nature and time of onset of this syndrome vary with drug actions and half-life. Slow tapering of the drug (e.g., 10-15% reduction in dosage per day or every other day) usually avoids the appearance of an abstinence syndrome.

### **Managing Non-Adherent Patients**

Patients who exhibit aberrant drug-related behaviors or non-adherence to an opioid prescription should be monitored more closely than compliant patients. Concern that a patient is non-adherent should prompt a thorough evaluation. The way clinicians interact with patients can affect the relationship (for better or worse) and influence treatment outcomes. A clinician's negative reactions to non-adherence might include anger at the patient, disappointment and sadness at the apparent betrayal of trust, or fear that the patient's behavior could expose the provider to legal jeopardy.<sup>104</sup>

The use of patient-provider agreements and/or informed consent documents can help clinicians navigate the uncertainties that can arise in cases of real or apparent non-adherence, and may help make the process less confrontational. Consultation with an addiction medicine specialist or psychiatrist may be necessary if addiction is suspected or if a patient's behavior becomes so problematic that it jeopardizes the clinician/patient relationship.

**Table 5: Chronic pain patients vs. patients with an OUD<sup>137</sup>**

Patient with chronic pain	Patient with an opioid use disorder
Medication use is not out of control	Medication use is out of control
Medication use improves quality of life	Medication use impairs quality of life
Wants to decrease medication if adverse effects develop	Medication use continues or increases despite adverse effects
Is concerned about the physical problem being treated with the drug	Unaware of or in denial about any problems that develop as a result of drug treatment
Follows the practitioner-patient agreement for use of the opioid	Does not follow opioid agreement
May have left over medication	Does not have leftover medication
	Loses prescriptions
	Always has a story about why more drug is needed

**Treatment Termination**

Reasons for discontinuing an opioid analgesic can include the healing of or recovery from an injury, medical procedure, or condition; intolerable side effects; lack of response; or discovery of misuse of medications. Regardless of the reason, termination should be accomplished so as to minimize unpleasant withdrawal symptoms by tapering the opioid medication slowly, by carefully changing to a new formulation, or by effectively treating an opioid use disorder if it has developed. Approaches to weaning range from a slow 10% reduction per week to a more aggressive 25 to 50% reduction every few days.<sup>28</sup> In general, a slower taper will produce fewer unpleasant symptoms of withdrawal; however, this may not be the safe course of action for a patient experiencing side effects or who has OUD.

Opioid therapy must be discontinued or re-evaluated whenever the risk of therapy is deemed to outweigh the benefits being provided. A clinician may choose to continue opioid treatment with intensified monitoring, counseling, and careful documentation if it is deemed in the best interest of the patient. This requires, however, careful consideration and a well-documented risk management plan that addresses the greater resources necessary for opioid continuation following evidence of misuse.

If termination of the physician/patient relationship is deemed necessary (though it rarely is), clinicians must ensure that the patient is transferred to the care of another physician or provider and ensure that the patient has adequate medications to avoid unnecessary risk, such as from uncontrolled or unpleasant withdrawal. Practitioners can be held accountable for patient abandonment if medical care is discontinued without justification or adequate provision for subsequent care.

**Caution with dose escalation**

When escalating opioid doses, be aware of two possible critical daily thresholds—50 and 90 MMED.<sup>34</sup> According to the CDC, doses >50 MMED are associated with more than double the risk of overdose compared to patients on <50 MMED.<sup>31</sup>

For patients on >90 MMED, a 9-fold increase in mortality risk was observed compared with the lowest opioid doses. Ninety MMED is considered by several guidelines as a “red flag” dose beyond which careful assessment, more frequent monitoring, and documentation of expected benefits are required (note, however, that this limit doesn’t apply to patients with severe cancer pain or end-of-life pain). The total MMED for all prescribed opioids should be used (MMED is automatically calculated on many state PDMP reports). Physician clinical judgment is also important in determining daily thresholds and the CDC limits can be used as a guide.

**Role of ER/LA opioids and methadone**

ER/LA opioids include methadone, transdermal fentanyl, and extended-release versions of opioids such as oxycodone, oxymorphone, hydrocodone, and morphine. A 2015 study found a higher risk for overdose among patients initiating treatment with ER/LA opioids than among those initiating treatment with immediate-release opioids.<sup>124</sup> As noted above, continuous, time-scheduled use of ER/LA opioids is not more effective or safer than intermittent use of immediate-release opioids, and ER/LA opioids increase risks for opioid misuse or addiction.<sup>31</sup>

The 2016 CDC guidelines suggest that ER/LA opioids should be reserved for severe, continuous pain and should be considered only for patients who have received immediate-release opioids daily for at least 1 week.<sup>31</sup> Additional caution is required when prescribing ER/LA opioids in older adults or patients with renal or hepatic dysfunction because decreased clearance of drugs among these patients can lead to accumulation of drugs to toxic levels and persistence in the body for longer durations.

When an ER/LA opioid is prescribed in the primary care setting, using an agent with predictable pharmacokinetics and pharmacodynamics is preferred to minimize unintentional overdose risk (i.e., the unusual characteristics of methadone and transdermal fentanyl make safe prescribing of these medications for pain more challenging).<sup>31</sup>

The use of methadone for chronic pain in primary care should generally be avoided because of higher methadone-related risks for QTc prolongation and fatal arrhythmias.<sup>31</sup> Equianalgesic dose ratios are highly variable with methadone, making conversion from other opioids difficult, with attendant increased risk of overdose. While methadone-related death rates decreased 9% from 2014 to 2015 overall, the rate increased in people ≥65 years of age.<sup>139</sup> If methadone or transdermal fentanyl is considered, refer patients to pain management specialists with expertise in using this medication.

**BEFORE MOVING ONTO THE NEXT SECTION, PLEASE COMPLETE CASE STUDY 5 ON THE NEXT PAGE.**

**Protecting against opioid-induced adverse events**

Prophylaxis for constipation—the most common opioid-induced adverse event—has been facilitated by the approval of methylaltrexone subcutaneous administration and naloxegol oral administration for patients with chronic non-cancer pain. Other, less expensive medications like senna and docusate, are also effective to guard against constipation.

Both male and female patients on long-term opioid therapy are at risk for hypogonadism, thus current guidelines suggest that the endocrine function of all patients should be assessed at the start of long-term opioid therapy and at least annually thereafter.

**Naloxone for opioid overdose**

Naloxone (e.g., Narcan) is an opioid antagonist that quickly reverses the effects of opioid overdose. Naloxone is increasingly available to first responders, patients, and friends and family members of those prescribed opioids, and a generic formulation of nasal-spray naloxone was approved by the FDA in April, 2019.<sup>141</sup>

## Case Study 5

Instructions: Spend 5-10 minutes reviewing the case below and considering the questions that follow.

Jeremiah has been your patient since he was a young boy. Now 33 years old, you have seen Jeremiah grow up into a physically strong, but emotionally vulnerable young man. Jeremiah struggled in school and chose to enter a training program for masons rather than pursue college. A self-described “partyer” who reports regular use of alcohol and cannabis, Jeremiah nonetheless has not reported any impacts of his substance use on his personal or work life. He has, in fact, been successful in both, earning a good living as a mason and supporting his wife and two sons.

But Jeremiah is currently on workman’s compensation to recover from a compound fracture of his left foot and ankle sustained when a large section of a chimney he was working on collapsed and fell. He also tore the rotator cuff in his right shoulder when he fell backwards against the scaffolding poles during the accident. Both injuries required surgical interventions and his recovery has been slow. Jeremiah was prescribed a short-acting opioid after each surgery, which he has continued to use.

He has been regularly attending physical therapy sessions to restore strength in his left leg and to increase the range of motion in his right shoulder, but he complains that the therapy sessions are painful and that he doesn’t think they’re helping. He says his boss suggested that a long-acting opioid would be easier to use and would provide him more steady pain relief.

1. How would Jeremiah’s substance use affect your decision-making process related to his request for an ER/LA medication?

---

---

2. What steps might you take before agreeing to a trial of an ER/LA medication for Jeremiah?

---

---

3. What specific kind/dose of ER/LA medication might be most appropriate for Jeremiah if no contraindications were found in the pain and substance abuse assessment?

---

---

4. Name three specific functional goals that might be used as the basis for a pain management agreement with Jeremiah.

---

---

Primary care providers should prescribe naloxone to patients at risk of overdose, including those:

- With renal or hepatic dysfunction
- Taking opioid doses >50 MMED
- Co-prescribed benzodiazepines or other sedating medications
- With a history of overdose or OUD
- Starting treatment for opioid use disorder

Many states allow patients, family members, caregivers, and/or friends to request naloxone from their local pharmacist. Anyone receiving naloxone should be taught how to use the device and about the common signs of overdose (slow or shallow breathing, gasping for air, unusual snoring, pale or bluish skin, not waking up or responding, pin point pupils, slow heart rate).

A variety of naloxone products are available. The intranasal device with atomizer and intramuscular (IM) shots require the most manipulation in order to administer. Intranasal naloxone and the auto-IM injector are easier to use, but vary greatly in terms of price and insurance coverage.

### Successful opioid tapering

Patients who do not achieve functional goals on stable or increasing opioid doses or those with unacceptable side effects, should have the opioid tapered or discontinued. Patients sometimes resist tapering or discontinuation, fearing increased pain. However, a 2017 systematic review found that dose reduction or discontinuation resulted in reduced pain (eight studies), improved function (five studies) and improved quality of life (three studies), although the evidence was not strong

because the analysis included poor-quality studies with uncontrolled designs and the interventions and outcome measures were heterogeneous.<sup>142</sup>

Recommendations for tapering schedules vary. One source recommends a 10% decrease weekly based on years of opioid use (i.e., 10% decrease monthly for patients using opioids  $\geq 4$  years). For patients on high-dose opioids (i.e.,  $\geq 90$  MMED), taper 10% until patient is taking 30% of the total initial dose, then recalculate 10% taper based on the new total opioid dose to slow taper.<sup>143</sup> The rate of opioid taper should be adjusted based on patient-specific factors such as the severity of withdrawal symptoms.



**Table 6: Recommendations for preventing or treating opioid-induced side effects<sup>140</sup>**

<b>Constipation</b>	Methylnaltrexone or naloxegol Prophylactic mild peristaltic stimulant (e.g. bisacodyl or senna) If no bowel movement for 48 hours, increase dose of bowel stimulant If no bowel movement for 72 hours, perform rectal exam If not impacted, provide additional therapy (suppository, enema, magnesium citrate, etc.)
<b>Nausea or vomiting</b>	Consider prophylactic antiemetic therapy Add or increase non-opioid pain control agents (e.g. acetaminophen) If analgesia is satisfactory, decrease dose by 25% Treat based on cause
<b>Sedation</b>	Determine whether sedation is due to the opioid – if so, lower opioid dose immediately Eliminate nonessential CNS depressants (such as benzodiazepines) Reduce dose by 20-30% Add or increase non-opioid or non-sedating adjuvant for additional pain relief (such as NSAID or acetaminophen)so the opioid can be reduced Change opioid Prescribe naloxone
<b>Pruritus</b>	Consider treatment with antihistamines Change opioid
<b>Hallucination or dysphoria</b>	Evaluate underlying cause Eliminate nonessential CNS acting medications
<b>Sexual dysfunction</b>	Reduce dose Testosterone replacement therapy may be helpful (for men) Erection-enhancing medications (e.g., sildenafil)

In 2019 the FDA, recognizing the risks associated with abrupt discontinuation of opioid analgesics, required new labeling for opioid analgesics to guide prescribers about safe tapering practices.<sup>138</sup>

The key elements include:<sup>144</sup>

- Do not abruptly discontinue opioid analgesics in patients physically dependent on opioids. Counsel patients not to discontinue their opioids without first discussing the need for a gradual tapering regimen.
- Abrupt or inappropriately rapid discontinuation of opioids is associated with serious withdrawal symptoms, uncontrolled pain, and suicide.
- Ensure ongoing care of the patient and mutually agree on an appropriate tapering schedule and follow-up plan.
- In general, taper by an increment of no more than 10-20% every 2-4 weeks.
- Pause taper if the patient experiences significantly increased pain or serious withdrawal symptoms.
- Use a multimodal approach to pain management, including mental health support (if needed).
- Reassess the patient regularly to manage pain and withdrawal symptoms that emerge and assess for suicidality or mood changes.
- Refer patients with complex comorbidities or substance use disorders to a specialist.

### **Opioid use disorder (OUD)**

OUD is a problematic pattern of opioid use that causes significant impairment or distress.<sup>145</sup> As with other chronic diseases, OUD usually involves cycles of relapse and remission. DSM-5 diagnosis of OUD is based on clinical evaluation and determination that a patient has problematic opioid use leading to clinically significant impairment or distress involving at least two of the following within a 12-month period:<sup>145</sup>

- Opioids taken in larger amounts, or for longer periods, than intended
- Persistent desire or unsuccessful attempts to control or reduce use
- Significant time lost obtaining, consuming, and recovering from opioids
- Craving or a strong desire or urge to use opioids
- Failure to complete obligations (i.e., work, home, or school) due to opioids
- Persistent or recurrent social or interpersonal problems due to opioids
- Giving up enjoyable social, work, or recreational activities due to opioids
- Recurrent opioid use in situations in which it is physically hazardous (e.g., driving)
- Continued use despite a physical or psychological problem caused by or worsened by opioid use
- Tolerance (unless opioids are being taken as prescribed)
- Using opioids to prevent withdrawal symptoms (unless opioids are being taken as prescribed)

OUD is not a binary diagnosis, rather it exists as a continuum, with DSM-5 describing 3 levels of severity:

- Mild OUD (2-3 criteria)
- Moderate OUD (4-5 criteria)
- Severe OUD (≥ 6 criteria)

More than 2 million Americans have OUD, and the number is growing.<sup>70</sup> OUD can be effectively managed with medication-assisted treatment (MAT), but only an estimated 20% of adults with OUD currently receive such treatment.<sup>146</sup>

### **Medications to treat OUD**

The FDA has approved three medications for treating OUD: buprenorphine, methadone, and extended-release naltrexone (Table 7). Buprenorphine and methadone can reduce opioid cravings and all three can prevent misuse.<sup>141</sup> Each medication has a unique mechanism of action and involve different formulations, methods of induction and maintenance, patterns of administration, and regulatory requirements.

### **Methadone**

Methadone is a synthetic, long-acting opioid agonist that fully activates mu-opioid receptors in the brain.<sup>148</sup> This activity reduces the unpleasant/dysphoric symptoms of opioid withdrawal, and, at therapeutic doses, it blunts the “highs” of shorter-acting opioids such as heroin, codeine, and oxycodone. Patients do not have to experience opioid withdrawal before starting methadone.

**Table 7. FDA-approved medications for OUD<sup>147</sup>**

Buprenorphine <ul style="list-style-type: none"> <li>• Buprenorphine/naloxone buccal film (Bunavail)</li> <li>• Buprenorphine/naloxone sublingual film (Suboxone, generics)</li> <li>• Buprenorphine/naloxone sublingual tablets (Zubsolv, generics)</li> <li>• Buprenorphine sublingual tablets (generics)</li> <li>• Buprenorphine subdermal implant (Probuphine)</li> <li>• Buprenorphine extended-release subcutaneous injection (Sublocade)</li> </ul>
Methadone <ul style="list-style-type: none"> <li>• Tablets (Dolophine, MethaDose, generics)</li> <li>• Oral concentrate (MethaDose, generics)</li> </ul>
Naltrexone extended-release injection (Vivitrol)

*“Buprenorphine treatment provides one of the rare opportunities in primary care to see dramatic clinical improvement: it’s hard to imagine a more satisfying clinical experience than helping a patient escape the cycle of active addiction.”*

--Wakeman et al. NEJM 2018;379(1):1-4

### Extended-release naltrexone

Naltrexone is not an opioid. It is a full antagonist of the mu-opioid receptor, which blocks both the euphoric and analgesic effects of all opioids, including endogenous opioids (i.e., endorphins) and also reduces cravings for opioids.<sup>153</sup> Naltrexone does not cause physical dependence, nor does it produce any of the rewarding effects of opioids. Patients may try to use opioids while on extended-release naltrexone, but it is unlikely that they will experience any rewarding effects from such use, unless the binding affinity of naltrexone is overcome.<sup>147</sup> The most common side effects of extended-release naltrexone are injection site pain, nasopharyngitis, insomnia, and toothache.

Treatment initiation requires a 7-10 day period during which the patient is free from all opioids, including methadone and buprenorphine. This is usually achieved with medically supervised withdrawal followed by at least 4 to 7 days without any opioids (including methadone and buprenorphine). This process is a very significant barrier to naltrexone use.<sup>147</sup>

Naltrexone is currently available both as a once-daily oral tablet and in a once monthly, extended-release depot injection. The oral formulation, however, was found to be no better than placebo in a 2011 Cochrane review of 13 trials with 1,158 participants,<sup>159</sup> and only the extended-release formulation has been approved for OUD by the FDA. Patients may have an increased risk of overdose when they approach the end of the 28-day period of the extended-release formulation.<sup>160</sup>

### Naloxone vs. Naltrexone: What’s the difference?

**Naloxone (Narcan)** is an opioid antagonist given by injection or nasal spray to reverse overdoses. It acts within minutes and lasts for only about an hour due to rapid metabolism.

**Naltrexone** has a very similar chemical structure to Naloxone and is also an opioid antagonist, but it acts more slowly and lasts longer. Extended-release naltrexone is used clinically to block cravings for opioids and other drugs.

It may, however, take days to weeks to achieve a therapeutic dose, which requires individualized monitoring in order to minimize cravings and reduce the risk of relapse.

As a full agonist, methadone sustains opioid tolerance and physical dependence, thus missing doses may precipitate opioid withdrawal. Overdose risk is highest in the first two weeks of methadone treatment,<sup>149</sup> after which risk is significantly lower compared to people who are not in treatment.<sup>150,151</sup>

Common side effects of methadone are constipation, vomiting, sweating, dizziness, and sedation. Although respiratory depression can be induced by methadone, the FDA advises that methadone not be withheld from patients taking benzodiazepines or other central nervous system depressants because the risk of overdose is even higher among patients not on methadone for OUD.<sup>152</sup> The other potential harms of methadone include hypogonadism, which is a potential side effect of chronic use of any opioid, and QTc segment prolongation.

### Buprenorphine

Buprenorphine is a high-affinity partial opioid agonist at the mu-opioid receptor as well as an antagonist of the kappa opioid receptor.<sup>153</sup> Like methadone, buprenorphine can relieve opioid withdrawal symptoms, and, because of its partial agonist effect, it can reduce the rewarding effect of other opioids used simultaneously with buprenorphine. Buprenorphine’s partial agonist status also translates into a lower risk of respiratory depression compared to methadone and other opioids,<sup>148</sup> and a therapeutic dose may be achieved within a few days.<sup>155</sup>

Buprenorphine is available as sublingual tablets, sublingual/buccal films, subdermal implants, or extended-release subcutaneous injection (Table 10). Some film and tablet formulations are combined with the opioid antagonist naloxone to discourage misuse by crushing and injecting the medication. (A buprenorphine-only patch [Butrans] is only FDA-approved as an analgesic.)

Some forms of buprenorphine can be self-administered by patients after filling their prescription at regular pharmacies.

In order to prescribe buprenorphine, physicians in the United States must complete an 8-hour training and apply for a waiver (informally called an X-waiver) from the Drug Enforcement Administration (for details see “Obtaining an X-waiver” section below). The Comprehensive Addiction and Recovery Act of 2016 authorized nurse practitioners and physician assistants to be eligible to apply for training and X-waivers, although the associated required training is 24 hours.<sup>156</sup>

As with methadone, buprenorphine sustains opioid tolerance and physical dependence in patients, so discontinuation can lead to withdrawal—although buprenorphine’s withdrawal syndrome may be less severe. The most common side effects are constipation, vomiting, headache, sweating, insomnia, and blurred vision. One risk of buprenorphine (as well as naltrexone) is the risk of precipitating opioid withdrawal at first dose if the patient has recently used either prescription or illicit drugs, due to buprenorphine’s partial-agonist properties high binding affinity for the opioid receptor.<sup>141</sup> Thus, a patient must be in mild to moderate withdrawal prior to initiation to avoid precipitating withdrawal. The risk of opioid overdose declines immediately when patients with OUD initiate buprenorphine treatment.<sup>145</sup> The risk of hypogonadism is lower with buprenorphine compared to methadone, and buprenorphine is not associated with QTc prolongation or cardiac arrhythmias.<sup>157</sup>

The various non-oral routes of buprenorphine avoid the significant hepatic metabolism inherent with oral administration, and appear to be largely equivalent in their efficacy for maintaining abstinence and reducing risk of overdose. For example, a randomized trial comparing buprenorphine implant to sublingual buprenorphine found higher levels of negative urine screens and abstinence with the implant, but the differences did not reach statistical significance.<sup>158</sup> (Note that use of implantable agents require stabilization on sublingual doses first.)

## Does MAT really work?

Abundant evidence from decades of randomized trials, clinical studies, and meta-analyses suggests that agonist or partial-agonist opioid treatment used for an indefinite period of time is the safest option for treating OUD.<sup>147, 155</sup> (The evidence base for extended-release naltrexone is much less robust.)<sup>147</sup>

A small randomized trial and a large cohort study demonstrated that people with OUD treated with methadone or buprenorphine are less likely to die, less likely to overdose, and more likely to remain in treatment.<sup>153, 161</sup> MAT is also associated with lower risks for HIV and other infections, and improved social functioning and quality of life compared to people not on MAT.<sup>30</sup>

Data suggest that MAT is more effective than psychotherapeutic interventions alone, and is just as effective whether psychotherapeutic interventions are used concurrently with medication treatment or not. For example, data from Massachusetts Medicaid beneficiary claims between 2004 and 2010 show significantly lower relapse rates with both buprenorphine and methadone compared to a behavioral health intervention alone.<sup>162</sup>

Although the evidence base for intramuscular naltrexone is less robust than for methadone or buprenorphine, it has been shown to significantly decrease opioid misuse in patients with mild-to-moderate OUD.<sup>147</sup> For example, one trial randomized 250 patients with OUD who completed inpatient detoxification ( $\geq 7$  days off all opioids) to 24 weeks of naltrexone intramuscular injection (380 mg/month) vs. placebo.<sup>163</sup> At follow-up, 90% in the naltrexone group were abstinent compared to 35% in the placebo group.

## Psychosocial treatments

Psychosocial and/or behavioral interventions can be used in combination with medications in order to treat the “whole patient” (e.g., comorbid psychiatric symptoms, social support needs). The National Academy of Sciences, however, notes that

psychosocial services may not be available to all patients and recommends that the lack of such supports should not be a barrier to using MAT.<sup>147</sup>

For example, a 2012 trial randomized 230 adults with OUD to one of three groups: methadone without extra counseling vs. methadone with standard counseling vs. methadone with counseling in the context of smaller caseloads.<sup>164</sup> At one-year follow-up there were no significant differences between the groups in rates of retention in treatment or urine tests positive for opioids. Three other randomized trials comparing buprenorphine with medical management alone vs. buprenorphine plus cognitive behavioral therapy or extra counseling sessions also found no significant differences in key opioid-related outcomes.<sup>165-167</sup>

Nonetheless, psychosocial, behavioral, and peer-support interventions may have many profoundly important benefits for patients beyond strictly opioid-related outcomes, such as improving self-confidence, self-advocacy, general quality of life, and improvements in legal, interpersonal, and occupational functioning.<sup>141</sup> Some guidelines and authors advocate for the use of psychosocial interventions, but suggest that the lack of such interventions at a given place or time should not be a barrier to the use of MAT.<sup>147, 169</sup>

## Tapering protocols

OUD guidelines do not recommend a duration of MAT treatment, which could be for an indefinite period of time because of the high risk of relapse with discontinuation.<sup>147</sup> For example, a population-based retrospective study of 14,602 patients who discontinued methadone treatment found that only 13% had successful outcomes (no treatment re-entry, death, or opioid-related hospitalization) within 18 months of taper.<sup>169</sup>

Nonetheless, some patients may want to stop opioid agonist therapy. An ideal time frame for a trial of MAT tapering has not been established. Tapering should always be at the patient's discretion, and all decisions should be based on a thorough dialogue between patient and provider.

Goals should be framed functionally, for example maintaining employment, avoiding using illicit opioids or other drugs, continuing with social/emotional support programs, etc.

## Misconceptions about OUD Treatment

Stigma and misunderstanding surround the issues of addiction in general and OUD in particular.<sup>147</sup> These include counterproductive ideologies that portray addiction as a failure of will or a moral weakness, as opposed to understanding OUD as a chronic disease of the brain requiring medical management, which is no different, in principle, from the approach used to manage other chronic diseases such as diabetes or hypothyroidism. Some stigma and misunderstanding may arise from a lack of awareness of how treatment of OUD has evolved in the past 15 years.<sup>170</sup> Table 8 summarizes some common misconceptions about OUD treatment.

## Addressing stigma

High levels of stigma persist among some medical professionals and recovery communities toward people with OUD and medications used to treat OUD.<sup>147</sup> A 2016 national opinion survey (n=264) found that 54% of respondents thought people addicted to opioid pain relievers were to blame for their addiction, 46% felt such people are irresponsible, and 45% said they would be unwilling to work closely with such people.<sup>162</sup>

A 2014 survey of 1,010 primary care physicians found similar, or even higher, levels of stigma related to people with OUD.<sup>167</sup> Interviews with patients using methadone for OUD confirm that this group experiences high rates of stigma and discrimination related to their medication use in interactions with the public and with health care professionals,<sup>174</sup> which erodes their psychological well-being and may inhibit them from entering treatment.<sup>147</sup>

**Table 8. Misconceptions vs. realities of OUD treatment<sup>171</sup>**

Misconceptions	Reality
Buprenorphine treatment is more dangerous than other chronic disease management.	Buprenorphine treatment is less risky than many other routine treatments, such as titrating insulin or starting anticoagulation and easier to administer. It is also safer than prescribing many opioids (e.g., oxycodone, morphine).
Using methadone or buprenorphine is simply a “replacement” addiction.	Addiction is compulsive use of a drug despite harm. When taken as prescribed, methadone and buprenorphine improve function, autonomy, and quality of life and patients using these drugs do not meet the definition of addiction.
Detoxification for OUD is effective.	No data show that detoxification programs are effective for OUD, and, in fact, such interventions may increase the risk of overdose death by eliminating tolerance.
Prescribing buprenorphine is time consuming and burdensome.	Buprenorphine treatment can be readily managed in a primary care setting, and in-office induction or intensive behavioral therapy are not required for effective treatment.

Health care professionals can combat stigma by examining their own attitudes and beliefs and by consciously and consistently using neutral, “person-first,” and non-stigmatizing language such as “being in recovery” instead of “being clean” or “person with opioid use disorder” rather than “addict,” “user,” or “drug abuser.”<sup>175</sup>

### **Pregnancy and OUD**

Pregnant women with untreated OUD have up to six times more maternal complications than women without OUD, including low birth weight and fetal distress, while neonatal complications among babies born to mothers with OUD range from neonatal abstinence syndrome and neurobehavioral problems to a 74-fold increase in sudden infant death syndrome.<sup>177</sup>

Both methadone and buprenorphine are recommended for treating OUD in pregnancy to improve outcomes for both mother and newborn.<sup>141</sup> The efficacy and safety of methadone treatment for OUD in pregnant women was established in the 1980s, showing that maternal and neonatal outcomes in women on methadone treatment during pregnancy are similar to women and infants not exposed to methadone.<sup>177</sup> More recent research suggests that buprenorphine treatment has similar, or superior, benefits in this population.<sup>178</sup>

The safety of extended-release naltrexone has not yet been established for pregnant women, and naltrexone is currently not recommended for the treatment of OUD in pregnant women.<sup>147</sup>

Despite this solid evidence base, most pregnant women with OUD do not receive any treatment with medications.<sup>179</sup> Among women who do receive treatment during pregnancy, many fall out of treatment during the post-partum period due to gaps in insurance coverage and other systemic barriers. An integrated approach with close collaboration between OUD treatment providers and prenatal providers has been described as the “gold standard” for care, and further research is needed to investigate interventions that could help to increase treatment retention.<sup>147</sup>

### **Treating acute pain in patients on MAT**

Some physicians may not prescribe effective opioid analgesia for patients with OUD on MAT due to concerns about respiratory depression, overdose, or drug diversion. As a result, this population is at particular risk of under-treatment for acute pain.

Physicians may also mistakenly assume that acute pain is adequately controlled with the long-term opioid agonist (i.e., methadone) or partial agonist (i.e., buprenorphine). Although potent analgesics, methadone and buprenorphine have an

analgesic duration of action (four to eight hours) that is substantially shorter than their suppression of opioid withdrawal (24 to 48 hours).<sup>180</sup>

Non-opioid analgesics (e.g., acetaminophen and NSAIDs) are first-line options for treating acute pain in this population. For moderate-to-severe pain not adequately controlled with non-opioids, however, judicious use of opioid analgesics should be considered. Patients on MAT generally have a high cross-tolerance for analgesia, leading to shorter durations of analgesic effects. Higher opioid doses administered at shorter intervals may thus be necessary. Concomitant opioids can be given for pain to a patient prescribed buprenorphine, but typically hydromorphone or fentanyl may be the most effective due to competitive binding at the opioid receptor.

Since extended-release naltrexone will block the effects of any opioid analgesics, acute pain in such patients (e.g., that associated with dental work, surgery, or traumatic injury) should be treated with regional analgesia, conscious sedation, non-opioid analgesics, or general anesthesia.<sup>30</sup>

### **Palliative Care**

Palliative care is specialized medical care for people with serious illness focused on relieving symptoms and improving quality of life for both the patient and the family. Palliative care involves three key areas: symptom management (e.g., pain, nausea, constipation), supporting patients and their loved ones as they cope with illness and death, and communication and education about the illness through advance care planning (ACP).<sup>181</sup> The field of palliative care emerged from a hospice tradition but in the past decade a more nuanced model of care has been introduced, which integrates palliative care with disease-modifying care across the duration of an illness and includes consideration of those affected by the death of the individual.

Pain control is a central focus of palliative care, but the goal of pain management is not simply the elimination of all pain, it is the control of pain sufficient for a given patient to achieve his or her highest quality of life in the moment.<sup>182</sup> In the palliative care setting, clinicians may need to manage acute pain (e.g., post-surgical or post-treatment pain) or chronic pain or both types of pain simultaneously.

Clinicians can avail themselves of a wide range of pharmacologic and non-pharmacologic approaches for pain management, which should be employed using the following general principles:

- Identify and treat the source of the pain, if possible, although pain treatment can begin before the source of the pain is determined

- Select the simplest approach first. This generally means using non-pharmacologic approaches as much as possible and/or trying medications with the least severe potential side effects, and at the lowest effective doses
- Establish a function-based management plan if treatment is expected to be long-term

A range of non-pharmacological treatments may help patients manage chronic pain, which can be used alone or in combination with pharmacological treatments:

- Physical therapy
- Yoga
- Acupuncture
- Massage
- Transcutaneous electrical nerve stimulation
- Cognitive behavioral therapy
- Mindfulness meditation
- Weight loss

Medications used to treat chronic pain in palliative settings include:

- acetaminophen
- non-steroidal anti-inflammatory drugs (NSAIDs)
- antidepressants
- anticonvulsants
- topical lidocaine or capsaicin
- cannabinoid-based therapies
- opioids

Opioids are classified by the Drug Enforcement Agency according to their presumed abuse and addiction potential, although the evidence base for making these differentiations continues to evolve. Tramadol, for example, is now known to have as much potential for abuse as opioids in more restrictive classes.<sup>171</sup>

### **Managing end-of-life pain**

Although pain relief is often considered—and may sometimes be—an end unto itself, pain management and control of symptoms at the end of life may be more appropriately viewed as means of achieving the more primary goal of improving or maintaining a patient’s overall quality of life. For some patients, mental alertness sufficient to allow maximal interactions with loved ones may be more important than physical comfort. Optimal pain management, in such cases, may mean lower doses of an analgesic and the experience, by the patient, of higher levels of pain.

The end of life is often characterized by a reduced level of consciousness or complete lack of consciousness. This can make assessments of pain very challenging. If a patient is not alert enough to communicate, nonverbal signs or cues must be used to determine if the patient is experiencing pain and to what degree an analgesic approach is effective. Signs of discomfort that are accompanied by more rapid breathing or heart rate should be taken more seriously.

Opioids are often valuable for providing effective analgesia at the end of life, and opioid formulations are available in such variety in the U.S. that, typically, a pain regimen can be tailored to each patient. Because there is great between-patient variability in response to particular opioid agents no specific agent is superior to another as first-line therapy. Opioid-related side effects must be considered in advance of treatment and steps must be taken to minimize these effects to the extent possible, since adverse effects contribute significantly to analgesic nonadherence. This is particularly true for constipation and sedation.

A stimulant, such as methylphenidate or dextroamphetamine, might be added to offset sedative effects, typically starting at a dose of 5 to 10 mg once or twice daily. Other adverse effects, including respiratory depression, are greatly feared and may lead to clinician under-prescribing and reluctance by patients to take the medication, despite the rarity of this event in persons with cancer.<sup>183</sup> Despite this fear, studies have revealed no correlation between opioid dose, timing of opioid administration, and time of death.<sup>184</sup>

A wide range of complementary and alternative therapies (CAT) are commonly used in end-of-life care. CAT interventions are aimed at reducing pain, inducing relaxation, and enhancing a sense of control over the pain or the underlying disease. Breathing exercises, relaxation, imagery, hypnosis, and other behavioral therapies are among the modalities shown to be potentially helpful to patients.<sup>185</sup> Psychosocial interventions for end-of-life pain may include cancer pain education, hypnosis and imagery based methods, and coping skills training. Educational programs are one of the most common interventions to address cancer pain barriers, and current studies provide high-quality evidence that pain education is feasible, cost-effective, and practical in end-of-life settings.<sup>186</sup>

## Conclusions

Managing pain is particularly challenging in an era when society is grappling with an epidemic of opioid misuse and overdose. This learning activity has reviewed an evidence-based path forward,

based on a biopsychosocial model of pain, and an emphasis on holistic assessment, individualized treatment planning, and multi-modal therapeutic approaches.

Physicians and caregivers need to base pain treatment plans on realistic functional goals and the level of pain management needed to reach those goals using a shared decision-making approach. As detailed in this activity, chronic pain syndromes respond differently to available pharmacologic and non-pharmacologic treatments, but, in general, non-drug options (which can be as effective as drug options) should be tried first when possible. When drug options are considered, it is important to maximize non-opioid options before prescribing opioids. For selected patients requiring opioids, the risk of long-term opioid treatment should be minimized through patient education, screening of high-risk patients for OUD, continuous monitoring, use of alternative non-opioid options, and careful tapering when appropriate.

Since much acute pain is self-limiting and remits with healing (typically within a month), helping patients frame expectations about acute pain and pain relief can provide reassurance and reduce fear, worry, and distress. Multimodal approaches should be used to manage acute pain, combining non-drug (e.g. interventional procedures, physical rehabilitation, and psychological support) as well as appropriate drug-based options. Opioid analgesics should be reserved for severe pain that does not respond to all other approaches, and then should be used at the lowest doses, and shortest durations, appropriate for the pain intensity expected with the precipitating event.

This activity has laid out the evidence supporting these conclusions and provides the basis for improved treatment and reduced risk, both for patients and society at large.

For Utah specific policies and information, please review the Utah Special Designation Materials and Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain at the end of this course.

## References

- Centers for Disease Control & Prevention. Prescription Painkiller Overdoses in the US. Vital Signs. 2011.
- Centers for Disease Control & Prevention. Understanding the epidemic. <https://www.cdc.gov/drugoverdose/epidemic/index.html>. Published 2019. Accessed April 1 2019.
- Centers for Disease Control & Prevention. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. *MMWR Morbidity and mortality weekly report*. 2011;60(43):1487-1492.
- Centers for Disease Control & Prevention. Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. [https://emergency.cdc.gov/han/2020/han00438.asp?ACSTrackingID=USCDC\\_511-DM44961&ACSTrackingLabel=HAN%20438%20-%20General%20Public&deliveryName=USCDC\\_511-DM44961](https://emergency.cdc.gov/han/2020/han00438.asp?ACSTrackingID=USCDC_511-DM44961&ACSTrackingLabel=HAN%20438%20-%20General%20Public&deliveryName=USCDC_511-DM44961). Accessed December 28, 2020.

- Centers for Disease Control & Prevention. 12 Month-ending provisional number of drug overdose deaths. <https://www.cdc.gov/nchs/hvss/vsrr/drug-overdose-data.htm>. Accessed December 28, 2020.
- Centers for Disease Control & Prevention. Opioid overdose: Understanding the Epidemic. <https://www.cdc.gov/drugoverdose/images/3-waves-2019.PNG>. Published 2021. Accessed June 10, 2021.
- Banta-Green CJ, Merrill JO, Doyle SR, Boudreau DM, Calsyn DA. Opioid use behaviors, mental health and pain—development of a typology of chronic pain patients. *Drug and alcohol dependence*. 2009;104(1-2):34-42.
- Boscarino JA, Rukstalis MR, Hoffman SN, et al. Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 vs. DSM-4 diagnostic criteria. *Journal of addictive diseases*. 2011;30(3):185-194.
- Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. *J Pain*. 2007;8(7):573-582.
- Centers for Disease Control & Prevention. 2018 Annual Surveillance Report of Drug-Related Risks and Outcomes—United States Surveillance Special Report 2. August 31 2018.
- Muhuri PK, Gfroerer JC, Davies MC. Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States. *SAMHSA*; August 2013.
- Busse JW, Wang L, Kamaleldin M, et al. Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis. *Jama*. 2018;320(23):2448-2460.
- Krebs EE, Gravely A, Nugent S, et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. *Jama*. 2018;319(9):872-882.
- Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. *Pain*. 1988;33(1):11-23.
- Covington EC. Anticonvulsants for neuropathic pain and detoxification. *Cleveland Clinic journal of medicine*. 1998;65 Suppl 1:S121-29.
- U.S. Department of Health and Human Services. Pain Management Best Practices Inter-Agency Task Force Report: Updates, Gaps, Inconsistencies, and Recommendations. <https://www.hhs.gov/ash/advisory-committees/pain/reports/index.html>. Published 2019. Accessed June 10 2019.
- Wells N, Pasero C, McCaffery M. Improving the Quality of Care Through Pain Assessment and Management. In: Hughes RG, ed. *Patient Safety and Quality: An Evidence-Based Handbook for Nurses*. Rockville (MD) 2008.
- Goodwin J, Bajwa ZH. Understanding the patient with chronic pain. In *Principles and Practice of Pain Medicine* 2nd ed. New York, NY: McGraw-Hill Companies, Inc.; 2004.
- Gordon DB, Dahl JL, Miasowski C, et al. American pain society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. *Archives of internal medicine*. 2005;165(14):1574-1580.
- Olsen MF, Bjerre E, Hansen MD, Tendal B, Hilden J, Hrobjartsson A. Minimum clinically important differences in chronic pain vary considerably by baseline pain and methodological factors: systematic review of empirical studies. *J Clin Epidemiol*. 2018;101:87-106 e102.
- Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. *The Clinical journal of pain*. 2004;20(5):309-318.
- Krebs EE, Lorenz KA, Bair MJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. *Journal of general internal medicine*. 2009;24(6):733-738.
- Krebs EE, Carey TS, Weinberger M. Accuracy of the pain numeric rating scale as a screening test in primary care. *Journal of general internal medicine*. 2007;22(10):1453-1458.
- Bjoro K, Herr K. Assessment of pain in the nonverbal or cognitively impaired older adult. *Clinics in geriatric medicine*. 2008;24(2):237-262.
- Schug SA, Bruce J. Risk stratification for the development of chronic postsurgical pain. *Pain Rep*. 2017;2(6):e627.

26. Traeger AC, Henschke N, Hubscher M, et al. Estimating the Risk of Chronic Pain: Development and Validation of a Prognostic Model (PICKUP) for Patients with Acute Low Back Pain. *PLoS Med.* 2016;13(5):e1002019.
27. Sipilä R, Estlander AM, Tasmuth T, Kataja M, Kalso E. Development of a screening instrument for risk factors of persistent pain after breast cancer surgery. *Br J Cancer.* 2012;107(9):1459-1466.
28. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *J Pain.* 2009;10(2):113-130.
29. Babor TF, McRee BG, Kassebaum PA, Grimaldi PL, Ahmed K, Bray J. Screening, Brief Intervention, and Referral to Treatment (SBIRT): toward a public health approach to the management of substance abuse. *Subst Abus.* 2007;28(3):7-30.
30. Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder Treatment Improvement Protocol 63. HHS Publication No SMA 18-5063FULLDOC. 2018.
31. Centers for Disease Control & Prevention. CDC guideline for prescribing opioids for chronic pain—United States, 2016. *MMWR Recommendations and Reports.* 2016;65(1):16.
32. Hauswirth B. Blunt calls for Missouri PDMP bill. <https://www.missourinet.com/2019/04/17/blunt-calls-for-missouri-pdmp-bill-emphasizes-importance-of-broadband/>. Published 2019. Accessed April 24 2019.
33. Federation of State Medical Boards. Prescription Drug Monitoring Programs State-by-state overview. <http://www.fsmb.org/siteassets/advocacy/key-issues/prescription-drug-monitoring-programs-by-state.pdf>. Published 2019. Accessed April 24 2019.
34. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. *MMWR Recomm Rep.* 2016;65(1):1-49.
35. Peppin JF, Passik SD, Couto JE, et al. Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain. *Pain medicine.* 2012;13(7):886-896.
36. Christo PJ, Manchikanti L, Ruan X, et al. Urine drug testing in chronic pain. *Pain physician.* 2011;14(2):123-143.
37. Food and Drug Administration. Opioid analgesic risk evaluation and mitigation strategy (REMS). <https://www.fda.gov/drugs/information-drug-class/opioid-analgesic-risk-evaluation-and-mitigation-strategy-rems>. Published 2018. Accessed June 10 2019.
38. Fransen M, McConnell S, Harmer AR, Van der Esch M, Simic M, Bennell KL. Exercise for osteoarthritis of the knee. *The Cochrane database of systematic reviews.* 2015;9(1).
39. Kang JW, Lee MS, Posadzki P, Ernst E. T'ai chi for the treatment of osteoarthritis: a systematic review and meta-analysis. *BMJ Open.* 2011;1(1):2010-000035.
40. Sherman KI, Cherkin DC, Weliman RD, et al. A randomized trial comparing yoga, stretching, and a self-care book for chronic low back pain. *Archives of internal medicine.* 2011;171(22):2019-2026.
41. Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. *Jama.* 2013;310(12):1263-1273.
42. Hinman RS, McCrory P, Pirota M, et al. Acupuncture for chronic knee pain: a randomized clinical trial. *Jama.* 2014;312(13):1313-1322.
43. Perlman AI, Sabina A, Williams AL, Njike VY, Katz DL. Massage therapy for osteoarthritis of the knee: a randomized controlled trial. *Archives of internal medicine.* 2006;166(22):2533-2538.
44. Reid MC, Eccleston C, Pillemer K. Management of chronic pain in older adults. *Bmj.* 2015;13(350).
45. Morley S, Eccleston C, Williams A. Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. *Pain.* 1999;80(1-2):1-13.
46. Hilton L, Hempel S, Ewing BA, et al. Mindfulness Meditation for Chronic Pain: Systematic Review and Meta-analysis. *Ann Behav Med.* 2017;51(2):199-213.
47. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. *J Am Geriatr Soc.* 2009;57:1331-46.
48. Lee WM. Acetaminophen (APAP) hepatotoxicity-Isn't it time for APAP to go away? *J Hepatol.* 2017;20(17):32148-32147.
49. Hawkey CJ, Svedberg LE, Naesdal J, Byrne C. Esomeprazole for the management of upper gastrointestinal symptoms in patients who require NSAIDs: a review of the NASA and SPACE double-blind, placebo-controlled studies. *Clinical drug investigation.* 2009;29(10):677-687.
50. Desai JC, Sanyal SM, Goo T, et al. Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study. *Digestive diseases and sciences.* 2008;53(8):2059-2065.
51. Food and Drug Administration. FDA Briefing Document: Joint meeting of the arthritis advisory committee and the drug safety and risk management advisory committee April 24 and 25 2018. 2018.
52. Brown T. CV safety of celecoxib similar to naproxen, ibuprofen, FDA panels say. *Medscape.* <https://www.medscape.com/viewarticle/895722>. Published 2018. Accessed April 19 2019.
53. Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. *The Cochrane database of systematic reviews.* 2017;1:CD007393.
54. ProCon.org. 36 legal medical marijuana states and DC. [https://medicalmarijuana.procon.org/view\\_resource.php?resourceID=000881](https://medicalmarijuana.procon.org/view_resource.php?resourceID=000881). Accessed February 1, 2021.
55. Rahn EL, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. *J Pharmacol Exp Ther.* 2008;327(2):584-591.
56. National Academies of Science. In: *The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research.* Washington (DC) 2017.
57. Mucke M, Phillips T, Radbruch L, Petzke F, Hauser W. Cannabis-based medicines for chronic neuropathic pain in adults. *The Cochrane database of systematic reviews.* 2018;3:CD012182.
58. Kraft B, Frickey NA, Kaufmann RM, et al. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. *Anesthesiology.* 2008;109(1):101-110.
59. Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. *Anesthesiology.* 2007;107(5):785-796.
60. Hill KP, Palastro MD, Johnson B, Ditte JW. Cannabis and Pain: A Clinical Review. *Cannabis Cannabinoid Res.* 2017;2(1):96-104.
61. Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. *Pain.* 2018;159(10):1932-1954.
62. Hill KP. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. *Jama.* 2015;313(24):2474-2483.
63. Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. *JAMA Intern Med.* 2014;174(10):1668-1673.
64. Shover CL et al. *Proc Natl Acad Sci USA.* 2019;116:12624-12626
65. Narang S, Gibson D, Wasan AD, et al. Efficacy of dronabinol as an adjunct treatment for chronic pain patients on opioid therapy. *J Pain.* 2008;9(3):254-264.
66. Walitt B, Klose P, Fitzcharles MA, Phillips T, Hauser W. Cannabinoids for fibromyalgia. *The Cochrane database of systematic reviews.* 2016;18(7).
67. Adel Y, Alexander SPH. Neuromolecular mechanisms of cannabis action. *Adv Exp Med Biol.* 2021;1264:15-28.
68. Schwenk ES, Viscusi ER, Buvanendran A, et al. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. *Regional anesthesia and pain medicine.* 2018;43(5):456-466.
69. Bruhl S. Complex regional pain syndrome. *BMJ.* 2015;351:h2730.
70. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. *Pain physician.* 2008;11(2 Suppl):S133-153.
71. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2017 National Survey on Drug Use and Health HHS Publication No SMA 18-5068, NSDUH Series H-53. 2018.
72. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. *The Clinical journal of pain.* 2008;24(6):479-496.
73. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. *Anesthesiology.* 2006;104(3):570-587.
74. Ruta NS, Ballas SK. The opioid epidemic and sickle cell disease: Guilt by association. *Pain Medicine* 2016; 17: 1793–1798.
75. Brandow AM, Carroll CP, Creary S, Edwards-Elliott R, Glassberg J, Hurley RW, Kutlar A, Seisa M, Stinson J, Strouse JJ, Yusuf F, Zempysky W, Lang E. American Society of Hematology 2020 guidelines for sickle cell disease management of acute and chronic pain. *Blood Adv.* 2020;48:241-248.
76. Carroll CP. Opioid treatment for acute and chronic pain in patients with sickle cell disease. *Neurosci Lett.* 2020; Jan 1;714:134534. doi: 10.1016/j.neulet.2019.
77. Pedersen L, Borchgreving PC, Breivik HP, Fredheim OM. A randomized, double-blind, double-dummy comparison of short- and long-acting dihydrocodeine in chronic non-malignant pain. *Pain.* 2014;155(5):881-888.
78. FDA blueprint for prescriber education for extended-release and long-acting opioid analgesics. In: Administration FaD, ed. Silver Springs, MD: US Department of Health and Human Services; 2017.
79. Food and Drug Administration. Extended-release and long-acting opioid analgesics shared system. <http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM348818.pdf>. Published 2015. Accessed.
80. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin.
81. Chronis Manolis CBG, and William Shrank. Mandating Coverage Of Abuse-Deterrent Opioids Would Be A Costly Distraction From More Effective Solutions. In. *Health Affairs* 2017.
82. Malonne H, Coffiner M, Sonet B, Sereno A, Vanderbist F. Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study. *Clinical therapeutics.* 2004;26(11):1774-1782.
83. Pharmacological management of persistent pain in older persons. *J Am Geriatr Soc.* 2009;57(8):1331-1346.
84. Zeng C, Dubreuil M, LaRochelle MR, et al. Association of Tramadol With All-Cause Mortality Among Patients With Osteoarthritis. *Jama.* 2019;321(10):969-982.
85. Drug Enforcement Administration. Tramadol information. Diversion Control Division, Drug & Chemical Evaluation Section. 2018.
86. Santos J, Alarcao J, Fareleira F, Vaz-Carneiro A, Costa J. Tapentadol for chronic musculoskeletal pain in adults. *The Cochrane database of systematic reviews.* 2015(5):CD009923.
87. Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health. *Annals of internal medicine.* 2017;167(5):293-301.
88. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. *Annals of internal medicine.* 2010;152(2):85-92.
89. Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. *Drug and alcohol dependence.* 2012;125(1-2):8-18.
90. Tuteja AK, Biskupiak J, Stoddard GI, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. *Neurogastroenterol Motil.* 2010;22(4):424-430.

91. Hale M, Wild J, Reddy J, Yamada T, Arjona Ferreira JC. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials. *Lancet Gastroenterol Hepatol*. 2017;2(8):555-564.
92. Miller M, Sturmer T, Azrael D, Levin R, Solomon DH. Opioid analgesics and the risk of fractures in older adults with arthritis. *J Am Geriatr Soc*. 2011;59(3):430-438.
93. Dublin S, Walker RL, Jackson ML, et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study. *J Am Geriatr Soc*. 2011;59(10):1899-1907.
94. Li L, Setoguchi S, Cabral H, Jick S. Opioid use for noncancer pain and risk of myocardial infarction amongst adults. *Journal of internal medicine*. 2013;273(5):511-526.
95. Deyo RA, Smith DH, Johnson ES, et al. Prescription opioids for back pain and use of medications for erectile dysfunction. *Spine*. 1976;38(11):909-915.
96. Review. IfCaE. Abuse Deterrent Formulations of Opioids: Effectiveness and Value Final Evidence Report. 2017.
97. Lee TH. Zero Pain Is Not the Goal. *Jama*. 2016;315(15):1575-1577.
98. Brummett CM, Waljee JF, Goesling J, et al. New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. *JAMA Surg*. 2017;152(6):e170504.
99. Calcaterra SL, Yamashita TE, Min SJ, Keniston A, Frank JW, Binswanger IA. Opioid Prescribing at Hospital Discharge Contributes to Chronic Opioid Use. *Journal of general internal medicine*. 2016;31(5):478-485.
100. Bateman BT, Franklin JM, Bykov K, et al. Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naïve women. *Am J Obstet Gynecol*. 2016;215(3):353 e351-353 e318.
101. Johnson SP, Chung KC, Zhong L, et al. Risk of Prolonged Opioid Use Among Opioid-Naïve Patients Following Common Hand Surgery Procedures. *The Journal of hand surgery*. 2016;41(10):947-957 e943.
102. Brat GA, Agniel D, Beam A, et al. Postsurgical prescriptions for opioid naïve patients and association with overdose and misuse: retrospective cohort study. *BMJ*. 2018;360:j5790.
103. Hall MJ, Schwartzman A, Zhang J, Liu X. Ambulatory Surgery Data From Hospitals and Ambulatory Surgery Centers: United States, 2010. *Natl Health Stat Report*. 2017(102):1-15.
104. Fishman SM. Responsible Opioid Prescribing: A Clinician's Guide, 2nd Ed. Washington, DC: Waterford Life Sciences; 2012.
105. Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. *British journal of anaesthesia*. 1997;78(5):606-617.
106. American Pain Society. Management of acute pain and chronic noncancer pain. <http://americanpainsociety.org/education/enduring-materials>. Accessed October 29 2018.
107. Fognier BK, Harwood K, Andrilla CHA, Schwartz M, Pines JM. Physical Therapy as the First Point of Care to Treat Low Back Pain: An Instrumental Variables Approach to Estimate Impact on Opioid Prescription, Health Care Utilization, and Costs. *Health Serv Res*. 2018;53(6):4629-4646.
108. Centers for Disease Control & Prevention. Module 2: Treating Pain Without Opioids. Course number WB2859. <https://www.cdc.gov/drugoverdose/training/nonopioid/508c/index.html>. Published 2018. Accessed February 10, 2019.
109. American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. *J Am Geriatr Soc*. 2012;60(4):616-631.
110. Food and Drug Administration. Don't double up on acetaminophen. <https://www.fda.gov/consumers/consumer-updates/dont-double-acetaminophen>. Published 2018. Accessed July 12 2019.
111. Paice JA, Ferrans CE, Lashley FR, Shott S, Vizgirda V, Pitrak D. Topical capsaicin in the management of HIV-associated peripheral neuropathy. *J Pain Symptom Manage*. 2000;19(1):45-52.
112. Low PA, Opfer-Gehrking TL, Dyck PJ, Litchy WJ, O'Brien PC. Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. *Pain*. 1995;62(2):163-168.
113. Macintyre PE, Ready LB. Acute Pain Management: A Practical Guide, 2nd Ed. London: Saunders; 2003.
114. Goodman CW, Brett AS. Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern? *N Engl J Med*. 2017;377(5):411-414.
115. Mathieson S, Maher CG, McLachlan AJ, et al. Trial of Pregabalin for Acute and Chronic Sciatica. *N Engl J Med*. 2017;376(12):1111-1120.
116. Blendon RJ, Benson JM. The Public and the Opioid-Abuse Epidemic. *N Engl J Med*. 2018;378(5):407-411.
117. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. *Pain*. 2015;156(4):569-576.
118. Wu CL, Raja SN. Treatment of acute postoperative pain. *Lancet*. 2011;377(9784):2215-2225.
119. Chang AK, Bijur PE, Esses D, Barnaby DP, Baer J. Effect of a Single Dose of Oral Opioid and Nonopioid Analgesics on Acute Extremity Pain in the Emergency Department: A Randomized Clinical Trial. *Jama*. 2017;318(17):1661-1667.
120. Poonai N, Datoo N, Ali S, et al. Oral morphine versus ibuprofen administered at home for postoperative orthopedic pain in children: a randomized controlled trial. *CMAJ*. 2017;189(40):E1252-E1258.
121. Hunold KM, Esserman DA, Isaacs CG, et al. Side effects from oral opioids in older adults during the first week of treatment for acute musculoskeletal pain. *Acad Emerg Med*. 2013;20(9):872-879.
122. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. *Archives of internal medicine*. 2010;170(22):1968-1976.
123. Gil JA, Gunaseelan V, DeFroda SF, Brummett CM, Bedi A, Waljee JF. Risk of Prolonged Opioid Use Among Opioid-Naïve Patients After Common Shoulder Arthroscopy Procedures. *Am J Sports Med*. 2019;47(5):1043-1050.
124. Miller M, Barber CW, Leatherman S, et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. *JAMA internal medicine*. 2015;175(4):608-615.
125. Kim N, Matzon JL, Abboudi J, et al. A Prospective Evaluation of Opioid Utilization After Upper-Extremity Surgical Procedures: Identifying Consumption Patterns and Determining Prescribing Guidelines. *J Bone Joint Surg Am*. 2016;98(20):e89.
126. Michigan Opioid Prescribing Engagement Network. Opioid prescribing recommendations for surgery. <https://opioidprescribing.info/>. Published 2019. Accessed May 1 2019.
127. Kroenke K, Bair MJ, Damush TM, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. *Jama*. 2009;301(20):2099-2110.
128. Payne R, Anderson E, Arnold R, et al. A rose by any other name: pain contracts/agreements. *The American journal of bioethics* : AJOB. 2010;10(11):5-12.
129. Roskos SE, Keenum AJ, Newman LM, Wallace LS. Literacy demands and formatting characteristics of opioid contracts in chronic nonmalignant pain management. *J Pain*. 2007;8(10):753-758.
130. Fishman SM, Mahajan G, Wiley B. Author response to: The trilateral opioid contract: bridging the pain clinic and the primary care physician through the opioid contract. *J Pain Symptom Manage*. 2003;25(5):403.
131. Chu J, Farmer B, Ginsburg B, et al. New York City emergency department discharge opioid prescribing guidelines. <https://www1.nyc.gov/site/doh/providers/health-topics/opioid-prescribing-resources-for-emergency-departments.page>. Published 2013. Accessed November 9 2018.
132. Cheng D, Majlesi N. Clinical practice statement: emergency department opioid prescribing guidelines for the treatment of noncancer related pain. Milwaukee, WI: American Academy of Emergency Medicine; 2013.
133. Thorson D, Biewen P, Bonte B, et al. Acute pain assessment and opioid prescribing protocol. Institute for Clinical Systems Improvement. <https://www.icsi.org>. Published 2014. Accessed November 9 2018.
134. Paone D, Dowell D, Heller D. Preventing misuse of prescription opioid drugs. *City Health Information*. 2011;30:23-30.
135. Cantrill SV, Brown MD, Carlisle RI, et al. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. *Annals of emergency medicine*. 2012;60(4):499-525.
136. Washington State Agency Medical Directors Group. Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain. 2010.
137. Webster LR, Dove B. Avoiding opioid abuse while managing pain. North Branch, MN: Sunrise River Press; 2007.
138. Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. *J Pain Symptom Manage*. 2009;38(3):426-439.
139. Rudd RA, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015. *MMWR Morbidity and mortality weekly report*. 2016;65(5051):1445-1452.
140. VA/DoD. The management of opioid therapy for chronic pain working group. VA/DoD clinical practice guidelines for the management of opioid therapy for chronic pain. 2003(contract number: V101 (93)).
141. Food and Drug Administration. FDA approves first generic naloxone nasal spray to treat opioid overdose. *FDA News Release*. April 19 2019.
142. Frank JW, Lovejoy TI, Becker WC, et al. Patient Outcomes in Dose Reduction or Discontinuation of Long-Term Opioid Therapy: A Systematic Review. *Annals of internal medicine*. 2017;167(3):181-191.
143. Berna C, Kulich RJ, Rathmell JP. Tapering Long-term Opioid Therapy in Chronic Noncancer Pain: Evidence and Recommendations for Everyday Practice. *Mayo Clin Proc*. 2015;90(6):828-842.
144. Food and Drug Administration. FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering. <https://www.fda.gov/Drugs/DrugSafety/ucm635038.htm>. Published 2019. Accessed April 19 2019.
145. American Psychiatric Association. DSM-5, Diagnostic and Statistical Manual of Mental Disorders: Fifth ed. Washington DC: American Psychiatric Association; 2013.
146. Wu LT, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. *Drug and alcohol dependence*. 2016;169:117-127.
147. National Academies of Sciences Engineering and Medicine. Medications for opioid use disorder save lives. The National Academies Press. 2019;doi: <https://doi.org/10.17226/25310>.
148. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. *Ann N Y Acad Sci*. 2000;909:186-216.
149. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. *Drug and alcohol dependence*. 2009;105(1-2):9-15.
150. Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. *Addiction*. 2011;106(1):32-51.
151. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. *BMJ*. 2017;357:j1550.
152. Food and Drug Administration. FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants. [www.fda.gov/Drugs/DrugSafety/ucm575307.htm](http://www.fda.gov/Drugs/DrugSafety/ucm575307.htm). Published 2017. Accessed May 15 2019.
153. Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. *Dialogues Clin Neurosci*. 2007;9(4):455-470.
154. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. *British journal of anaesthesia*. 2006;96(5):627-632.
155. Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. *Harv Rev Psychiatry*. 2015;23(2):63-75.

156. American Society of Addiction Medicine. Buprenorphine Waiver Management. <https://www.asam.org/resources/practice-resources/buprenorphine-waiver-management#NPPA>. Published 2019. Accessed May 15 2019.
157. Fareed A, Patil D, Scheinberg K, et al. Comparison of QTC interval prolongation for patients in methadone versus buprenorphine maintenance treatment: a 5-year follow-up. *Journal of addictive diseases*. 2013;32(3):244-251.
158. Rosenthal RN, Lofwall MR, Kim S, et al. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial. *Jama*. 2016;316(3):282-290.
159. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. *The Cochrane database of systematic reviews*. 2011(4):CD001333.
160. Binswanger IA, Glanz JM. Potential Risk Window for Opioid Overdose Related to Treatment with Extended-Release Injectable Naltrexone. *Drug Saf*. 2018;41(10):979-980.
161. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. *Lancet*. 2003;361(9358):662-668.
162. Clark RE, Baxter JD, Awah G, O'Connell E, Fisher WH, Barton BA. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History. *J Subst Abuse Treat*. 2015;57:75-80.
163. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. *Lancet*. 2011;377(9776):1506-1513.
164. Schwartz RP, Kelly SM, O'Grady KE, Gandhi D, Jaffe JH. Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings. *Addiction*. 2012;107(5):943-952.
165. Fiellin DA, Barry DT, Sullivan LE, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. *The American journal of medicine*. 2013;126(1):74 e11-77.
166. Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J. Comparison of behavioral treatment conditions in buprenorphine maintenance. *Addiction*. 2013;108(10):1788-1798.
167. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. *Arch Gen Psychiatry*. 2011;68(12):1238-1246.
168. Schwartz RP. When Added to Opioid Agonist Treatment, Psychosocial Interventions do not Further Reduce the Use of Illicit Opioids: A Comment on Dugosh et al. *Journal of addiction medicine*. 2016;10(4):283-285.
169. Nosyk B, Sun H, Evans E, et al. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. *Addiction*. 2012;107(9):1621-1629.
170. Substance Abuse and Mental Health Services Administration. Buprenorphine. <https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine>. Published 2019. Accessed May 15 2019.
171. Wakeman SE, Barnett ML. Primary Care and the Opioid-Overdose Crisis - Buprenorphine Myths and Realities. *N Engl J Med*. 2018;379(1):1-4.
172. Kennedy-Hendricks A, McGinty EE, Barry CL. Effects of Competing Narratives on Public Perceptions of Opioid Pain Reliever Addiction during Pregnancy. *J Health Polit Policy Law*. 2016;41(5):873-916.
173. Kennedy-Hendricks A, Busch SH, McGinty EE, et al. Primary care physicians' perspectives on the prescription opioid epidemic. *Drug and alcohol dependence*. 2016;165:61-70.
174. Woo J, Bhalerao A, Bawor M, et al. "Don't Judge a Book Its Cover": A Qualitative Study of Methadone Patients' Experiences of Stigma. *Subst Abuse*. 2017;11:1178221816685087
175. Words matter handout. [https://d14rmgtwzf5a.cloudfront.net/sites/default/files/words\\_matter\\_handout.pdf](https://d14rmgtwzf5a.cloudfront.net/sites/default/files/words_matter_handout.pdf). Accessed May 16 2019.
176. Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. *The Cochrane database of systematic reviews*. 2013(12):CD006318.
177. Kaltenbach K, Finnegan LP. Developmental outcome of children born to methadone maintained women: a review of longitudinal studies. *Neurobehav Toxicol Teratol*. 1984;6(4):271-275.
178. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. *N Engl J Med*. 2010;363(24):2320-2331.
179. Metz VE, Brown QL, Martins SS, Palamar JJ. Characteristics of drug use among pregnant women in the United States: Opioid and non-opioid illegal drug use. *Drug and alcohol dependence*. 2018;183:261-266.
180. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. *Annals of internal medicine*. 2006;144(2):127-134.
181. Jacobsen J, Jackson V, Dahlin C, et al. Components of early outpatient palliative care consultation in patients with metastatic nonsmall cell lung cancer. *J Palliat Med*. 2011;14(4):459-464.
182. Forrow L, Smith HS. Pain management in end of life: palliative care. In: Warfield CA BZ, ed. *Principles & Practice of Pain Medicine*. 2nd ed. New York, NY: McGraw-Hill; 2004.
183. Morita T, Tsunoda J, Inoue S, Chihara S. Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. *J Pain Symptom Manage*. 2001;21(4):282-289.
184. Sykes N, Thorns A. The use of opioids and sedatives at the end of life. *The Lancet Oncology*. 2003;4(5):312-318.
185. Paice JA, Ferrell B. The management of cancer pain. *CA Cancer J Clin*. 2011;61(3):157-182.
186. Keefe FJ, Abernethy AP, L CC. Psychological approaches to understanding and treating disease-related pain. *Annu Rev Psychol*. 2005;56:601-630.



## Utah Special Designation Materials

### A. Scope of the controlled substance abuse problem in Utah and the nation

Drug poisoning deaths are the leading cause of injury in Utah, outpacing firearms, falls, and motor vehicle crashes.<sup>1</sup> Every week, 10 Utah adults die from drug overdose, eight of which are from opioids, of which four are due specifically to prescription opioids.<sup>1</sup> (Opioid-related deaths include prescription opioids, synthetic opioids other than methadone [principally illicit fentanyl], and heroin).<sup>2</sup> In the year 2020, it was determined that 82.2% of drug poisoning deaths were unintentional, compared to 14.1% self-inflicted, and 5.5% undetermined.<sup>1</sup>

As mentioned above, prescription opioids accounted for 41% of the state's unintentional and undetermined deaths due to drug poisoning between the years of 2000-2020.<sup>1</sup> The number of prescriptions for opioid medications increased 5-fold in Utah between the years of 1997-2002, leading to establishment of programs to reduce harm and death by the Utah Department of Health. In 2009, The Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain was published and provides comprehensive recommendations for safe prescribing and use of opioid medications.<sup>2</sup>

### B. National and Utah specific resources available to prescribers to assist in appropriate controlled substance and opioid prescribing

#### National resources:

- The clinical assessment and decision-making tools found in the guidelines can be downloaded and printed here: <http://www.health.utah.gov/prescription/guidelines.html>
- Centers for Disease Control and Prevention (CDC) has provided a checklist for prescribing opioids for chronic pain: <http://stacks.cdc.gov/view/cdc/38025>
- Opioid Basics contains information for patients: <https://www.cdc.gov/opioids/patients/index.html>
- Understanding the Epidemic: <https://www.cdc.gov/drugoverdose/epidemic/index.html>

#### Utah resources:

- The prescription drug monitoring program in Utah is called the Controlled Substance Database and can be found here: <https://dopl.utah.gov/csd/index.html>. Controlled substance prescribing and dispensing are tracked here, and may be accessed by healthcare providers' for information on individuals' prescription drug use.<sup>3</sup>
- Utah-specific tools and tamper-resistant requirements for prescriptions can be found here: <http://www.health.utah.gov/prescription/tools.html>

- The Talk to Your Pharmacist outreach program encourages pharmacists to start a conversation with patients who have been prescribed an opioid and can be found here: [https://cdn.ymaws.com/www.upha.com/resource/resmgr/Talk\\_To\\_Your\\_Pharmacist\\_Tool.pdf](https://cdn.ymaws.com/www.upha.com/resource/resmgr/Talk_To_Your_Pharmacist_Tool.pdf)
- The Know your Script campaign (<https://knowyourscrip.org>) is designed to prevent and reduce the misuse and abuse of prescription pain medications in Utah by providing information and strategies regarding safe use, safe storage, and safe disposal.
- The Utah Department of Health-developed "Stop the Opioid Epidemic" website (<https://www.opioid.org/>), a public education campaign for Utah residents, includes signs and symptoms of an opioid overdose, a list of common opioids, and a directory of support groups and rehabilitation centers.
- Drug Take-Back events are held twice a year through partnerships with the Utah Attorney General's office and other state and national bodies. The "Utah Take Back" website (<https://attorneygeneral.utah.gov/tag/utah-take-back/>) provides general information about substance abuse and event locations.

### C. Patient record documentation for controlled substance and opioid prescribing

Utah guidelines recommend the Pain Assessment and Documentation Tool to set and monitor treatment goals.<sup>2</sup>

A detailed patient medical record should be completed on initial assessment and maintained at every subsequent clinical visit. It should include:<sup>4</sup>

- History of present illness including information regarding current and past treatments.
- Characteristics and intensity of pain.
- Medical, social, and psychiatric history, and review of systems.
- Results of physical exam, diagnostic, and imaging tests.
- Risk assessment for substance use disorder: may utilize screening instrument.
- Rationale for opioid treatment.
- Signed copies of the treatment agreement and informed consent.
- Description of and response to all treatments provided (date, type, dose, quantity).
- Prescription of naloxone provided and rationale.
- All prescription orders for opioids and other controlled substances.
- Instructions to patient, including addressing nonadherence and ongoing discussions of risks vs. benefits with the patient and significant others.
- Assessments of progress toward achieving therapeutic goals.
- Notes on consultations with specialists.

- Presence of adverse events and how addressed.
- Adherence to prescribed therapies, including results of urine drug tests and prescription database checks.
- Notes on continuing, revising, or terminating treatment.
- Authorization for release of information to other treatment providers.

The informed consent form typically includes information about the:<sup>2</sup>

- Prescriber's policies and expectations.
- Likelihood of tolerance developing.
- Possible drug interactions.
- Limited evidence of the benefit of long-term opioid therapy.
- Specific reasons for adapting or discontinuing opioid therapy.
- That patients should not expect complete relief of pain, and improved function is the main criterion for continuing opioid treatment.

Recommendations of what an opioid treatment agreement should contain include patient agreement to:<sup>2</sup>

- Take medications as prescribed.
- Have regular office visits.
- Refrain from use of mood-modifying drugs that have not been prescribed.
- Participate in assessments of other recommended pain treatment programs.
- Help self in progress toward treatment goals with healthy habits (e.g., smoking cessation, weight control, exercise).

### D. Office policies, procedures, and implementation

#### Initiating opioid trial:

Before issuing an initial opioid prescription (including no opioid in the past year), a prescriber must discuss with the patient or the patient's parent or guardian:<sup>2</sup>

- Risks of addiction and overdose.
- Dangers of taking with alcohol, benzodiazepines, and other central nervous system.
- Depressants.
- Reasons why the prescription is necessary.
- Alternative treatments that may be available.
- Associated risks.

This discussion is not required for:

- Treatment of active cancer.
- Care from a licensed hospice.
- Medication for treatment of substance abuse or opioid dependence.

### **Treatment recommendations for chronic pain:<sup>2</sup>**

- Check disease-specific guidelines for recommendations of treatments for specific diseases or conditions.
- Re-check urine drug screens in 1-2 months if “the condition started with acute pain and there is consideration for chronic use”.
- Educate family members and caregivers about the patient’s treatment goals and plan.
- Prevent prescription fraud.
  - Write on tamper-resistant paper or e-prescribe.
  - Write legibly.
  - Keep in records for minimum of two years, as required by Drug Enforcement Administration.
- Consider that a clinically meaningful threshold for pain and function score is 30% improvement during reevaluation.
- Avoid parenteral opioids (with exceptions for inpatient and palliative care).
- Evaluate risks associated with sleep apnea and adjust treatment.
  - Assess risk and strongly consider formal screening.
  - Risk factors include congestive heart failure and obesity.
  - Mild sleep apnea: careful monitoring, titration.
  - Moderate or severe sleep apnea: avoid prescribing opioids.
  - Provide naloxone with sleep apnea risk
  - Counsel family members.
- Monitor “5 A s” (analgesia, activities, aberrant behaviors, and adverse effects).
- Emphasize consultation during treatment management with complex pain conditions or serious comorbidities.
- Perform electrocardiogram in patients to receive methadone.
- Know that antidepressants may increase risk of cardiac death when co-prescribed with methadone.

### **Utah Controlled Substance Database:**

Prescribers are required to check the prescription drug-monitoring program, called the Utah Controlled Substance Database (<https://dopl.utah.gov/csd/index.html>), before issuing the first prescription of an opioid to a patient, unless the prescription is written for 3 or fewer days, the prescriber has prior knowledge of the patient’s prescription history, or the prescription is written for a 30-day post-surgery supply. For ongoing opioid prescriptions, prescribers are required to periodically check the database or similar records.

### **Prescription duration/dosage limits:**

As of October 2018, at least 33 states have enacted legislation related to opioid prescription limits.<sup>5</sup> Utah law limits first-time opioid prescription to a seven-day supply for acute, noncomplex, non-chronic pain conditions.<sup>3,5</sup>

Exceptions are for surgeries when the provider has determined that a quantity exceeding seven days is needed, in which case the provider may prescribe up to a 30-day supply (partial fill at the provider’s discretion). The seven-day limit does not apply in cases of complex or chronic conditions that are documented as such in the medical record.<sup>5</sup>

Utah does not have a statutory limit on milligram doses per day.<sup>5</sup> Utah’s prescribing limits are set in state statute rather than being directed by health departments or regulatory boards, although other bodies may create their own evidence-based policies related to opioid prescribing.<sup>5</sup>

### References

1. Utah Department of Health Indicator-Based Information System for Public Health Web site. 2021; [https://ibis.health.utah.gov/ibisph-view/indicator/complete\\_profile/PoiDth.html](https://ibis.health.utah.gov/ibisph-view/indicator/complete_profile/PoiDth.html). Accessed October 13, 2022.
2. Utah Department of Health (2018). Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain. [https://dopl.utah.gov/pharm/opioid\\_guidelines.pdf](https://dopl.utah.gov/pharm/opioid_guidelines.pdf). Accessed October 13, 2022.
3. U.S. Department of Health and Human Services. Factsheet: Utah’s Oversight of Opioid Prescribing and Monitoring of Opioid Use. February 2019; <https://oig.hhs.gov/oas/reports/region7/71805115.asp>. Accessed October 13, 2022.
4. Federation of State Medical Boards (FSMB). Guidelines for the chronic use of opioid analgesics. April 2017; <https://www.fsmb.org/opioids/>. Accessed October 13, 2022.
5. National Conference of State Legislatures (NCSL). Prescribing Policies: States Confront Opioid Overdose Epidemic. June 30, 2019; <http://www.ncsl.org/research/health/prescribing-policies-states-confront-opioid-overdose-epidemic.aspx>. Accessed October 13, 2022.

### Acute Pain Opioid Treatment Recommendations

#### **Acute Pain Recommendation 1: Use Non-pharmacologic and Non-opioid Pharmacologic Therapies as Alternative Treatments to Opioids**

Opioid medications should only be used for the treatment of acute pain when the severity of the pain warrants that choice and after determining that other non-opioid pain medications or therapies are either contraindicated or will not provide adequate pain relief. Unless contraindicated, non-opioid analgesics, adjuvant analgesics (e.g., anticonvulsants, antidepressants, non-steroidal anti-inflammatory drugs [NSAIDs], corticosteroids) and non-pharmacologic therapies (e.g., cognitive behavioral therapy, physical therapy) are the preferred method of treatment of acute pain.

Most acute pain can be effectively and safely treated with non-pharmacologic or non-opioid therapies (e.g., acetaminophen, non-steroidal anti-inflammatory drugs [NSAIDs], or therapies such as exercise, or specific stretching) rather than opioid medications, which have less desirable adverse effects. Care should be taken to assure that use of opioid pain treatment does not interfere with early implementation of functional restoration programs, such as exercise and physical therapy.

#### **Acute Pain Recommendation 2: Check the Utah Controlled Substance Database (CSD)**

The CSD should be checked before prescribing opioids for acute pain to learn more about the patient's controlled substance prescription history at the inception of a patient-prescriber relationship and when prescribing opioids. Document the results of this review in the patient's record.

The Utah Division of Occupational and Professional Licensing (DOPL) maintains the CSD Program. Access to the data is provided to authorized individuals by going online at [www.dopl.utah.gov](http://www.dopl.utah.gov). Individuals who are licensed to prescribe controlled substances in Utah or staff assigned by the prescriber must register with DOPL to use the CSD. A prescriber can designate one or more employees who can access the CSD on the prescriber's behalf.

Information from the CSD may be included in a patient's medical chart or file and shared with other medical professionals authorized to receive the information pursuant to Utah law and HIPAA.

Recently passed Utah law requires a prescriber to check the database before the first time the prescriber issues a Schedule II or III opioid prescription, unless the prescription is for three or fewer days, the prescriber has prior knowledge of the patient's prescription history, or it is a post-

surgical prescription written for a duration of 30 days or less. A prescriber is also required to check the Utah Clinical Guidelines on Prescribing Opioids for the Treatment of Pain database or similar records if the prescriber is repeatedly prescribing Schedule II or III opioids to a patient (Utah Code Ann 58-37f-304(2)(b)).

The following controlled substances are not required to be reported in the CSD:

- Prescriptions filled at federal facilities, such as military facilities. The Veteran's Administration provides data in accordance to Public Law 115-86 115th Congress.
- Prescriptions filled for individuals by pharmacies located outside the State of Utah.
- Controlled substances administered in an inpatient setting.

#### **Acute Pain Recommendation 3: Consider Patient Risks**

Proactively consider initial and ongoing risks associated with opioid exposure based on age of the patient; history of substance use disorder; or psychiatric, physical, or medical comorbidities.

The developing brain may be more susceptible to addiction when exposed to opioid medications and nonmedical use is more common among younger people. Those risks should be considered when prescribing to an adolescent<sup>3</sup>.

Patients with mental health conditions are at increased risk for developing chronic pain; therefore, physicians should be cognizant of a patient's psychological status and potential for substance use disorder.

"Because psychological distress frequently interferes with improvement of pain and function in patients with chronic pain, using validated instruments such as the Generalized Anxiety Disorder (GAD)-7 and the Patient Health Questionnaire (PHQ)-9 or the PHQ-4 to assess for anxiety, post-traumatic stress disorder, and/or depression (205), might help prescribers improve overall pain treatment outcomes. Experts noted that prescribers should use additional caution and increased monitoring to lessen the increased risk for opioid use disorder among patients with mental health conditions (including depression, anxiety disorders, and PTSD), as well as increased risk for drug overdose among patients with depression<sup>4</sup>."

The GAD-7 and PHQ-4 and PHQ-9 can be found in the Tools and Resources section.

#### **Acute Pain Recommendation 4: Prescribe Immediate-release/Short-acting Opioids (IR/SA)**

When opioids are indicated for the treatment of acute pain, prescribe immediate-release/short-acting (IR/SA) opioids. Extended-release/long-acting (ER/LA) opioids, including methadone,

should rarely, if ever, be prescribed for acute pain, including post-operative pain. Severe acute pain that persists longer than the expected healing time warrants re-examination.

Patients with acute pain who fail to recover in a usual timeframe or otherwise deviate from the expected clinical course for their diagnosis should be carefully evaluated. The continuation of opioid treatment in this situation may represent the initiation of opioid treatment for a chronic pain condition. The diagnosis and appropriateness of interventions should be re-evaluated and the patient's medical history should be reviewed for comorbidities that could interact with opioid treatment and for risk factors during opioid treatment, including current or history of substance use disorder. It is also recommended that the prescriber check the Utah Controlled Substance Database at the time they prescribe an opioid.

#### **Acute Pain Recommendation 5: Prescribe the Lowest Effective Dose**

When opioid medications are prescribed for treatment of acute pain, prescribers should prescribe the lowest effective dose and no more than the number needed for the usual duration of pain associated with that condition, usually 3-5 days and rarely more than seven days.

Utah law states, "an opiate...issued for an acute condition shall be completely or partially filled in a quantity not to exceed a seven-day supply as directed on the daily dosage rate of prescription." The exception is a surgery when the surgeon determines more is needed, in which case up to a 30-day supply may be prescribed, with a partial fill at the prescriber's discretion (Utah Code 58-37-6 (7) iii, effective May 9, 2017).

Prescribing more medication than the amount likely to be needed leads to unused medications being available for abuse or diversion. Use of opioid pain medications should be stopped when pain severity no longer requires opioid medications and when function and quality of life has improved.

#### **Acute Pain Recommendation 6: Avoid and Counsel Against Combining Opioids with CNS Depressants**

Avoid prescribing, and counsel against, concurrent use of opioids and benzodiazepines. Patients should also be counseled against concurrent use of opioids with other sedating substances, including alcohol muscle relaxant drugs, and sedative hypnotics including prescription and over-the-counter sleep aids, etc.

Concurrent use of alcohol, benzodiazepines, and other CNS depressants increases the risk of respiratory depression, which can potentially cause death.

Concurrent use of benzodiazepines requires explicit medical justification due to the serious risk of respiratory depression. For putative psychiatric indications, psychiatric consultation should be sought to treat the patient's condition with potentially less toxic drug-to-drug interactions. Prescribers should warn patients of the high-risk interaction of opioids and CNS depressants.

### **Acute Pain Recommendation 7: Counsel Patients on the Risks of Opioid**

The patient should be counseled on the risks of taking opioids that including dependency, addiction, and death. In addition, patients should be advised of the signs of an opioid overdose and informed of Utah Clinical Guidelines on Prescribing Opioids for the Treatment of Pain the availability of naloxone. Patients should be encouraged to securely store their medications, not share with others, and to dispose of opioids properly when the pain has resolved to prevent non- medical use of the medications.

Patients and family/caregivers should learn to recognize the signs of an opioid overdose:

- Extremely pale face and/or feels clammy to the touch
- Body goes limp
- Fingernails or lips have a purple or blue color
- Vomiting or making gurgling noises
- Unable to be awakened or unable to speak
- Breathing or heartbeat slows or stops

For patient education materials and resources on the risks of taking opioids and signs of an opioid overdose, visit [www.opidemic.org](http://www.opidemic.org).

For information on safe storage and disposal, visit [www.useonlyasdirected.org](http://www.useonlyasdirected.org). For information on naloxone information, visit [naloxone.utah.gov/](http://naloxone.utah.gov/).

### **Chronic Pain Opioid Treatment Recommendations**

#### **Prior to Prescribing Opioids (1.1-3.3)**

#### **Chronic Pain Recommendation 1: Assessment**

##### ***Chronic Pain Recommendation 1.1: Use Non-pharmacologic and Non-opioid Pharmacologic Therapies as Alternative Treatments to Opioids***

Opioid medications should only be used for treatment of chronic pain when the severity of the pain warrants that choice and after determining that other non-opioid pain medications or therapies are either contraindicated or will not provide adequate pain relief. Unless contraindicated, non-opioid analgesics, adjuvant analgesics (e.g., anticonvulsants, antidepressants, non-steroidal anti-inflammatory drugs [NSAIDs], corticosteroids) and non-pharmacologic therapies (e.g., cognitive behavioral therapy, physical therapy) are the preferred method of treatment of chronic pain.

Opioid medications are not the appropriate first line of treatment for most patients with chronic pain. Other non-pharmacologic and non-opioid pharmacologic therapies, should be tried and the outcomes of those therapies documented first. Opioid therapy should be considered only when other potentially safer and more effective therapies are proven inadequate. Care should be taken to assure that use of opioid pain treatment does not interfere with early implementation of functional restoration programs, such as exercise and physical therapy.

##### ***Chronic Pain Recommendation 1.2: Identify if Benefits Outweigh the Risks***

Proactively consider initial and ongoing risks associated with opioid exposure based on age of the patient, history of substance use disorder, or psychiatric, physical, or medical comorbidities. Prescribers should only consider opioid therapy for a patient when expected benefits of pain improvement, function, and quality of life are anticipated to outweigh the risks.

Identify if benefits outweigh the risks by completing recommendation sections 2. Comprehensive Evaluation and 3. Screening for Risk of Substance Use Disorder and by determining desired treatment outcomes.

#### **Chronic Pain Recommendation 2: Comprehensive Evaluation**

##### ***Chronic Pain Recommendation 2.1: Complete a Comprehensive Patient Evaluation***

A comprehensive evaluation should be performed before initiating opioid treatment for chronic pain.

The comprehensive evaluation consists of the patient's social/work history, medical history, mental health/substance use history, and physical examination. The goal of the comprehensive evaluation is to determine the nature of the patient's pain; evaluate how the pain is impacting the patient's job requirements, activities of daily living, and quality of life; identify other conditions or circumstances that could affect the choice of treatment or the approach to managing that treatment; assess and evaluate prior approaches to pain management; and serve as a basis in establishing a treatment plan and evaluation of treatment outcomes.

For more specific information about what the comprehensive evaluation includes, see the Tools and Resources section.

##### ***Chronic Pain Recommendation 2.2: Check Disease-specific Guidelines***

Prescribers should refer to disease-specific guidelines for recommendations of treatment for specific diseases or conditions of chronic pain.

#### **Chronic Pain Recommendation 3: Risk of Substance Use Disorder Screening**

##### ***Chronic Pain Recommendation 3.1: Screen for Risk of Opioid Use Disorder***

Use a validated screening tool to assess the patient's risk of opioid use disorder prior to prescribing an opioid medication long-term for chronic pain.

Long-term use of opioid medications to treat chronic pain safely requires the commitment of adequate resources to regularly monitor and evaluate outcomes and identify occurrence of adverse consequences. The screening tool results are intended to assist the prescriber in determining whether opioid therapy is appropriate and in determining the level of monitoring appropriate for the patient's level of risk.

Prescribers may use one of the standardized screening forms to help determine personal and family risks:

- Patient Health Questionnaire (PHQ-4) or (PHQ-9)
- Opioid Risk Tool (ORT<sup>©</sup>)
- Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R<sup>®</sup>)
- Current Opioid Misuse Measure (COMM<sup>®</sup>)
- Alcohol, Smoking, and Substance Screening Test (ASSIST)

These forms can be found in the Tools and Resources section.

##### ***Chronic Pain Recommendation 3.2: Obtain a Urine Drug Screen***

Urine drug screening is strongly recommended before initiating opioid treatment for chronic pain.

Research and experience have shown that drug testing can identify problems, such as use of undisclosed medications, non-use of reported medications (i.e., drug hoarding or diversion), undisclosed use of alcohol, or use of illicit substances. It is recommended that drug testing be conducted, especially when other factors suggest a patient is at risk for opioid misuse, abuse, or overdose. If the condition started with acute pain and there is consideration for chronic use, at least one drug screen in approximately 1-2 months is advised.

A positive drug screen indicates the need for caution, but does not preclude opioid use for treatment of pain. Consideration should be given to referring the patient to substance abuse counseling and/or to a pain management specialist. If urine drug screening is positive for drugs that were not prescribed, are Utah Clinical Guidelines on Prescribing Opioids for the Treatment of Pain illegal, or for the absence of the prescribed meds, document this in the patient's record and counsel the patient about adherence to a drug treatment plan or initiating a drug contract.

### **Chronic Pain Recommendation 3.3: Check the Utah Controlled Substance Database (CSD)**

The CSD should be checked at the inception of a patient-prescriber relationship and before prescribing opioids for chronic pain to learn more about the patient's controlled substance prescription history. Document the results of this review in the patient's record.

The Utah Division of Occupational and Professional Licensing (DOPL) maintains the CSD Program. Access to the CSD is provided to authorized individuals by going online at [www.dopl.utah.gov](http://www.dopl.utah.gov). Individuals who are licensed to prescribe controlled substances in Utah or staff assigned by the prescriber must register with DOPL to use the CSD. A prescriber can designate one or more employees who can access the CSD on the prescriber's behalf.

Recently passed Utah law requires a prescriber to check the database before the first time the prescriber issues a Schedule II or III opioid prescription, unless the prescription is for three or fewer days, the prescriber has prior knowledge of the patient's prescription history, or it is a post-surgical prescription written for a duration of 30 days or less. A prescriber is also required to check the database or similar records if the prescriber is repeatedly prescribing Schedule II or III opioids to a patient (Utah Code Ann 58-37f-304(2)(b)).

Information from the CSD may be included in a patient's medical chart or file and shared with other medical professionals authorized to receive the information pursuant to Utah law and HIPAA.

The following controlled substances are not required to be reported in the CSD:

- Prescriptions filled at federal facilities, such as military facilities. The Veteran's Administration provides data in accordance to Public Law 115-86 115th Congress.
- Prescriptions filled for individuals by pharmacies located outside the State of Utah.
- Controlled substances administered in an inpatient setting.

### **Establish Treatment Goals and a Written Treatment Plan (4.1-5.2)**

#### **Chronic Pain Recommendation 4: Goals and Treatment Plan**

##### **Chronic Pain Recommendation 4.1: Establish a Written Treatment Plan**

A patient-provider collaborative written opioid treatment plan should be established before opioid therapy and be reviewed and updated on a regular basis.

Prescribers should tailor the treatment goals to the patient's circumstances, cultural preferences, and to the characteristics and pathophysiology of the pain.

The pathophysiologic basis of the pain can help establish a prognosis for future improvement (or worsening) in function and pain, and should influence the treatment goals. Non-opioid treatment modalities should be included in the treatment plan whenever possible to maximize the likelihood of achieving treatment goals.

Patient responsibilities include properly obtaining, filling, and using prescriptions as directed, and adherence to the treatment plan. The treatment plan is usually combined with a consent form. See Recommendation 5.1 for more information.

A sample treatment plan can be found in the Tools and Resources section.

##### **Chronic Pain Recommendation 4.2: Identify Measurable Treatment Goals**

Treatment goals should include measurable goals for function, quality of life, and improved pain control and should be developed jointly by the patient and prescriber.

Prescribers have observed and adherence literature confirms that when patients are engaged in their own healthcare and assume responsibility for their rehabilitation, they are more likely to improve; and that when they participate in goal setting, they are more likely to achieve their goals. As with any other chronic illness (e.g., diabetes or heart disease), the prescriber should focus not just on pain control, but also on treating the patient's underlying diseases and encouraging them to engage in the full spectrum of their health.

These measures of improvement or worsening can be reported by the patient, family members, and/or employer. Permission to discuss the patient's condition with these persons should have previously been obtained and documented.

##### **Chronic Pain Recommendation 4.3: Maintain Accurate Patient Records**

Prescribers should obtain and document information about the patient's treatment and history.

Prescribers should document the treatment, interactions, and findings throughout their professional relationship with the patient. Providing thorough documentation throughout the treatment plan is essential for patient safety and prescriber protection.

##### **Chronic Pain Recommendation 4.4: Plan to Modify or Discontinue Opioid Therapy**

The treatment plan and goals should explicitly include a plan to modify or discontinue opioid therapy when benefits do not outweigh the risks or when the patient fails to adhere to the agreed upon treatment plan.

Prescribers should evaluate benefits and harms with patient within 1-4 weeks of starting opioid therapy or at the time of dose escalation; then continue to evaluate the benefits and harms of therapy with the patient every three months or more frequently if needed. If the benefits do not outweigh the harms of continued opioid therapy, prescribers should optimize other therapies and work with the patients to taper opioids to lower dosages or to taper and discontinue opioids<sup>5</sup>. (See Chronic Recommendation 10.2)

#### **Chronic Pain Recommendation 5: Informed Consent**

##### **Chronic Pain Recommendation 5.1: Obtain Signed Informed Consent Form**

Prescribers should discuss with patients the known risks and realistic benefits of opioid therapy and patient and prescriber responsibilities for managing therapy, including any conditions for continuation of opioid treatment. This discussion should be documented using a written and signed informed consent form, which is often combined with the treatment plan.

The informed consent form typically includes information about the:

- Potential risks and benefits of controlled substance use, including the risk of misuse, dependence, addiction, overdose, and death
- Adverse effects
- Likelihood of tolerance and dependence developing
- Possible drug interactions and risk of over-sedation
- Limited evidence of the benefit of long-term opioid therapy
- Risk of impairment while operating motor vehicles or equipment or performing other tasks
- Prescriber's policies and expectations
- Specific reasons for adapting or discontinuing opioid therapy

Informed consent should also include explaining to patients that they should not expect complete relief of their pain. Improved function is the main criterion for continuing opioid treatment.

##### **Chronic Pain Recommendation 5.2: Educate Patient and Family/Caregivers**

Educational material about the patient's opioid treatment plan should be provided in written form and discussed in person with the patient and, when applicable, the patient's family or caregivers.

For patient education materials and resources on the risks of taking opioids and signs of an opioid overdose, visit [www.opioidemic.org](http://www.opioidemic.org).

For information on safe storage and disposal, visit [www.useonlyasdirected.org](http://www.useonlyasdirected.org). For information on naloxone information, visit [naloxone.utah.gov/](http://naloxone.utah.gov/).

Discuss with the patient the involvement of family and caregivers in their care and receive written permission from the patient to involve the family or caregivers. This is best done before starting to treat the patient, because it can be more difficult to obtain consent after an issue occurs.

Utah Code Section 58-37f-301(5) allows a person for whom a controlled substance is prescribed to designate a third party who will be notified when a controlled substance is prescribed to the person. Prescribers should discuss this designation with patients.

*Note:* Consultation with others, in the absence of consent, must be done within the guidelines and constraints of HIPAA.

## **Initiating and Adjusting Opioid Treatment (6.1-6.7)**

### **Chronic Pain Recommendation 6: Opioid Treatment Trial**

#### **Chronic Pain Recommendation 6.1: Combine Therapies**

When opioid treatment is indicated, non-opioid analgesics, adjuvant analgesics, and non-pharmacologic therapies should be used in combination with opioid treatment as appropriate for the patient.

Combination products with opioid and non-opioid analgesics may result in better pain relief than either drug alone, but the opioid dose is limited by the non-opioid. The use of adjunctive medications, as well as other therapies, such as physical therapy, exercise, stretching, and other alternative therapies, can reduce the dose of opioid needed for adequate pain relief; and consequently, improve a patient's functionality.

#### **Chronic Pain Recommendation 6.2: Initiate Short-term Treatment Trial**

Opioid medication should be initiated as a short-term trial to assess the effects of opioid treatment on pain intensity, function, and quality of life.

The prescriber should clearly explain to the patient that initiation of opioid treatment is not a commitment to long-term opioid treatment and that treatment will be stopped if the trial is determined to be unsuccessful. The trial should be for a specific time period with pre-determined evaluation points as defined in the treatment plan measures. The decision to continue opioid medication treatment beyond the trial period should be based on the balance between benefits gained in function and quality of life, and adverse effects experienced. Criteria for cessation should be determined before treatment begins.

When a new patient has already been receiving opioid therapy for a chronic condition, the same recommendations apply: assess the patient's

chronic pain, complete a comprehensive evaluation, screen for risk of substance use disorder, establish a treatment plan and informed consent, initiate treatment trial, mitigate risks, and consider a multi-disciplinary approach. The evaluation process may require more time than the initial appointment, so the prescriber must use their professional judgement if opioids are deemed necessary. If opioid treatment is necessary, it is suggested that the dose be limited and only long enough to complete an adequate evaluation and to seek consultation, as needed.

#### **Chronic Pain Recommendation 6.3: Begin with Immediate Release/Short-Acting (IR/SA)**

The trial should begin with immediate-release/short-acting (IR/SA) opioid medication.

Immediate-release, short-acting (IR/SA) opioid medications are generally safer and easier to titrate to an effective dose. CDC experts agreed that for patients not already receiving opioids, prescribers.

Utah Clinical Guidelines on Prescribing Opioids for the Treatment of Pain should not initiate opioid treatment with extended-release/long-acting opioids (ER/LA) and should not prescribe ER/LA opioids for intermittent use.

ER/LA opioids should be reserved for severe continuous pain and should be considered only for patients who have received IR/SA opioids daily for at least one week. Initial treatment should not use methadone, fentanyl, or the combination of opioids and benzodiazepines.

#### **Chronic Pain Recommendation 6.4: Prescribe the Lowest Effective Dose**

When opioids are prescribed for the treatment of chronic pain, prescribers should prescribe the lowest effective dose. Prescribers should use caution when prescribing opioids at any dosage, should carefully re-assess evidence of individual benefits and risks when increasing dosage to > 50 morphine milligram equivalents (MME)/day, and should avoid increasing dosage to > 90 or carefully justify a decision to titrate dosage to > 90 MME/day.

The CDC states that although there is not a single dosage threshold below which overdose risk is eliminated, holding dosages below 50 MME/day would likely reduce risk among most patients who would experience fatal overdose at higher prescribed dosages. Utilization of any dose should be based on incremental functional gains.

Benefits of high-dose opioids for chronic pain are not established. At the same time, risks for serious harm increase at higher opioid doses. Opioid overdose risk increases in a dose-response manner. Dosages of 50-100 MME/day increase risks for opioid overdose by 1.9-4.6 times and dosages > 100 MME increase risk by 2.0-8.9 times as compared with the risk at 1-20 MME/day<sup>6</sup>.

#### **Chronic Pain Recommendation 6.5: Prevent Prescription Fraud**

The prescription for opioid therapy should be written on tamper-resistant prescription paper or e-prescribed to prevent prescription fraud.

To reduce the chance of tampering with the prescription, write legibly and keep a copy in your records. According to the Drug Enforcement Administration (DEA), all records related to controlled substances must be maintained and be available for inspection for a minimum of two years.

#### **Chronic Pain Recommendation 6.6: Implement Dose Titration and Re-evaluation**

Regular face-to-face visits with the patient and evaluation of progress against goals should be scheduled during the period when the opioid dosage is being adjusted. The opioid trial or long-term treatment should be continually evaluated for functional benefit and achievement of treatment goals, using appropriate tracking tools.

Clinically meaningful improvement has been defined as a 30% improvement in scores for both pain and function. Monitoring progress toward patient-centered functional goals (e.g., walking the dog or walking around the block, returning to part-time work, attending family sports or recreational activities) can also contribute to the assessment of functional improvement. Prescribing providers should use these goals in assessing the benefits of opioid therapy for individual patients and in weighing benefits against risks of continued opioid therapy<sup>7</sup>.

There are a variety of tracking tools that can be used to set and monitor treatment goals:

- Pain Assessment and Documentation Tool (PADTTM)
- Brief Pain Inventory (BPI©)
- Treatment agreement
- Patient Health Questionnaire (PHQ-4 or PHQ-9)

These forms can be found in the Tools and Resources section.

#### **Chronic Pain Recommendation 6.7: Avoid Parenteral Opioids**

Parenteral (intravenous, intramuscular, or subcutaneous) administration of opioids for chronic pain is strongly discouraged, unless prescribing within an inpatient or palliative care setting.

Any circumstance warranting parenteral administration should be clearly justified by clinical exigencies (e.g., bowel obstruction, terminal care, etc.).

These guidelines do not consider intrathecal administration and this recommendation was not intended to discourage trained and qualified physicians from using intrathecal opioid medications when indicated.

Daily intramuscular (IM) or subcutaneous (SC) injections should be avoided except in a highly supervised environment, such as during an admission to the hospital or hospice.

### **Mitigating risks (7.1-7.7)**

#### **Chronic Pain Recommendation 7: Risk Mitigation**

##### **Chronic Pain Recommendation 7.1: Avoid and Counsel Against Combining Opioids with CNS Depressants**

Avoid prescribing, and counsel against, concurrent use of opioids and benzodiazepines. Patients should also be counseled against concurrent use of opioids with other sedating substances, including alcohol muscle relaxant drugs, and sedative hypnotics including prescription and over-the-counter sleep aids, etc.

Concurrent use of alcohol, benzodiazepines, and other CNS depressants increases the risk of respiratory depression, which can potentially cause death. Concurrent use of benzodiazepines requires explicit medical justification due to the serious risk of respiratory depression. For putative psychiatric indications, psychiatric consultation should be sought to treat the patient's condition with potentially less toxic drug-to-drug interactions. Prescribers should warn patients of the high-risk interaction.

##### **Chronic Pain Recommendation 7.2: Evaluate Risks Associated with Sleep Apnea**

Prescribers should assess the patient's risk for sleep apnea and strongly consider formal screening.

Risk factors for sleep-disordered breathing include congestive heart failure and obesity. Experts noted that careful monitoring and cautious dose titration should be used if opioids are prescribed for patients with mild sleep-disordered breathing. Prescribers should avoid prescribing opioids to patients with moderate or severe sleep-disordered breathing whenever possible to minimize the risk of opioid overdose<sup>8</sup>.

Naloxone rescue medication should be provided to the family/caregivers, as well as education on when to administer naloxone if the patient has risk of sleep apnea, regardless of total daily dose of MME used.

Educating the family/caregivers about the signs of an opioid overdose may help detect problems before they lead to a serious complication. Patients and family/caregivers should learn to recognize the danger signs of respiratory depression and know to how to offer help and summon medical help immediately if a person demonstrates any of the following signs while on opioids:

- Episodic cessation of breathing;
- Periods of irregular or other sleep-disordered breathing.
- Extreme drowsiness and difficulty being awakened.
- Slow, shallow breathing with little chest movement.
- Increased or decreased heartbeat or palpitations.
- Feeling faint, dizzy, or confused.

##### **Chronic Pain Recommendation 7.3: Obtain Urine Drug Screens**

Prescribers should perform drug screening on randomly selected visits and any time aberrant behavior is suspected.

A good practice is to give all patients taking chronic controlled substance prescriptions at least an annual urine tests and high-risk patients more frequent random urine tests with no advance notice. Drug testing has been shown to identify the presence of illegal drugs, unreported prescribed medication, unreported alcohol use, or the absence of the patient's prescribed medication. This assists the prescriber in determining whether the opioid therapy is appropriate and in determining the required frequency of monitoring. It also provides an opportunity to discuss the risks of opioid treatment. Random pill counts may also be useful.

Immunoassays can be done in the office. These screening tests determine if opioids are present but do not identify specific ones, which can subsequently be determined by confirmatory laboratory testing. However, in many cases, confirmation testing can be eliminated by carefully going over the results of the initial in-office test with the patient. Prescribers need to recognize that immunoassays have both false positive and false negative results. Over-the-counter medication, for example, can cause a positive result. Many synthetic opioids are not detected by urine immunoassay screening and require confirmation testing if suspected. The prescriber may want to consider confirmatory testing or consultation with a Certified Medical Review Officer if drug test results are unclear.

An abnormal drug screen should be specified in the treatment plan as a possible reason to cease treatment.

##### **Chronic Pain Recommendation 7.4: Check the Utah Controlled Substance Database (CSD)**

During treatment of chronic pain with opioid medications, the CSD should be checked at least quarterly.

Prescribers should review the patient's history of controlled substance prescriptions to determine whether the patient is receiving opioid dosages or dangerous combinations that put them at high risk for overdose. Prescribers should communicate with others managing the patient or prescribing controlled substances to coordinate care and to improve patient's safety.

Aberrant findings in the CSD (or from urine drug screening) necessitate a frank conversation with the patient. Such findings, based upon the treatment plan, may be cause for tapering/discontinuing controlled substances, referring the patient to a pain management specialist, or developing a new treatment plan.

##### **Chronic Pain Recommendation 7.5: Co-prescribe Naloxone**

As an intervention to prevent a potential opioid overdose death, co-prescribe an approved naloxone delivery kit for patients receiving opioids for treatment of chronic pain.

Prescribers should mitigate the risk of an opioid overdose by offering patients naloxone when increased opioid overdose risk factors are present, such as a history of overdose or substance use disorder, higher opioid dosages ( $\geq 50$  MME/day), or concurrent benzodiazepine use. Naloxone administration is intended to reverse life-threatening respiratory depression. Naloxone is commercially available by prescription for emergency use in autoinjector and intranasal administration forms.

See Chronic Pain Recommendation 7.6 for the duration of action of naloxone and additional information.

On December 8, 2016, the Utah Department of Health issued a standing order that pharmacists may dispense naloxone to concerned family members, caregivers, friends, and patients without a written prescription. However, pharmacies are not required to participate in the standing order.

For patient education materials and resources on naloxone, visit [naloxone.utah.gov/](http://naloxone.utah.gov/).

##### **Chronic Pain Recommendation 7.6: Provide Overdose Education and Counseling**

Provide the patient and family/caregivers information on the signs and symptoms of an opioid overdose, how to obtain naloxone, and the timely and proper administration of naloxone.

Patients and family/caregivers should learn to recognize the danger signs of an opioid overdose:

- Extremely pale face and/or feels clammy to the touch.
- Body goes limp.
- Fingernails or lips have a purple or blue color.
- Vomiting or making gurgling noises.
- Unable to be awakened or unable to speak.
- Breathing or heartbeat slows or stops.

Educating the family/caregivers about the signs of an opioid overdose may help detect problems before they lead to a serious complication. Patients and family/caregivers should also learn to recognize the danger signs of respiratory depression (see Recommendation 7.2) and know how to offer help and summon medical help immediately.

Counseling about administration of naloxone for suspected overdose should be provided in those cases where naloxone is co-prescribed. Naloxone can be prescribed by a healthcare provider or by a pharmacist, as per the Utah Department of Health standing order.

Once naloxone is administered, professional emergency care needs to be provided by calling 911. Naloxone wears off in 30-90 minutes, so naloxone administration may need to be repeated. Meanwhile, CPR or mouth-to-mouth resuscitation may also need to be administered, so family/caregivers should receive training in both when naloxone is prescribed. Warning: The standard IV dosage of naloxone is 0.4 mg and the intranasal dose is 2-4 mg. Administering an excessive amount of naloxone by repeating doses too frequently or using a high-dose preparation can cause the patient to experience acute opioid withdrawal symptoms which can cause seizures or even be life threatening.

See Instructions for Naloxone Administration in the Tools and Resources section. Additional information about naloxone for the public, prescribers, pharmacists, and first responders can be found at [naloxone.utah.gov/](http://naloxone.utah.gov/).

### **Chronic Pain Recommendation 7.7: Counsel Patients on Safe Storage, Disposal, and Diversion**

Patients should be encouraged to securely store their medications, not share with others, and to dispose of opioids properly when the pain has resolved to prevent non-medical use of the medications.

For patient education materials and resources on safe storage and disposal, visit [www.useonlyasdirected.org](http://www.useonlyasdirected.org).

Naloxone may not be effective if opioids are misused in combination with other sedatives or stimulants. It is not effective in treating overdoses of benzodiazepines or stimulant overdoses involving cocaine and amphetamines<sup>9</sup>.

## **Treatment Management (8.1-10.2)**

### **Chronic Pain Recommendation 8. Monitoring Treatment and Dose Adjustments**

#### **Chronic Pain Recommendation 8.1: Monitor Opioid Therapy**

Once a stable dose has been established, regular monitoring should be conducted at face-to-face visits. During these visits, treatment goals, affect and mood, analgesia, activity and level of function, adverse effects, and aberrant behaviors should be monitored. These assessments can be remembered as the “5 A’s.”

#### **5 A’s Opioid Therapy Monitoring Tool:**

- Affect: determine if pain has impacted the patient’s mood
- Analgesia: inquire about level of pain (current, recent, trends, etc.)
- Activity: assess both the patient’s function and overall quality of life
- Adverse events: determine whether the patient is having medication side effects
- Aberrant behavior: regularly evaluate for possible substance use disorder related behavior

Also, it is recommended to assess the patient’s airway and sleep apnea status<sup>10</sup>.

#### **Chronic Pain Recommendation 8.2: Evaluate Patient Progress**

Continuation or modification of therapy should depend on the prescriber’s evaluation of progress towards stated treatment goals.

Prescribers should evaluate benefits and harms of continued opioid therapy with patients every three months or more frequently. If benefits do not outweigh harms of continued opioid therapy, prescribers should optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids<sup>11</sup>.

#### **Chronic Pain Recommendation 8.3: Adjust and Prescribe Medication During Clinic Visit**

Medication adjustments, if necessary, should be made and prescriptions provided during a clinic visit.

Face-to-face follow-up visits should occur at least every 2-4 weeks during any period when dosages are being adjusted. More frequent follow-up visits may be advisable when prescribing opioid medication to a patient with a known addiction problem, suspected aberrant behavior, or co-existing psychiatric or medical problems.

Options for medication adjustments include reducing medication or rotating opioid medication. Opioid rotation can be an effective means of reducing opioid dose, reducing adverse side effects or improving efficacy. However, when switching from one opioid to another, extreme caution is required due to incomplete cross-tolerance among various opioids. Refer to opioid rotation guidelines before attempting an opioid switch (opioid rotation). When it is documented that the patient is compliant

In general, if the patient’s underlying medical condition is chronic and unchanging and if opioid-associated problems (hyperalgesia, substantial tolerance, important adverse effects) have not developed, it is recommended that the effective dose achieved through titration not be lowered once the patient has reached a plateau of adequate pain relief and functional level<sup>12</sup>.

## **Chronic Pain Recommendation 9. Multi-Disciplinary Approach**

### **Chronic Pain Recommendation 9.1: Obtain a Second Opinion or Consultation**

Prescribers should obtain a consultation for a patient with complex pain conditions or serious comorbidities.

Reasons to refer patients include:

- The prescriber has reached a limit of what he or she feels comfortable prescribing.
- The treatment needs a multi-disciplinary approach.
- The pain has progressed to a complex level.
- Significant risk factors for substance use disorder are identified.
- There is a need to re-evaluate the patient’s diagnosis and/or confirm the continued diagnosis.

A multidisciplinary approach for chronic pain may result in a better outcome compared to medical management alone. The results generally indicate a reduction in pain, better functional restoration, reduced healthcare costs, higher return-to-work rates, and reduced disability costs.

Patients with serious comorbidities may benefit from a Palliative Care consultation if the goal is to improve a person’s quality of life while living with chronic or serious illness. These patients usually have exhausted other traditional therapies for their illnesses (congestive heart failure, COPD, advanced cancer) or live with a high symptom burden during treatment of their illness. They are not hospice eligible, because they live longer than a traditional hospice patient or may have aggressive medical goals. Patients that receive palliative care may have less frequent hospitalizations, improved quality of life, and improved physical function<sup>13</sup>.

### **Chronic Pain Recommendation 9.2: Refer to a Substance Use Disorder Specialist for Treatment**

Patients at high risk for Substance Use Disorder (SUD) or those exhibiting behaviors of abuse, diversion, or addiction should be referred to a SUD specialist for treatment.

Find Substance Abuse Agencies by county at [dsamh.utah.gov/substance-use-disorders/](http://dsamh.utah.gov/substance-use-disorders/). Also, see the Tools and Resources section for a list of Opioid Use Disorder Providers.

### **Chronic Pain Recommendation 9.3: Offer Medication-Assisted Treatment**

Prescribers should offer or arrange evidence-based treatment for a patient with opioid use disorder, which usually includes medication-assisted treatment with buprenorphine, naltrexone, or methadone in combination with behavioral therapies.



The prescriber may consider opioid medication for pain when monitoring is performed during the titration and maintenance phase and the patient understands and consents to the risks, even if the patient has a self-reported or documented previous problem with opioids. Opioid treatment in this case requires more structured ongoing assessment for loss of control and nonadherence. Co-management with or a referral to an addiction medicine specialist is recommended. The specialist is required to have a special registration to provide medication-assisted treatment; otherwise, there is a provision in the Utah Controlled Substance Act in which the provider may apply to receive a waiver of the special registration requirements to treat with buprenorphine. This can be done through the Substance Abuse Mental Health Services Administration Buprenorphine Waiver Management at [www.samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-management](http://www.samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-management).

#### **Chronic Pain Recommendation 9.4: Refer to Mental Health Services**

Patients with co-existing psychiatric disorders should receive ongoing mental health support and treatment while being treated for chronic pain.

Unless the prescriber treating the patient is qualified to provide the appropriate care and evaluation of the coexisting psychiatric disorder, consultation should be obtained to assist in formulating the treatment plan and establishing a plan for coordinated care of both the chronic pain and psychiatric conditions.

Because psychological distress frequently interferes with improvement of pain and function in patients with chronic pain, use validated instruments such as the Generalized Anxiety Disorder (GAD)-7 and the Patient Health Questionnaire (PHQ)-9 or the PHQ-4 to assess for anxiety, post-traumatic stress disorder, and/or depression (205)<sup>14</sup>.

Opioid therapy should not be initiated during acute psychiatric instability or uncontrolled suicide risk, and prescribers should consult a behavioral health specialist for any patient with a history of suicide attempt or psychiatric disorder. In addition, patients with anxiety disorders and other mental health conditions are more likely to receive benzodiazepines, which can exacerbate opioid-induced respiratory depression and increase the risk for overdose. For treatment of chronic pain in patients with depression, prescribers should strongly consider using tricyclic or SNRI antidepressants for analgesic as well as antidepressant effects<sup>15</sup>.

#### **Chronic Pain Recommendation 10. Discontinuing Opioid Treatment**

##### **Chronic Pain Recommendation 10.1: Discontinue Treatment**

Opioid treatment should be discontinued when pain problems have been resolved, treatment goals are not being met, adverse effects outweigh

benefits, or dangerous or illegal behaviors are demonstrated.

Dangerous or illegal behaviors may include frequent requests for refills prior to the expected use date, positive urine drug screens for non-prescribed medications, negative urine drug screens for opiates that have been prescribed and the patient states they are taking, and suspicion of diverting medications to others.

The decision to discontinue opioid treatment should ideally be made jointly with the patient and the family/caregivers when appropriate (Federation of State Medical Boards, 2004). This decision requires careful consideration of the treatment outcomes and the need to provide ongoing monitoring.

When the patient is discharged, the prescriber is obliged to offer continued monitoring for 30 days post-discharge. Once a provider-patient relationship is established, the prescriber owes a continuing duty to provide care until that relationship is appropriately terminated. Prescribers should adhere to the standard of care for their specific discipline when dismissing a patient. The failure to do so may constitute neglect or abandonment.

##### **Chronic Pain Recommendation 10.2: Safely Taper and Refer to Treatment**

When a patient chooses to stop treatment or has been discharged for treatment plan violations, offer assistance to safely taper medications or obtain appropriate treatment.

When tapering a patient from opioid treatment, the rate of taper will depend on their medical, social, and mental health factors. Medicine should be dispensed in small increments, no more than a weekly supply. Strategies for Tapering and Weaning can be found in the Tools and Resources section. For prescribers who are not familiar with opioid tapering within the context of pain care (i.e., no opioid use disorder co-morbidity), consultation with a pain medicine specialist is recommended. If opioid use disorder is suspected, consultation with a SUD specialist is recommended.

When patients receiving both benzodiazepines and opioids require tapering to reduce risk for fatal respiratory depression, it might be safer and more practical to taper opioids first (see Recommendation 7). The reason for this is because there is a greater risk of benzodiazepine withdrawal relative to opioid withdrawal and tapering opioids can be associated with anxiety. Prescribers should taper benzodiazepines gradually, because if discontinued abruptly this may cause withdrawal with rebound anxiety, hallucinations, seizures, delirium tremens, and, in rare cases, death. A commonly used benzodiazepine tapering schedule that has been used safely and with moderate success is a reduction of the benzodiazepine dose by 25% every 1–2 weeks<sup>16</sup>.

#### **Chronic Pain Recommendation 11. Methadone**

##### **Chronic Pain Recommendation 11.1: Avoid Methadone Unless Trained**

Methadone should not be used for pain unless the prescriber has extensive training or experience in its use and when the benefits outweigh the known risks.

Methadone has highly complex and variable pharmacokinetics and pharmacodynamics, making it unsuitable as a preferred (1st or 2nd line) extending-release/long-acting (ER/LA) opioid analgesic for the management of chronic pain when around-the-clock opioids are indicated. Its use for this indication has been associated with a disproportionately high incidence of prescription opioid-related deaths.

Methadone is one option for maintenance therapy for patients who are addicted to opioids, who have been transitioned from their other opioid medications, and who are under a frequent urine drug screening plan. The DEA requires special registration as a Narcotic Treatment Program (NTP) for prescribers to use methadone for this purpose. Buprenorphine is another option for long-term therapy of opioid use disorder.

An ECG screening should be performed on patients who will be receiving methadone.

Caution: Anti-depressants may prolong the QT interval and increase the risk of cardiac death when taken with methadone.

##### References:

- Utah Department of Health (2009). Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain, p. 14. Salt Lake City, UT: Utah Department of Health.
- Centers for Disease Control and Prevention [Patients with Mental Health Conditions]. MMWR 2016; 65(No. 1): [27].
- Centers for Disease Control and Prevention. [Patients with Mental Health Conditions]. MMWR 2016;65(No. 1):[27]
- Centers for Disease Control and Prevention. [Patients with Mental Health Conditions]. MMWR 2016;65(No. 1):[23].
- Centers for Disease Control and Prevention. [Patients with Mental Health Conditions]. MMWR 2016;65(No. 1):[20].
- Centers for Disease Control and Prevention. [Patients with Mental Health Conditions]. MMWR 2016;65(No. 1):[26]
- Substance Abuse and Mental Health Services Administration. [Naloxone]. (2016, March 03). Retrieved June 28, 2017, from <https://www.samhsa.gov/medication-assisted-treatment/treatment/naloxone>.
- Federation of State Medical Boards. [Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain]. 2013 [11]
- Centers for Disease Control and Prevention. [Patients with Mental Health Conditions]. MMWR 2016;65(No. 1):[16]
- Department of Veterans Affairs, Department of Defense. [VA/DoD Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain]. 2003.
- April Krutka, Palliative Care Medical Director, McKay Dee Hospital.
- Centers for Disease Control, 2016.
- Centers for Disease Control and Prevention. [Patients with Mental Health Conditions]. MMWR 2016;65(No. 1):[27].
- Centers for Disease Control and Prevention. [Patients with Mental Health Conditions]. MMWR 2016;65(No. 1):[32].

# EFFECTIVE MANAGEMENT OF ACUTE AND CHRONIC PAIN WITH OPIOID ANALGESICS

## Self-Assessment

Choose the best possible answer for each question and mark your answers on the self-assessment answer sheet at the end of this book.  
There is a required score of 70% or better to receive a certificate of completion.

- 1. Nonpharmacologic and self-management treatment options have been found to be effective alone or as part of a comprehensive pain management plan for which types of pain?**
  - A. Nociceptive and neuropathic pain.
  - B. Acute pain > 48 hours after tissue trauma.
  - C. Neuropathic and chronic pain.
  - D. Musculoskeletal and chronic pain.
- 2. What is the maximum recommended daily dose of acetaminophen for healthy adult patients?**
  - A. 2500 mg.
  - B. 3000 mg.
  - C. 3500 mg.
  - D. 4000 mg.
- 3. Which non-opioid analgesic has been successfully used to treat such acute pain conditions as sickle cell crises, renal colic, and trauma?**
  - A. Ketamine.
  - B. Cannabis.
  - C. Capsaicin.
  - D. Anticonvulsants.
- 4. Which of the following topics should be routinely covered as part of patient education about opioid analgesics?**
  - A. Background information about acute vs. chronic pain.
  - B. Criteria for Opioid Use Disorder.
  - C. Safe medication disposal.
  - D. Difference between nociceptive and neuropathic pain.
- 5. Which of the following is an example of a functional goal?**
  - A. Reduced anxiety about pain.
  - B. Reduced need for rescue analgesia.
  - C. Reduced daily dose of opioid analgesic.
  - D. Resumed sexual relations.
- 6. Which of the following is a possible reason for prescribing naloxone to a patient who has been prescribed an opioid analgesic?**
  - A. The patient is taking a dose of an opioid > 50 MMED.
  - B. The patient has recently entered prison.
  - C. The patient has history of hypertension.
  - D. The patient has a concurrent prescription for an SSRI antidepressant.
- 7. According to the Centers for Disease Control and Prevention, what amount of opioid analgesic is appropriate for most painful conditions?**
  - A. 2-day supply.
  - B. 3-day supply.
  - C. 5-day supply.
  - D. 7 day supply.
- 8. Which of the following medications is a full mu-receptor agonist used to treat Opioid Use Disorder?**
  - A. Methadone.
  - B. Buprenorphine.
  - C. Extended-release naltrexone.
  - D. Naloxone.
- 9. Which of the following medications can be self-administered by patients with a medication obtained from a regular pharmacy?**
  - A. Methadone.
  - B. Buprenorphine.
  - C. Extended-release naltrexone.
  - D. Naloxone.
- 10. For which of the following must clinicians obtain a special waiver from the DEA prior to being able to prescribe the medication?**
  - A. Methadone.
  - B. Buprenorphine.
  - C. Extended-release naltrexone.
  - D. Naloxone.

# GUIDANCE ON PROFESSIONAL BOUNDARIES AND SEXUAL MISCONDUCT

COURSE DATES:	MAXIMUM CREDITS:	FORMAT:
Release Date: 1/2022 Exp. Date:12/2024	2 AMA PRA Category 1 Credits™	Enduring Material (Self Study)

## TARGET AUDIENCE

This course is designed for all physicians and other health care providers.

## COURSE OBJECTIVE

The purpose of this course is to provide important information to help understand and maintain professional boundaries and appropriate relations with patients, including strategies for initiating and conducting sensitive examinations and the communication that is required as a component of such examinations.

## **HOW TO RECEIVE CREDIT:**

- Read the course materials.
- Complete the self-assessment questions at the end. A score of 70% is required.
- Return your customer information/ answer sheet, evaluation, and payment to InforMed by mail, phone, fax or complete online at program website.

## LEARNING OBJECTIVES

**Completion of this course will better enable the course participant to:**

1. Understand requirements for qualified chaperones, intimate exam recommendations, and respectful communication with patients.
2. Describe types of sexual misconduct and how to maintain appropriate boundaries with patients.
3. Understand professional boundaries in practice, including recognizing prevalence and underreporting of sexual misconduct.
4. Identify the ethical and legal imperatives as well as appropriate channels to report sexual misconduct and understand what is meant by trauma-informed care.

## ACCREDITATION STATEMENT

InforMed is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

## DESIGNATION STATEMENT

InforMed designates this enduring material for a maximum of 2 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **FACULTY**

### **Sarab Sodhi, MD, MAUB**

Assistant Professor  
Cooper Medical School of Rowan University

### **Beth Dove**

Medical Writer  
Dove Medical Communications

## **ACTIVITY PLANNER**

### **Michael Brooks**

CME Director  
InforMed

## **DISCLOSURE OF INTEREST**

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, InforMed implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.

## **FACULTY/PLANNING COMMITTEE DISCLOSURE**

The following faculty and/or planning committee members have indicated they have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

- Sarab Sodhi, MD, MAUB
- Beth Dove
- Michael Brooks

## **STAFF AND CONTENT REVIEWERS**

InforMed staff, input committee and all content validation reviewers involved with this activity have reported no relevant financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

## **DISCLAIMER**

\*2023. All rights reserved. These materials, except those in the public domain, may not be reproduced without permission from InforMed. This publication is designed to provide general information prepared by professionals in regard to the subject matter covered. It is provided with the understanding that InforMed, Inc is not engaged in rendering legal, medical or other professional services. Although prepared by professionals, this publication should not be utilized as a substitute for professional services in specific situations. If legal advice, medical advice or other expert assistance is required, the service of a professional should be sought.

## **COURSE SATISFIES**



---

This course awards two (2) *AMA PRA Category 1 Credits™*

---

The Utah Division of Occupational and Professional Licensing (DOPL) requires physicians (MD/DO), physician assistants (PA), and podiatrists (DPM) to complete at least forty (40) credit hours of approved CME during each two (2) year license period. Dentists (DDS), Optometrists (OD), and Advanced Registered Nurses (ARNP) are required to complete thirty (30) credit hours.

## Introduction

*Into whatsoever houses I enter, I will enter to help the sick, and I will abstain from all intentional wrong-doing and harm, especially from abusing the bodies of man or woman, bond or free.*

~Hippocratic Oath (translated from 1923 Loeb edition)

Trust is implicit and imperative in the physician-patient relationship. From the Hippocratic Oath to the American Medical Association's (AMA) Code of Medical Ethics, members of the medical profession are charged to give medical care that is competent, compassionate, and respects human dignity and rights. AMA Core values include the ethical responsibility to place patient welfare above the physician's self-interest.<sup>3</sup> When care is disrupted by sexual misconduct on the part of the physician, repercussions are severe and ongoing.

The trauma experienced when physicians cross a line endures, harming patients' mental, psychological, emotional, and physical health.<sup>1</sup> Repercussions extend to families, communities, and the wider public.<sup>1</sup> Targeted patients are known to refrain from seeking necessary medical care down the line with associated implications for morbidity and mortality. Thus, sexual violations committed by a minority of practicing physicians undermine the integrity of the entire medical field.<sup>1</sup>

Efforts are underway to examine the extent of physician misconduct and to scrutinize current practices of state medical boards and professional regulatory authorities. A workgroup formed by the Federation of State Medical Boards (FSMB) reviewed available data on sexual misconduct regarding incidence and severity of behaviors, disciplinary actions, and barriers to reporting.<sup>1</sup> Additionally, the workgroup scrutinized and examined how professional culture influences willingness to report physician impropriety. According to the workgroup report published in May 2020, physician sexual misconduct is underreported by patients and medical professionals in the workplace, and shared efforts are necessary to enact widespread cultural and systemic changes.<sup>1</sup>

Calls for more accountability come from many quarters. The #MeToo and Time's Up movements – and the accompanying societal attention -- have grown into advocacy and victim support networks that reach into every strata and corner of society, including the physician's exam room. Media accounts highlight not only egregious misconduct but the organizational complacency that failed to halt it. Examples published on MedPage Today include:<sup>4</sup>

- 17 women who sued Columbia University and its affiliated hospitals claiming the institutions concealed known sexual assaults during office visits by Robert Hadden, MD, a former obstetrician-gynecologist at New York-Presbyterian

- Dozens of men who filed suits against Ohio State University alleging that former wrestling team doctor Richard Strauss, MD, sexually abused them under the guise of medical examinations
- More than 200 women who alleged that George Tyndall, MD, the longtime campus gynecologist at the University of Southern California, assaulted them during their appointments, prompting a grand jury investigation
- More than 150 women, many minors at the time, who testified to being sexually abused by former USA Gymnastics team doctor Larry Nassar, DO, at Michigan State University

As important and timely as this topic is, it is rarely and inadequately covered in medical training. Historically, psychiatry is the field with the most attention paid to professional boundaries regarding patients, but the need is pressing for more formal education that occurs earlier within the framework of broader clinical practice.<sup>1,2</sup> For example, a 2007 search of the University of Vermont College of Medicine's curriculum revealed a dearth of teaching on the concept of professional boundaries.<sup>2</sup> Furthermore, although maintaining professional boundaries begins with respectful communication, which is particularly important when conducting sensitive exams, clinical communications skills receive limited curricular time in U.S. medical schools and even less so for practicing physicians.<sup>5</sup> In recognition of these deficiencies the FSMB workgroup called for education beginning in medical school and residency and continuing throughout the life of a physician's (or other healthcare professional's) career.<sup>1</sup>

At minimum, physicians and medical students should:<sup>1,6</sup>

- Know what constitutes appropriate physician-patient boundaries
- Identify and avoid common and potential consequences to both the patient and the physician when professional boundaries are not maintained
- Know what defines physician sexual misconduct
- Learn the prevalence of physician sexual misconduct and be encouraged to remain vigilant and report it
- Be educated regarding the degree of harm patients experience as a result of sexual trauma

Physicians require skills in self-monitoring and self-reflection as well in enacting and enforcing practice policies to ensure sexual misconduct is prevented, detected sooner, stopped from recurring, and reported to the appropriate regulatory and legal authorities without fear of repercussions from colleagues or superiors. Training or review is also necessary on how to initiate and conduct sensitive examinations with patients and the communication that is required as a component of such examinations. This CME activity presents important information to help physicians understand and

maintain professional boundaries and appropriate relations with patients. These skills are aimed at improving outcomes for patients, facilitating ongoing practice-based learning, and providing a framework for risk management.

## Prevalence of Physician Sexual Misconduct

It is known that sexual harassment is common in academic medicine and in healthcare work environments.<sup>7</sup> However, the prevalence of sexual misconduct or assault experienced by patients from the physicians entrusted to care for them has not been well studied.<sup>5,8</sup> Prevalence data are based on disciplinary actions by state medical boards or federal agencies or on self-reported anonymous surveys (Table 1).<sup>9</sup> Anonymous surveys indicate the problem is more widespread than would be inferred from disciplinary actions alone.

Sexual misconduct is among the most common reasons healthcare professionals are disciplined by medical boards.<sup>6,10</sup> Data from past decades show that 761 physicians were disciplined for sex-related offenses from 1981 through 1996.<sup>11</sup> In 1994, the year with the most reports, 5.2% of all orders were sex related, and 0.02% of 621,129 practicing physicians in the country were disciplined for sex-related offenses.<sup>11</sup> Although few physicians were disciplined, reports of offenses were increasing and incidents were relatively severe, involving patients 75% of the time and including sexual intercourse, rape, sexual molestation, and sexual favors for drugs.<sup>11</sup> Most alarming, "a substantial proportion" of offenders were allowed to continue or return to practice. Because offenders often repeat their misconduct, many patients can be affected over years or even decades.

More recent reports in media outlets have led to increased public awareness of the scope of the problem. In 2016, the Atlanta Journal-Constitution published a six-part series on doctors and sex abuse.<sup>12</sup> Reporters examined more than 100,000 disciplinary documents from across the country, eventually identifying more than 3,100 doctors accused of sexual infractions who were publicly disciplined since January 1, 1999. Of those sanctioned, more than 2,400 of the violations clearly involved patients. The investigation found that about 70% more physicians were accused of sexual misconduct than were classified as such in the public version of the National Practitioner Data Bank (NPDB), which tracks complaints against physicians.<sup>6,12</sup> Furthermore, the reporters identified an additional 450 physicians from allegations during 2016 and 2017.<sup>13</sup>

When self-report by physicians is anonymous, the rates of reported violations are higher than those pulled from disciplinary actions. While a literature review published in 2009 reported a rate of approximately 1.6% of U.S. physicians disciplined for sexual boundary violations with patients, when the same report combined self-report survey samples, closer to 6.8% (257 of 3758) of respondents admitted to such boundary violations.<sup>9</sup>

**Table 1. Prevalence of Sexual Boundary Violations by U.S. Physicians (adapted from Sansone and Sansone)<sup>1</sup>**

Study Authors	Characteristics	Prevalence		
		Number	%	% Male
From Disciplinary Actions				
Post <sup>2</sup>	New York State	68/40,000	0.20%	--
Enbom and Thomas <sup>3</sup>	Oregon State Medical Board	77/4931	1.60%	97.4
Dehlendorf and Wolf <sup>4</sup>	Federal agencies/state medical boards	761/?*	0.02%	--
Morrison and Wickersham <sup>5</sup>	Medical Board of California	37/104,000	0.04%	97.3
From Anonymous Self-Report Surveys				
Kardener et al <sup>6</sup>	California medical society (males only)	33/460	7.20%	100.00
Gartrell et al <sup>7</sup>	AMA Members	176/1891	9.30%	93.2
Bayer et al <sup>8</sup>	AMA Members	26/787	3.30%	96.3

AMA=American Medical Association

\*Total number not reported

1. Sansone RA, Sansone LA. Crossing the line: sexual boundary violations by physicians. *Psychiatry (Edmont (Pa : Township))*. 2009;6(6):45-48.
2. Post J. Medical discipline and licensing in the State of New York: a critical review. *Bull N Y Acad Med*. 1991;67(1):66-98.
3. Enbom JA, Thomas CD. Evaluation of sexual misconduct complaints: the Oregon Board of Medical Examiners, 1991 to 1995. *Am J Obstet Gynecol*. 1997;176(6):1340-1346; discussion 1346-1348.
4. Dehlendorf CE, Wolfe SM. Physicians disciplined for sex-related offenses. *JAMA*. 1998;279(23):1883-1888.
5. Morrison J, Wickersham P. Physicians disciplined by a state medical board. *JAMA*. 1998;279(23):1889-1893.
6. Kardener SH, Fuller M, Mensh IN. A survey of physicians' attitudes and practices regarding erotic and nonerotic contact with patients. *Am J Psychiatry*. 1973;130(10):1077-1081.
7. Gartrell NK, Milliken N, Goodson WH, 3rd, Thiemann S, Lo B. Physician-patient sexual contact. Prevalence and problems. *The Western journal of medicine*. 1992;157(2):139-143.
8. Bayer T, Coverdale J, Chiang E. A national survey of physicians' behaviors regarding sexual contact with patients. *South Med J*. 1996;89(10):977-982.

Therefore, although an estimated 5-10% of physicians have had sexual contact with patients, the true extent of violations is probably underreported.<sup>13,14</sup>

### Underreporting and Consequences of Physician Misconduct

Most patients who are sexually violated by medical practitioners do not report it, estimated as 1 in 10, which is significantly lower than the overall U.S. rate of 36% of female rape or sexual assault.<sup>6</sup> The underreporting of sexual misconduct exist within a culture in which all types of physician misconduct toward patients often goes unreported: 18% of U.S. adults have experienced some type of unprofessional conduct from a physician, but only 33% reported the behavior or filed a complaint, according to survey results released by FSMB with data from 2,018 respondents.<sup>15</sup> Women were twice as likely as men to experience unprofessional conduct from physicians (24% vs 12%) but were less likely to report it (41% vs 30%).

Patients do not report their experiences of sexual misconduct for a variety of reasons that include:<sup>1,6</sup>

- Distrust in institutions (e.g., state medical boards, hospitals, other healthcare organizations)
- Fear of abandonment or retaliation by the physician
- Stigma, shame, embarrassment, and unwillingness to relive trauma

- Lack of knowledge in how to file complaints
- Uncertainty over whether a traumatic event was truly unprofessional and unethical (e.g., not realizing that an ungloved vaginal examination was medically unnecessary)
- Complicity in the violation (e.g., to obtain drugs)
- Being unaware of the violation (e.g., under sedation)

Patients frequently lack faith that boards and organizations charged with taking action will actually do so in cases of sexual misconduct. If they do wish to report the misconduct, they often feel intimidated or confused by the reporting process. Shame and guilt may arise as they wonder if they "did something" to invite the misconduct. The nature of an intimate examination may cause them to question their own version of events and wonder whether what happened was truly a violation. Even if they should overcome these barriers and come forward, many believe authorities ultimately would take a physician's word over theirs.

Unfortunately, these fears may not be unfounded. According to the Atlanta-Journal Constitution, physicians who behave inappropriately with patients have numerous advantages that protect them from consequences.<sup>6,16</sup>

- Colleagues and nurses do not fulfill their duty to report offenses
- Hospitals and healthcare organizations minimize accusations

- Organizations quietly discharge physician-offenders or push them to resign without reporting them to law enforcement or state agencies
- State medical boards give physician-offenders second chances
- Prosecutors dismiss or reduce charges with the goal of keeping physicians practicing and off sex offender registries
- Communities support physician-offenders

When it comes to disciplinary actions, sex-related offenses tend to be treated more stringently than non-sexual violations with 72% involving revocation, surrender, or suspension of a medical license in one study.<sup>11</sup> However, as of March 1997, approximately 40% of physicians disciplined for sex-related offenses between 1981 and 1994 were still licensed to practice.<sup>11</sup>

For patients, the lasting effects of sexual trauma are devastating and can be life-altering. As with survivors of sexual violence in the general population, experiences of physician misconduct can produce depression, anger, drug and alcohol abuse, trust issues, and post-traumatic stress disorder (PTSD) symptoms.<sup>6,17</sup> They may also feel shame and guilt about the encounter. Any combination of these reactions can have the effect that the patient avoids gynecological exams or even the entire medical profession altogether with serious health consequences.<sup>14</sup> Thus, physician misconduct disrupts continuity of care, which is a patient right.<sup>18</sup>

### Physician Characteristics Involved in Misconduct

Sexual misconduct happens in all types of practice settings in all states.<sup>1</sup> Some reports indicate that greater numbers of reported allegations involve the fields of family medicine, psychiatry, internal medicine, and obstetrics and gynecology.<sup>9,13</sup> Sexual misconduct by physicians during labor and delivery has been reported in a large survey of U.S. and Canadian obstetric support personnel, who reported hearing use of sexually degrading language with laboring women or witnessing the performance of genital examinations or procedures without patient consent.<sup>19</sup> An investigation conducted by The Atlanta Journal-Constitution also found acts of physician sexual abuse in anesthesiology, ophthalmology, pediatrics, and radiology.<sup>12</sup> Encouragingly, there is some indication that education and awareness, the identification of high-risk practitioners, and the appropriate use of deterrence in the form of disciplinary action by state boards are useful in lowering the number of complaints.<sup>13,20</sup>

A question is whether there are some commonalities of sexual misconduct in physician characteristics. Of 101 cases of sexual violations in medicine analyzed for physician and patient characteristics, practice settings, kinds of violations, and consequences to the perpetrator, the five most common characteristics of offenders were:<sup>6</sup>

- Male physicians (100%)
- Older than age 39 (92%)
- Not board certified (70%)
- Practiced in nonacademic settings (94%)
- Always examined patients alone (85%)

Primary forms of sexual violations were as follows:<sup>6</sup>

- 33% inappropriate touching
- 31% non-penile anal or vaginal penetration without consent
- 16% rape
- 14% child molestation
- 7% consensual sex

Physicians who molested children were more likely to commit sexual offenses such as exhibitionism or voyeurism with other patients than were physicians who engaged in other forms of sexual abuse.<sup>6</sup> Physicians who committed child molestation, nonconsensual, non-penile anal or vaginal penetration, and rape were much more likely to engage in inappropriate comments and touching with other patients than physicians who engaged in consensual sex. Personality disorders were suspected most frequently in cases of rape, and board certification was more common in cases of consensual sex with patients.<sup>6</sup>

In another study, a chart review of 120 physicians monitored for boundary violations by a single Physician Health Program (PHP) in Colorado found that, compared to the general PHP population, more individuals with violations were men between 40 and 49 years of age, had been mandated for evaluation, and reported an abusive history.<sup>21</sup> Diagnoses varied, but mood disorders, adjustment disorder, and substance-use disorders were common (Figure 1).<sup>21</sup>

Although certain physician characteristics (older, male, non-board-certified, in private practice) were associated with more deviations, these characteristics are also frequently shared by the vast majority of physicians who never commit any type of offense. Therefore, characteristics alone cannot and should not be used to infer that a physician is likely (or unlikely) to be an offender. Physician sexual misconduct is usually male to female but can happen to anyone of any age, racial or ethnic background, gender identity, or sexual orientation. Furthermore, reports of sexual boundary violations of patients by females do occur.<sup>22</sup>

In most cases, misconduct happens more than once and when a physician is alone with a patient without a chaperone present.<sup>6</sup> However, some instances of misconduct take place with others present: 19% of cases of nonconsensual, non-penile anal or vaginal penetration occurred with a chaperone, parent, nurse, or other individual in the room with the patient and physician.<sup>6</sup>

Ambulatory or office-based settings are at risk for boundary-violating behavior, perhaps because there is less scrutiny and oversight, and the physician is more often a sole authority.<sup>23</sup> Cases also have been publicized of physicians violating unconscious or otherwise compromised patients.<sup>14</sup> In any practice setting, including hospitals and emergency rooms, patients with special vulnerabilities for abuse include anesthetized patients, patients who do not speak English or whose immigration status make them less likely to report misconduct, minors, and patients with limited mental capacity.

### Definitions and Kinds of Misconduct


Preventing sexual misconduct begins with preventing sexual harassment. The AMA Code of Medical Ethics Opinion 9.1.3 defines sexual harassment as “unwelcome sexual advances, requests for sexual favors, and other verbal or physical conduct of a sexual nature.”<sup>24</sup> Sexual harassment of colleagues by physicians is an unethical abuse of power that interferes with work performance and appropriate professional advancement. The hostile environment created by harassment sets a culture in which professional boundary violations with patients become conceivable.

A professional boundary is a term that encompasses respect for the personal bodily and psychological integrity and separateness of the patient.<sup>25</sup> A boundary crossing is a benign modification of the therapeutic relationship on behalf of the patient, such as accepting a hug or a gift of modest value from an appreciative patient.<sup>25</sup> Boundary crossings may differ across specialties and context, lack the motive of exploitation, and can usually be discussed and altered. In contrast, sexually-motivated contact with a patient is an absolute (i.e. black-and-white) boundary violation. One example of a boundary violation would be including a patient’s confidential clinical information in a published report without consent. Sexual misconduct with a patient is an extreme and egregious boundary violation.

Physician sexual misconduct is defined by the FSMB as behavior that exploits the physician-patient relationship in a sexual way.<sup>1</sup> The behavior may be verbal or physical, occur in person or virtually, and may include expression of thoughts and feelings or gestures that are of a sexual nature or that a patient (or patient surrogate) may reasonably construe as sexual.<sup>1</sup> The FSMB further divides sexual misconduct into two categories: sexual impropriety and sexual violations. (Examples may include but are not limited those shown in Table 2).<sup>1,13</sup>

Sexual misconduct behaviors exist along a continuum of escalating severity. Behaviors that constitute sexual impropriety might include inappropriate gestures or expressions that are seductive, sexually suggestive, disrespectful of patient privacy, or sexually demeaning to a patient.<sup>1</sup> Inappropriate language or gestures have the effect of embarrassing, shaming, and humiliating the patient. Such sexual impropriety can take place in person, but may also occur online, by mail, by phone call, and by text.<sup>1</sup>

**Figure 1. Diagnoses Among Physicians with Boundary Violations<sup>21</sup>**



**Table 2. Examples of Physician Sexual Misconduct<sup>1,2</sup>**

<b>Sexual Impropriety</b>	<b>Sexual Violations</b>
Neglecting to employ disrobing or draping practices respecting patient privacy or Deliberately watching patient dress or undress	Sexual intercourse, genital-to-genital contact
Performing intimate examination or consultation without clinical justification or appropriate consent	Oral-to-genital contact
Subjecting patient to intimate examination in presence of medical students or other parties without patient's informed consent or informed consent withdrawn	Oral-to-anal contact, genital-to-anal contact
Examining or touching genital mucosal areas without the use of gloves (or with gloves without clinical justification)	Kissing in a romantic or sexual manner
Making inappropriate gestures or comments about or to the patient, including but not limited to: <ul style="list-style-type: none"> <li>• sexual comments about patient's body or underclothing</li> <li>• sexualized or sexually demeaning comments to patient</li> <li>• criticizing patient's sexual orientation</li> <li>• non-clinically-relevant comments during examination about potential sexual performance</li> </ul>	Touching breasts, genitals, or any sexualized body part for any purpose other than appropriate examination or treatment or when the patient has refused/withdrawn consent
Using patient-physician relationship to solicit date/romantic relationship	Encouraging the patient to masturbate in the presence of physician*
Initiating conversation regarding physician's sexual problems, preferences, or fantasies	Masturbating by physician while patient is present
Requesting details of sexual history, likes, or dislikes not indicated for type of examination or consultation	Offering practice-related services, such as drugs, in exchange for sexual favors
*The American College of Obstetricians and Gynecologists recognizes the value of physician-guided sexual health counseling in the proper clinical context by an appropriately trained provider.	
1. Sexual Misconduct: ACOG Committee Opinion, Number 796. <i>Obstet Gynecol.</i> 2020;135(1):e43-e50.	
2. Federation of State Medical Boards (FSMB). Report and Recommendations of the FSMB Workgroup on Physician Sexual Misconduct. 2020; <a href="http://www.fsmb.org/siteassets/advocacy/policies/report-of-workgroup-on-sexual-misconduct-adopted-version.pdf">http://www.fsmb.org/siteassets/advocacy/policies/report-of-workgroup-on-sexual-misconduct-adopted-version.pdf</a> . Accessed November 10, 2021.	

Severity further increases with physical contact that is explicitly sexual or reasonably interpreted as such. An example of a sexual violation might include performing an intimate exam without medical necessity or without obtaining informed consent. It might also involve any type of sexually-motivated physical contact with the patient. Sexual assault is any nonconsensual sexual act proscribed by federal, tribal, or state law.<sup>13</sup> Assault occurs through physical force, threats of force, coercion, manipulation, imposition of power, or circumstances where a person lacks the capacity to provide consent due to age or other circumstances.<sup>1</sup> Actions that constitute sexual assault range from sexual coercion to unwanted kissing, touching, or fondling to rape.<sup>13</sup>

Grooming behaviors may not be misconduct but serve as precursors to more severe violations and include such actions as adjusting appointment timing to facilitate time alone with a particular patient, contacting the patient outside of clinic hours, or divulging personal information to a patient as a means to gain trust or to gauge whether an abuse opportunity exists.<sup>1</sup> Grooming behaviors should be taken seriously because severity of sexual misconduct tends to escalate: in one study of sexual violations by physicians, inappropriate comments or touching preceded 94% of cases of nonconsensual, non-penile anal or vaginal penetration and 88% of cases of rape.<sup>6</sup>

It is important to understand that consent or seeming consent on the part of the patient does not alter the finding of a violation of the physician-patient relationship.<sup>6</sup> A sexual relationship concurrent with a treatment relationship is sexual misconduct.<sup>25</sup>

Physical sexual contact between a physician and patient is a violation, whether or not the contact was initiated by the patient.<sup>1</sup> Data indicate that such encounters occur most frequently with patients whose mental health status make them vulnerable and are marked by considerable disparities in power, status, and emotional vulnerability.<sup>17</sup> Consider that the patient sees a physician because of a medical problem, and there may be implicit or explicit suggestion that continued care is contingent on willingness to accept sexual contact. Furthermore, treating as a patient a person with whom a physician has a current romantic or sexual relationship may violate the ethical proscription against treating family members. Physicians, therefore, must respect the inherent power differential and understand that sexual relationships with patients that are consensual or believed to be consensual breach one's professional commitment to provide respectful, competent medical care.

#### Relationships with Former Patients, Others in the Clinical Context

The imperative to treat patients professionally does not stop when they leave a practice. It is also unethical to misuse the trust, knowledge, or influence from a professional relationship to pursue a sexual or romantic relationship with a former patient.<sup>13</sup> From a risk management standpoint, at minimum, if a sexual relationship is to be initiated with a patient or employee, the person must be referred elsewhere for medical care or dismissed as an employee.<sup>26</sup> Regardless, consent by the patient to sexual contact is not considered valid if it occurs

shortly after termination of the clinical context<sup>1</sup> and, in some circumstances, such relationships are never permitted.

Some professional groups and disciplinary or licensing boards designate time limits for commencing a sexual relationship with a former patient following termination of a physician-patient relationship, but consensus is not complete. The American Psychiatric Association prohibits sexual activity with former patients,<sup>27</sup> and such relationships are viewed with grave concern by other professional associations because of the potential for undue influence and abuse of power. The American Association of Orthopaedic Surgeons (AAOS) acknowledges the variety of opinions and notes that ethical propriety depends on the nature and context of the former relationship.<sup>14</sup> Other professionals believe relationships with former patients are always unethical.<sup>14</sup>

Importantly, some states prohibit dating a former patient no matter how much time has elapsed.<sup>26</sup> Questions that may come up are whether the termination of treatment was formally documented, whether the patient's care was transferred to another provider, how long the treating relationship lasted, the time lapse since the physician-patient relationship ended, how much personal private information the patient confided, the nature of the patient's health problem, and the degree of patient emotional dependence and vulnerability.<sup>1</sup> It is unacceptable and still considered sexual misconduct if one terminates a physician-patient relationship so that sexual contact can occur.<sup>1</sup>



Furthermore, it would be grossly unethical to use private information obtained during treatment to coerce a former patient into a sexual relationship under threat of disclosing the information.

A physician also often interacts with third parties (e.g., spouses or partners, parents, guardians, and proxies), offering them information, advice, and emotional support. Factors to consider in judging the appropriateness of engaging in sexual or romantic relationships with third parties include the following:<sup>28</sup>

- Nature of the patient's medical problem
- Length of the professional relationship
- Degree of the third party's emotional dependence on the physician
- Importance of the clinical encounter to the third party and the patient

The AMA Code of Medical Ethics suggests that third-party relationships are more troubling when the person is deeply involved in the clinical encounter and in medical decision making for the patient.<sup>28</sup> Physicians should refrain from pursuing such relationships with key third parties if based on the use or exploitation of trust, knowledge, influence, or emotions derived from a professional relationship.

**BEFORE MOVING ON TO THE NEXT SECTION, PLEASE COMPLETE CASE STUDY 1.**

### Maintaining Professional Boundaries

Each state's Medical Practice Act defines unprofessional conduct within that state. Many states have commonalities in examples of unprofessional conduct, which often include:<sup>29</sup>

- Alcohol and substance abuse
- Sexual misconduct
- Neglect of a patient
- Failing to meet the accepted standard of care in a state
- Prescribing drugs in excess or without legitimate reason
- Dishonesty during the license application process
- Conviction of a felony
- Fraud
- Inadequate record keeping
- Failing to meet continuing medical education requirements

Establishing professional boundaries to prevent sexual misconduct begins with recognizing and preventing workplace sexual harassment, which may range from inappropriate to unlawful. Any sexual harassment permitted within a professional culture risks dire consequences to patients and fosters an unwillingness by bystanders to report misconduct.<sup>1,24</sup> In the case of consensual relationships involving professional colleagues, no supervisory role is appropriate and should be eliminated if both parties wish to pursue a relationship. Firm and enforceable policies around sexual harassment set the tone and culture for professional practices that will extend to respecting and safeguarding patients.

The responsibility to set and maintain professional boundaries in interactions with patients lies with the physician.<sup>13,14,30</sup> Because of lack of education or awareness, practicing physicians may encounter situations in which they have unknowingly violated their state Medical Practice Acts through boundary violations.<sup>1</sup> Dubois and colleagues notes that 40% of boundary violations in their study involved inappropriate touching or consensual sex, suggesting an opportunity to remediate ignorance in regard to medical professionalism by developing better insight into one's behavior and its impact on others.<sup>1,6</sup> One way to do this is ask oneself the motivation for any action that would be considered clinically unorthodox and to know that it is misconduct if it is sexually motivated.

### **Boundary Crossings**

Some actions with patients may be benign (or thought to be benign) but lie outside of usual clinical practice. Boundary crossings consist of actions that deviate from a physician's standard practice and represent forays into a "gray zone."<sup>2</sup> The concept of the "slippery slope" from the field of psychiatry says boundary crossings may progress to boundary violations down the line. Whether a boundary crossing is harmful, neutral, or beneficial can only be assessed within the clinical context. Therefore, it is important to consider the relevance to the patient and the motivation by the physician for any deviation from usual practice.

### Case Study 1

**Instructions: Please read through the case study below and consider the questions that follow.**

*A 22-year-old college student sought care from her family physician of four years for a suspected urinary tract infection. A diagnosis was made via urinalysis, and antibiotics were prescribed. During the clinic visit, the student mentioned a possible wish for birth control, and the physician suggested she make an appointment for a full gynecological exam. He mentioned that he could check "her equipment" for any problems she might have achieving orgasms and that he could help her performance live up to her "porn star" looks. He was otherwise kind, professional, and attentive to her other clinical concerns, including checking an ankle she had recently strained, suggesting that she continue to elevate it nightly for a week or two and use ibuprofen as needed. The student attended college out-of-state from her hometown and so sought medical care for the first time on her own with this physician. She first saw him at age 18 for treatment of dehydration following a severe case of seasonal flu. At that time, she had found him to be professional and competent. She now felt confused by his statements regarding her purported intimate concerns, which he, not she, had raised.*

**1. Does the behavior on the part of the physician constitute grooming?** \_\_\_\_\_

\_\_\_\_\_

**2. What issues are raised in regard to professional boundaries (e.g., sexual impropriety vs. violation)?** \_\_\_\_\_

\_\_\_\_\_

Discussion: The physician's comments go beyond grooming behaviors, which might include maneuvering to see a patient after normal clinic hours meant to "test the waters" to see whether a patient will object and/or whether an opportunity for misconduct exists. The inappropriate comments were meant to create an environment of intimacy and were a form a sexual impropriety that may also be a precursor to other, more severe forms of sexual misconduct.

The nine boundary domains identified by Guthail and Gabbard along with some examples of issues or motivations to consider concerning these domains are:<sup>31</sup>

1. Role (e.g., is that part of what a doctor does? Are you also a friend, spiritual mentor, other?)
2. Time (e.g., standard vs. special hours, alone in building at end of day)
3. Place and Space (e.g., deviating from usual settings)
4. Money (e.g., reduced fees for which gratitude or other “currency” is expected)
5. Gifts and Services (e.g., set policy regarding max dollar value, perceived obligation)
6. Clothing (e.g., self-expression vs. cultural/community norms, institutional expectations)
7. Language (e.g., first names, colloquialisms, humor)
8. Self-Disclosure (e.g., rapport, reassure patient, burden patient, patient curiosity)
9. Physical Contact (e.g., handshake standard pre-pandemic, touch on shoulder, hugs)

Regardless of intent, physicians should avoid any clinical or nonclinical contact with a patient that could be construed as sexual or romantic.<sup>13</sup> Examples might include any evaluation of a patient outside the usual clinic setting that could be seen as blurring the boundaries between professional and nonprofessional interactions (exceptions might include an emergency or medically-indicated home visit). During clinic visits, expressions of humor should steer clear of sexual innuendo and provocation. Interactions by telephone, e-mail, text, or social media all should reflect the same high standard of professional boundaries.

Physicians should be aware that physical contact that may be intended as a comforting gesture (e.g., placing a hand upon a patient’s knee) may be experienced differently by the patient. The American College of Obstetricians and Gynecologists (ACOG) Committee on Ethics issued the opinion that under some circumstances, limited physical contact between a physician and a patient, including a brief hug or holding a patient’s hand, may provide valuable therapeutic support with clear indication that the patient is open to such contact and its duration is appropriately limited.<sup>13</sup> The patient’s age, gender identity, nationality, community norms, and many other factors influence how physical gestures are received. A handshake has been considered standard and expected when good hand-washing practices are observed;<sup>2</sup> however, Covid-19 protocols have shifted practices in this regard. When in doubt, ask the patient. If the patient offers an appreciative hug, it is best to consider one’s own comfort level with the gesture and to respond accordingly. This might entail tactfully deflecting physical gestures that lie outside the clinical context. If a patient initiates inappropriate contact, physicians should separate themselves from the patient, reinforce professional boundaries, and, if feeling unsafe, exit the room and request any needed assistance.<sup>32</sup>

Awareness is key to preventing the progression to boundary violations. Physicians are asked to reassess their motivations and to ask the primary question of whether an action that is not within the one’s usual practice is beneficial to the patient and relevant to the patient’s medical care.<sup>2</sup> Physicians are also asked to reflect upon personal vulnerabilities that might motivate instances of self-disclosure, non-clinically-indicated touch, or other crossings of professional boundaries. Questions for self-reflection might include what circumstances might be affecting one’s decision making, including whether one is bored, sick, lonely, recently divorced, or experiencing other life stresses.

#### A “Slippery Slope” Scenario<sup>2</sup>

- » Patient starts addressing you by your first name
- » You start scheduling that patient on Fridays, at the end of the day
- » You share a recent personal crisis with the patient
- » The patient gives a hug at the end of that appointment
- » Weeks later, you accept the patient’s invitation for coffee
- » The relationship moves on to dating and physical intimacy

#### Duty to Report

State medical boards depend on individuals and entities to submit information pertinent to patient safety to fulfill their mission to regulate medicine in the best interests of patients. Physicians and medical students are ethically and often legally required to report suspected instances of sexual misconduct and patient harm.<sup>1,25,30</sup> Failure to report may be considered professional misconduct and is subject to disciplinary action by medical boards.<sup>14</sup> The FSMB further suggests that when self-regulation fails, state medical boards should be empowered to levy fines against institutions who fail to report egregious conduct, perhaps publicizing the reasons, increasing reputational risk and thus incentive for institutions to report.<sup>1</sup>

Many professional organizations (AMA, AAOS, ACOG) as well as state licensing and disciplinary agencies require reporting of sexual misconduct as an ethical standard.<sup>14</sup> The AMA states that responsibility to the patient is paramount and includes the imperative to report physicians engaged in unethical behavior.<sup>33</sup> An FSMB position statement on the duty to report highlights the professional obligation to “do no harm” and the “ethical principle of beneficence.”<sup>34</sup> These obligations encompass preventing direct harm (or circumstances with high risk of harm) to patients and also by removing conditions that would lead to harm. Thus, the duty to report is considered fundamental to fulfilling the principle of beneficence by removing potentially harmful conditions.

The AMA website lists reporting incompetent or unethical behaviors by colleagues among the top 10 ethical issues students should learn in medical school.<sup>35</sup> This requirement goes to the heart of medicine’s long tradition of self-regulation, which calls on physicians to safeguard patients’ welfare. Professional codes of ethics and other statements from medical associations are expressions of self-regulation but lack strong enforceability, being limited to such actions as censure or loss of membership.<sup>23,36</sup>

In most jurisdictions, there is also a legal obligation to report physician misconduct.<sup>14</sup> Most states make it a condition of licensure for physicians to formally report to the board of licensure any reasonable basis to believe another licensee has violated any of the board’s regulations.<sup>25</sup> In addition, most states protect from lawsuits those who report in good faith.<sup>25</sup>

State Medical Practice Acts and other relevant legislation outline responsibilities in regard to patient welfare.<sup>34</sup> For a good example of the duties incumbent upon physicians, organizations, hospital leaders, medical officers, and medical staff in reporting professional misconduct or incompetence to state medical boards see the document, “Essentials of a State Medical and Osteopathic Practice Act.” <https://www.fsmb.org/siteassets/advocacy/policies/essentials-of-a-state-medical-and-osteopathic-practice-act.pdf>. Similar language is included in most state law. However, states vary in how legislation describes the mandatory duty to report with language that may require actual or first-hand knowledge, reasonable cause, or reasonable probability (as distinguished from mere probability) that an action constitutes misconduct.<sup>1</sup> The FSMB suggests the “theme of reasonability” as a guide to reporting colleague actions. Therefore, if “it is reasonable” to believe misconduct occurred, physicians must report the actions to the state medical board and (with some exceptions) to law enforcement.<sup>1</sup> State medical boards also may take disciplinary action against licensed physicians who fail to report misconduct.<sup>1</sup>

#### **The Challenge to Report**

Unfortunately, much misconduct observed among medical colleagues and in learning environments goes unreported, despite the ethical and legal imperatives. A survey of 3504 physicians found that while 96% of respondents agreed that physicians should report impaired or incompetent colleagues to authorities, 45% of respondents had encountered such colleagues and not reported the information.<sup>37</sup> Other data indicate that the patient is nearly always the one to report misconduct, rarely another member of the medical team.<sup>6</sup>

Physicians and other healthcare colleagues fail to report misbehavior in the workplace and educational environment for several reasons that include:<sup>1,25</sup>

- Moral distress and discomfort with reporting colleagues
- Power dynamics that put reporting physicians at risk for professional consequences

- Institutions that neglect prioritizing reporting and transparency
- Fear of damaging colleagues
- Fear of retaliation
- Confusion about what happened
- Uncertainty about what to report and to whom
- Concerns over loss of friendships
- Concerns over having one's motives questioned
- Misunderstood requirements of confidentiality
- Reduced motivation stemming from conflicting and unpredictable responses by institutions (e.g., hospitals, professional societies, licensing boards)

These barriers cause fear and discomfort in physicians who observe professional misconduct, leading to avoidance, denial, and a wish to rationalize away the behavior. But there is no duty of confidentiality when a colleague has violated or is danger of violating the rights of a patient. Confidentiality is a duty in such a situation only if the offender is one's patient or another person receiving a formal consultation.

Concerns may also arise that patients may be harmed more by a physician workforce shortage, but such excuses for leniency are not acceptable. The report from the FSMB workgroup puts it this way: "In cases involving sexual misconduct, it is simply not true that unsafe or high-risk care is better than no care at all. A single instance, let alone many instances, can cause an extremely high degree of damage to individuals and the communities in which they reside."<sup>1</sup>

Physicians who are not appropriately reported are not stopped. They may move to other states or practices and continue to reoffend.<sup>38</sup> Failure to report results in avoidable additional harms to patients as nearly all professional breaches are repeated, suggesting that many incidents of sexual misconduct go undetected for years.<sup>6</sup> In short, nothing supersedes the ethical and legal duty to report an unfit colleague.

### How to Report Misconduct

Early reporting of sexual misconduct can facilitate prevention and remediation of any harms and is one of the few ways less egregious conduct (such as grooming behaviors) can be addressed before it can lead to more egregious violations.<sup>1</sup> In addition to state medical boards, other entities may need to be notified, including law enforcement, hospital or medical staff administration, and medical school or residency program directors and supervisors.<sup>1</sup> When colleagues have substance-use disorders or other problems that interfere with safe practices, physicians' assistance organizations can offer opportunity for rehabilitation. Sexual assaults, as defined earlier, should be reported to law enforcement immediately, except in cases where reporting would contravene the wishes of an adult complainant and such non-reporting is permitted by state law.<sup>1,13</sup>

Steps to take when one becomes aware of or strongly suspects conduct that threatens patient welfare include the following:<sup>33</sup>

- Report the conduct to appropriate clinical authorities (i.e., peer review body if in a hospital) in the first instance misconduct is observed or suspected so that patient welfare can be assessed and any needed remedial action taken
- Report directly to the state licensing board when there is an immediate threat to the health and safety of patients or a violation of state licensing provisions
- Report to a higher authority if the conduct continues unchanged despite initial reporting
- Protect the privacy of any involved patients to the greatest extent possible, consistent with due process
- Report to the appropriate authorities (e.g., sexual assaults to law enforcement)
- Physician-supervisors who receive reports of alleged incompetent or unethical conduct should:
  - evaluate the information critically and objectively
  - hold the matter in confidence until resolved
  - ensure that identified deficiencies are remedied or reported to other appropriate authorities for action
  - Notify the reporting physician when appropriate action has been taken, except in cases of anonymous reporting.

If one is uncertain after observing something troubling in this domain, it is recommended to consult with an experienced clinician and not to avoid the issue through rationalization.<sup>25</sup> As Glass wrote in the *AMA Journal of Ethics*, "Ask yourself not just, 'What should I do?' but, when the rubber meets the road, 'Who do I hold myself to be?'"<sup>25</sup>

### BEFORE MOVING ONTO THE NEXT SECTION, PLEASE COMPLETE CASE STUDY 2 ON THE NEXT PAGE.

#### State Medical Board Investigations

The mission of state medical boards is to protect the public. To accomplish this, boards have investigative power and ability to impose punitive measures. Sexual misconduct is grounds for disciplinary action. Sexual misconduct that falls under the category of sexual violation or assault also may meet the criteria for criminal prosecution.<sup>13</sup>

When a party makes a complaint, it sets an investigative process in motion that may encompass interviews, audits of patient charts, and/or visits by undercover agents to pose as patients.<sup>23</sup> Medical boards will also review any previous complaints to identify a pattern of behavior. Even before an investigation is complete, a board may issue an emergency suspension against a physician's license to practice medicine if the physician is judged to pose a risk of imminent harm to patients,

whether this determination is made by a pattern of complaints or a single egregious incident.<sup>1,29</sup> Statutes of limitations may not apply in cases of rape, sexual assault, and other forms of sexual misconduct, as a trend toward removing these time thresholds is growing within state legislatures.<sup>1</sup> This is being done in recognition that a person who experiences trauma may need time to process the event or to be willing to relive it as part of a complaint process.

If the investigation shows a high probability sexual misconduct took place, the board may order a comprehensive evaluation of the physician with the goal of understanding the behavior.<sup>1</sup> The evaluation may require input from multiple disciplines and include conclusions about fitness to practice. Information sought includes any illness, impairment, or underlying conditions that may have predisposed the physician to engage in sexual misconduct or that might put patients at risk and whether any maladaptive behavior is a longstanding pattern.

If the board finds enough evidence, the next step is usually to initiate formal charges and schedule an administrative hearing. In most jurisdictions, this step is information that is available to the public.<sup>1</sup> In subsequent hearings and other legal encounters, a physician may offer factual and mitigating defenses. Some states require hearings to be public, although others do have statutory authority to close a hearing during testimony that could reveal the patient-complainant's identity.<sup>1</sup> Overall, a priority of the board is to guard against public disclosure that might discourage a patient from coming forward with a legitimate complaint against a physician. Expert witnesses may testify to provide insight into factors that led to the alleged sexual misconduct, the level of harm sustained by the patient, and the physician's risk for recidivism and potential to be rehabilitated. The witnesses may testify as to professional standards expected of a treating physician, the mental health diagnosis, treatment, and relevant status of the accused physician, including level of insight and change.<sup>1</sup>

The FSMB calls for fairness in the treatment of complainants and physicians alike.<sup>1</sup> Questioning of complainants and physicians is meant to collect information, not to serve as an aggressive cross-examination.<sup>1</sup> Patient-complainants must be granted fair treatment throughout the regulatory process and be afforded opportunities to report injustices committed against them. Similarly, physicians who are accused of sexual misconduct must be granted due process as cases are investigated and adjudicated. If discipline is required, it should be proportional to the offense. The principle of proportionality in the discipline of physicians highlights the significant shame that is visited upon a disciplined physician and also guides severity of discipline with egregious forms of sexual impropriety.<sup>1</sup>

## Case Study 2

**Instructions: Please read through the case study below and consider the questions that follow.**

Two male physician-colleagues in a group practice are having lunch together when one begins to describe an unusual pattern of meeting with a patient, a 34-year-old woman. The patient has severe ongoing headaches that have been recalcitrant to treatment, and she makes frequent clinic appointments. The physician who sees her describes her as attractive, resembling, he says, his ex-wife. She does not get along with others in the clinic office, however, and has had verbal altercations with the office staff. He believes he can help her and has offered to meet with her at a coffee shop across the street from the clinic for her regular follow-up, so as not to subject her to upsetting encounters, which cause her pain levels to spike. Not long after this lunch, the physician who served as the confidante notices that the ongoing coffee shop encounters are now scheduled at the end of the work day and last longer than a typical clinic appointment. At the two men's next lunch together, the treating physician shares beach photos of the patient, which he says she texted to him. He mentions that he and she are making plans for a play date, as they are both divorced and have young children. He reports that her headaches appear to be improving, and he is hopeful that his combination of prescribed medication and cognitive behavioral therapy is helping her.

1. **Is there a legal duty to report the treating physician's behavior, and what considerations inform this decision?** \_\_\_\_\_

2. **Is there an ethical duty involved for the colleague who witnessed this behavior, and how are decisions reached regarding what to do?** \_\_\_\_\_

Discussion: A "slippery slope" scenario is when the fraying of treatment boundaries is apparent but the behavior by physician has not crossed any legal lines. Because colleagues work together, they may be first to recognize behavior that can serve as a warning that a colleague's judgment may be off in regard to a particular patient. It is better to address the behavior early before it becomes even more concerning. The ethical duty to report impaired or unprofessional colleagues is bound up in the duty to patients with safety being the crucial issue. Because the patient is not in imminent danger, a possible first step might be to voice concerns about the non-clinical encounters directly to the treating physician. For example, "It is obvious that you care about this patient, but it sounds like her treatment is evolving in a way that she could misunderstand and could end up as a problem for you."<sup>25</sup> This would give the treating physician an opportunity for self-reflection and correction and also enable the confidante to gauge whether other problems, such as mental-health or substance-use disorders might be causing impairment of judgment. Reporting might next involve a supervisor if the behavior subsequently is unmodified or worsens.

### Reducing Implicit Bias

Medical boards are encouraged to seek training in implicit bias related to gender, gender identity, race, and ethnicity to ensure fair processes in investigations. Areas investigators are asked to be mindful of any personal bias that might affect their judgments, including status as having experienced sexual assault or having been accused of sexual misconduct.<sup>1</sup> The FSMB suggests that public members on state medical boards serve to reduce bias while amplifying the patient perspective.

Some of the factors medical boards consider in determining the appropriate disciplinary response include:<sup>1</sup>

- Patient harm
- Severity of behavior and context
- Culpability of physician-licensee
- Existence of a physician-patient or therapeutic relationship along with its scope and depth
- Inappropriate termination of physician-patient relationship
- Age and competence of patient
- Vulnerability of patient
- Number of times behavior occurred
- Number of patients involved
- Period of time relationship existed

- Prior professional misconduct, including disciplinary and malpractice history
- Results of evaluation and assessment and recommendations by evaluating or treating professionals and/or state PHP
- Risk of reoffending

### Range and Variation in Possible Disciplinary Actions

If a physician is found culpable, the medical board report will detail particulars of the misconduct and cite which sections of the state Medical Practice Act have been violated. The board will then match the infraction with a broad range of possible sanctions that might include one or more of the actions shown in Table 3.<sup>29</sup>

A license to practice medicine is likely to be lost in cases of forced sexual contact.<sup>14</sup> If mitigating factors exist, a license revocation may be stayed in favor of practice limitations or conditions of probation.<sup>1</sup> A physician may be allowed to continue to practice with gender- or age-based restrictions in place, although the FSMB cautions boards only to take this action with a high degree of confidence the physician is not at risk of reoffending.<sup>1</sup> Practice monitors may be required to protect patients and must be properly trained and lack existing relationships with the monitored physician.<sup>29</sup> In addition, the physician may undergo a special evaluation and be required to attend courses on ethics and boundary violations. Physicians found

guilty of sexual misconduct may also face other professional liability claims and criminal charges, when the circumstances warrant them.

The FSMB workgroup report states that private letters of warning are inappropriate in cases involving sexual misconduct.<sup>1</sup> When behavior is concerning (e.g., grooming) but does not rise to the level deserving disciplinary action, boards may issue a non-disciplinary letter of education that remains on the physician's record to facilitate revisiting cases to identify patterns that might pose future risk to patients.<sup>1</sup>

Medical boards may choose not to inform law enforcement of violations under certain conditions that include request by the complainant or less egregious misconduct (e.g., inappropriate language).<sup>1</sup> It is important to know that some states and some circumstances require mandatory reporting to law enforcement. There is increased discussion toward requiring state medical boards to report credible allegations of sexual misconduct to law enforcement authorities, particularly if the patient is vulnerable by definition.<sup>5</sup> Only 11 states require medical boards to report sexual violations to police or prosecutors when the victim is an adult.<sup>6,12</sup> Any abuse of a child, minor, or dependent adult must be reported to law enforcement, regardless of complainant wishes.<sup>1</sup> Each person has a responsibility to ensure the safety of children in healthcare settings and to scrupulously follow legal and ethical reporting procedures.<sup>39</sup>

**Table 3. Possible Disciplinary Actions by State Medical Boards<sup>1</sup>**

Administrative action	Non-punitive action
Fine	Monetary penalty against physician
Continuing medical education required (CME)	Physician required to complete CME
Conditions required	Physician must fulfill certain conditions to avoid further sanction
License denied	Physician's application/renewal denied
License restricted	Physician may practice medicine within limitations (e.g., loss of prescribing privileges)
License revoked	Physician can no longer practice medicine within state or territory
License surrendered	Physician voluntarily surrenders medical license, sometimes during disciplinary investigation
License suspended	Physician may not practice medicine for specified period, perhaps due to investigation or until board requirements fulfilled
Probation	Physician's license monitored by state board for specified period
Reprimand	Physician issued warning or letter of concern

1. Federation of State Medical Boards (FSMB). About Physician Discipline: How State Medical Boards Regulate Physicians after Licensing. <https://www.fsmb.org/u.s.-medical-regulatory-trends-and-actions/guide-to-medical-regulation-in-the-united-states/about-physician-discipline/> Accessed December 13, 2021.

Some states detail what behaviors are considered sexual misconduct while others give only brief definitions.<sup>14</sup> Furthermore, variation in state responses to physician misconduct has had the effect of sending many physicians with severe disciplinary actions back to practice.<sup>38</sup>

Recommendations to help heighten boards' consistency and prevent egregious misconduct include the following:<sup>38</sup>

- Permanently revoke or suspend medical licenses for first-time egregious offenses (e.g., rape)
- Permanently revoke or suspend medical licenses for repeated lesser offenses following remediation efforts
- Routinely ask victims of sexual abuse whether they want to pursue criminal charges and respect patient wishes (knowing requirements of mandatory reporting)
- Be cognizant that boards have the authority to remove physicians from medical practice more swiftly than the criminal justice system.

To prevent the physicians from changing jurisdictions undetected, medical boards voluntarily share licensee data with the FSMB's Physician Data Center. This information can allow the FSMB Disciplinary Alert Service to alert state boards within 24 hours when one of their physician-licensees receives disciplinary action in another state or territory.<sup>29</sup>

Public disclosure of information regarding the outcome of investigative findings and any disciplinary actions is important to guard patient welfare but also restricted by state statute in many jurisdictions. With the public welfare in mind, the FSMB workgroup favors making information available via state medical board websites, the FSMB Physician Data Center, and the NPDB.<sup>1</sup> Certain states, including California and Washington, require patient notification at the point of making an appointment when a physician's license has any restrictions related to sexual misconduct.<sup>1</sup> Other states may follow suit.

### **Remediation and Education**

Remedial educational programs can be one component of disciplinary orders. Current risk stratification for choosing remediation involves considering severity of actions along with mitigating and aggravating factors, such as:<sup>1</sup>

- Physician character
- Physician insight and remorse
- Physician understanding of how actions violated ethics and legislative strictures
- Consequences to patient and public of allowing remediation/practice re-entry

Remediation efforts should be aimed at stopping offenders both initially and before they can reoffend, and in setting and enforcing professional guidelines for basic and intimate patient examinations that include recommended chaperones and other best practices. Partners in remediation are to be given access to investigative information so as to tailor remedial education to the context in which the sexual misconduct took place. To successfully complete remediation, participants must articulate why their actions were wrong, how they arrived at the point of committing the actions, and how they intend to guard against committing such actions in the future. Following remediation efforts, the physician is monitored during practice to ensure avoidance of circumstances similar to those of the sexual misconduct.

The ProBE Program (an acronym for "Professional Problem-Based Ethics") is one source of professional ethical remediation for physicians with disciplinary orders.<sup>36</sup> Between 1992 and 2013, 11.4 percent of ProBE participants were referred for sexual misconduct.<sup>36</sup> The program uses small-group settings to help participants discover and articulate how their misconduct violated ethical and professional responsibilities and recommit to professional ideals. The program parameters do not include predatory or addictive sexual behavior but rather sexual boundary violations with patients in which physicians "exercised poor judgment in a personal relationship that created a professional vulnerability."

Remediation emphasizes the role of judgment and self-regulation. This and similar programs of remediation are in line with FSMB recommendations when there are "some less egregious forms of sexual impropriety with mitigating circumstances."<sup>1</sup>

Successful remediation includes the following components:<sup>1</sup>

- Have clearly outlined goals
- Outline expectations for acceptable physician performance
- Be completed in person (online or distance learning is insufficient)
- Be related to the offense (which is fully disclosed)
- Be targeted to individual vulnerabilities and risks for committing sexual misconduct
- Have tailored remedial education particular to the context of misconduct
- Have a longitudinal mechanism for maintaining the physician's engagement
- Ensure longitudinal mechanism demonstrates the physician's commitment to accountability and the board's monitoring reach

When a license has been revoked, the potential goal of remediation is to reinstate the license, but medical boards are to remain mindful that remediation and reinstatement should be abandoned if the physician demonstrates any risk of reoffending.<sup>1</sup> Petitions to remove license restrictions should be considered in coordination with any treating professionals and the state PHP or other approved evaluation team.<sup>1</sup> The PHP model provides therapeutic alternatives to discipline for physicians with substance-use and mental health disorders; however, in cases that involve sexual misconduct, PHPs offer support to state medical boards but cannot serve as an alternative to discipline.<sup>30</sup> If asked, PHPs may coordinate comprehensive, multidisciplinary assessments or forensic evaluations to identify any treatable condition that may have contributed to poor judgment or assist with determining fitness for duty, sometimes with restrictions.<sup>30</sup>

Although remediation may be appropriate for some misconduct, evidence regarding its effectiveness is limited and recidivism is hard to study. More research is needed in many areas, including group learning experiences, instruction in victim empathy, the effect of adding other interventions to remediation, and how to identify those at an elevated risk of reoffending.<sup>1</sup>

Another factor that hampers study is indistinct coding when behavior is reported, and the specific label “sexual misconduct” is recommended over vaguer terms such as “disruptive physician behavior,” “boundary violation,”<sup>1</sup> or “other.”<sup>38</sup> Furthermore, the category “not applicable” in reports to the NPDB has been called “unhelpful, overused, and unnecessary,” perhaps even enabling the non-reporting of serious offenses.<sup>12</sup>

### **Monitoring Physician Behavior**

Monitoring capabilities and resources to track a physician’s behavior going forward vary among states. A practice monitor (distinct from a chaperone) who is required to be present at all patient encounters or those restricted by gender and age, is one method that might be mandated by a state medical board.<sup>1</sup> Patients must be informed that the practice monitor is mandated as part of a practice restriction. If the patient is uncomfortable with the presence of the practice monitor, they must seek care from a different physician. Patient supporters such as family members or friends also may be present but do not replace a mandated practice monitor.

Criteria for practice monitors recommended by the FSMB workgroup include the following:<sup>1</sup>

- Formal training in role, including safe and appropriate ways to intervene
- A clinical background
- Not an employee or colleague of monitored physician
- If unknown contact is not available, existing professional relationship is disclosed (helpful if licensed in another health discipline)
- No disciplinary history
- Submits regular reports to state medical board

### **Guidelines for a Professional Practice**

A healthcare practice requires strong policies and supporting interventions to end misconduct by physicians. Leadership within the organization is imperative. All parties within the system should understand the organization’s guidance on professional behaviors and the duty to report unprofessional conduct. All members of the team should see role models for this behavior in daily practice.

Studies show that physicians can make positive changes given the right feedback and that serious practice violations may be prevented when there is a systematic approach to observation.<sup>38</sup> Peer review can be provided through medical society-sponsored registries of risky, invasive procedures.<sup>38</sup>

Solo medical practitioners can receive peer review from afar through use of electronic medical records.<sup>38</sup>

Physicians and other colleagues in the workplace, including those in training, should be able to report sexual misconduct “without fear or loss of favor.”<sup>33</sup> The persons reporting must be protected from retaliation (including through whistleblower legislation)<sup>40</sup> and any implication that progress through medical school and training or in promotions or other career advancement might be impeded.<sup>1</sup> Providing channels to remain anonymous while making complaints and during the hearing processes encourages a culture that reports adverse events without fear of retaliation or jeopardy to inter-professional relations.<sup>34</sup> When anonymous complaints are impossible or infeasible, complainants’ identities should remain confidential and physicians with a complaint against them should not contact complainants.<sup>34</sup>

Physicians should promote and adhere to strict sexual harassment policies in medical workplaces.<sup>24</sup> The National Academies of Sciences reports that organizational culture that enables and appears to accept harassment leads to behaviors that are typically repeated and harmful to medical students and trainees.<sup>7</sup> A culture that permits harassment extends perceived license to engage in such behaviors, putting patients at risk for dire consequences.<sup>1</sup>

Grievance committees should represent diverse colleagues to ensure balanced discussion and decisions in regard to gender identity, age, ethnicity, sexual orientation, profession, and employment status.<sup>24</sup> Committees should make themselves available to those they are charged to serve and be able to enforce the policies they enact.

A summary of recommendations to create professional practices with ethical boundaries in place include the following:<sup>8,38</sup>

- Educate physicians at every training stage about the enormity of sexual misconduct, how to avoid it, and how to seek help if they are struggling with boundary challenges
- Educate the public how to prevent, recognize, and report physician sexual misconduct
- Encourage and empower patients who observe wrongdoing to report it and establish standardized processes for doing so
- Mandate reporting of observed misconduct by medical colleagues, medical students, residents, nurses, and others in the workplace and establish standardized processes for doing so
- Institute necessary measures to prevent reprisal against individuals who report misconduct
- Investigate credible complaints in a timely manner, balancing concerns for privacy with need for transparency
- Recognize that sexual harassment is strictly prohibited
- Never tolerate behavior that threatens patients or creates a hostile workplace

- Conduct physician evaluations with objective data comparing them to peers or 360° (multisource) evaluations from diverse stakeholders (e.g., colleagues, patients, caregivers, family members, supervisors, peers, allied health co-workers, trainees)
- Provide chaperones by default when an intimate examination is medically indicated
- Institute a systematic approach to peer review and oversight of group practices
- Warn all members of the healthcare team not to submit false or malicious reports or expect disciplinary action in response to any frivolous claim.<sup>1</sup>

A change in culture is achieved by making failure to report a professional liability in itself, one that is well understood to be unacceptable and liable for sanction.<sup>1</sup> Any false or frivolous reporting, whether driven by competition, personal animosity, or some other reason, should be met with stern disciplinary action.<sup>1</sup> The goal is to make the duty to report a core component of the medical profession rather than a burden that falls on the shoulders of a few.

### **Guidelines for Basic and Intimate Examinations**

Good professional conduct starts with respectful, clear communication. Communication should occur throughout any examination that takes place without general anesthesia and should convey:<sup>39</sup>

- The medical necessity
- What the exam/procedure will involve
- Any discomfort the patient might experience
- Expected benefits
- Potential risks
- Any findings

For intimate examinations, it is especially important to communicate clearly to explain the parameters of interaction for physician and patient and minimize potential misunderstandings of the physician’s actions.<sup>39</sup> Misunderstandings arise when sexual misconduct has occurred but the patient does not recognize it as such, as well when a patient perceives an interaction as sexual or romantic when the physician had no such intent.<sup>13</sup> Interactions that require sensitive physical examinations and disclosure of private information must be respected as times of intense vulnerability for patients.

Respecting a patient’s dignity during intimate physical examinations requires providing a comfortable and considerate atmosphere. Some best practices include the following:<sup>13,41</sup>

- Provide appropriate gowns
- Provide private facilities for undressing
- Use draping sensitively
- Clearly and appropriately explain components of the physical exam
- Perform only with the patient’s consent
- Perform with minimum amount of physical contact to inform diagnosis and treatment
- Offer the patient the opportunity to ask questions or raise concerns about any element of the exam

- Have a chaperone present for all breast, genital, and rectal exams
  - irrespective of gender of the examining physician
  - in inpatient and outpatient settings
  - during labor and delivery
  - during diagnostic studies (e.g., transvaginal ultrasonography and urodynamic testing)
- Report observed or suspected sexual misconduct to appropriate authorities
  - Supervisors
  - Department chairs or other institutional authorities
  - Peer review organizations
  - Professional licensing boards
  - Law enforcement, in cases of sexual or physical assault
- Create and follow clear guidelines for staff to report without fear of retaliation
- Educate students and trainees regarding the inherent power imbalance in the patient-physician relationship, procedures for reporting suspected misconduct, risk factors for sexual misconduct, and need to avoid sexually offensive or denigrating language

### **More on Use of Chaperones**

Chaperones in the exam room reassure the patient of the professional nature of the exam and intent of the physician, witness all events that take place, and deter potential inappropriate behavior.<sup>13</sup> Guidelines from an ACOG committee now recommend routine use of chaperones for all intimate examinations, which is a change from the organization's previous "opt-in" approach when mandated by policy or requested by the patient.<sup>13</sup> Exceptions would be in an emergency when a failure to perform the exam would result in significant and imminent harm to the patient or when a patient declines the use of a chaperone.<sup>13</sup> A patient who declines having a chaperone present should be counseled as to the reason a chaperone is integral to providing good medical care and be informed that the policy is to protect both patient and physician. The physician should listen to any concerns of the patient and, if possible, take steps to address the concerns. If the patient still refuses the chaperone, the physician is to respect and document the decision.<sup>13</sup> A physician may elect to defer breast, genital, or rectal exams if they are to be performed unchaperoned. Therefore, patients may opt out of a chaperoned exam, but physicians are not compelled to examine without the protection of chaperone except in cases of medical emergencies. All information regarding chaperones, should be documented in the medical record.

The AMA position regarding chaperones is that physicians should ensure:<sup>41</sup>

- Patient are free to request a chaperone during any physical exam, and that this policy is communicated to patients
- A patient's request for a chaperone is honored

- A chaperone is an authorized member of the health care team
- Chaperones are held to clear expectations of upholding professional standards of privacy and confidentiality of health information
- There is general use of chaperones even when a patient's trusted companion is present
- Opportunities occur for private conversation with the patient without the chaperone present
- Inquiries or history taking of a sensitive nature is minimized during a chaperoned examination

Chaperones should be trained in best clinical practices and empowered to report misconduct through an independent process.<sup>13</sup> Use of trainees, such as medical students or residents, as chaperones is discouraged unless they are similarly trained in best practices and empowered to report any concerns independent of the physician.<sup>13</sup> Family members may be present if requested by patients but are not to be used as chaperones.<sup>13</sup> Staffing should be adequate to protect patient privacy and permit routine use of chaperones. Any failure by a physician to adhere to policy concerning chaperones should be reported to the appropriate manager (e.g., medical director, chief, or chair). Organizations should have channels for anonymous reporting either by phone or by online template.

Unfortunately, sexual misconduct can and does occur with a chaperone (or others) present. It is telling that disgraced gymnastics doctor Nassar engaged in sexual misconduct with patients with parents present in the room.<sup>38</sup> Chaperones sometimes look away or engage in doing paperwork out of a mistaken idea that they are respecting patient privacy or implying trust in the process. It is essential that the chaperone be properly trained to observe while maintaining patient privacy, to remain engaged, to recognize inappropriate behavior, and to know how to speak up if sexual misconduct is seen.<sup>6</sup>

**BEFORE MOVING ONTO THE NEXT SECTION, PLEASE COMPLETE CASE STUDY 3 ON THE NEXT PAGE.**

### Respectful Communication/Social Media Use

Generational values evolve in terms of what is considered respectful communication. In the past, such values might have manifested in speaking of "romantic relationships" with patients or as fear of putting physicians "out of work" by reporting misconduct. The FSMB report on sexual misconduct states that so-called "romantic" behavior between a physician and a patient would at least constitute grooming and is never appropriate despite any appearance of consent on the part of the patient.<sup>1</sup>

There are other examples of generational change. Previous calls to separate personal and professional identities online have been lately criticized as unnecessary or impossible.<sup>42</sup> Some modern physicians are not sticklers for being addressed as "Doctor" rather than by their first names. Guidelines can be expected to change

further along with technology and the larger culture. Yet however culture changes, principles of medical professionalism are still rooted in respectful recognition of boundaries.<sup>43</sup> The goal is to earn and retain the public's trust.

Some best practices in every circumstance include to:<sup>43</sup>

- Guard against excessive self-disclosure
- Maintain integrity, compassion, and respect for others
- Respect patient privacy and autonomy
- Maintain accountability to patients, society, and the profession
- Be sensitive to diverse populations
- Commit to ethical principles regarding care, confidentiality, informed consent, and business practices

Lines may become blurred when there is limited access to medical care, including in rural areas where physicians are well-known members of the community. Even so, well-established professional boundaries can help protect physician practices and preserve quality patient care. Suggestions for properly establishing the physician-patient relationship and precluding even the appearance of impropriety include:<sup>44</sup>

- Discouraging informal inquiries by insisting patients be seen in-office whenever possible
- Engaging in ongoing evaluation of objectivity in treating friends or family members
- Realizing when objectivity is compromised regarding any patient and referring immediately to another physician
- Redirecting patients who call outside of office hours to the on-call physician or to wait until morning, excepting emergencies
- Always charging for services
- Examining members of the opposite gender only with a staff person of same gender as the patient in the room
- Politely but firmly deflecting any behavior (e.g., hug or kiss on the cheek from a close friend) that may be regarded by staff or others as inappropriate conduct with a patient
- Referring intimate partners to another physician
- Refraining from intimate partnerships with staff members and patients

Communication skills include using social media professionally. Social media is now part of medical education, patient engagement, and quality improvement initiatives<sup>43</sup> and also provides professional opportunities, camaraderie with others in the medical field, and opportunities to disseminate beneficial public health messages. With these privileges come responsibilities and new challenges to the patient-physician relationship. Social media posts are public and can have immense longevity and reach as a result of being shared by others.<sup>43</sup>

### Case Study 3

**Instructions: Please read through the case study below and consider the questions that follow.**

A woman presented to a male family medicine physician for treatment of a spinal injury suffered in the workplace. A female chaperone was invited into the room by the physician and was present throughout the examination. The physician began by assessing the patient's pain level and history of injuries. The physician then handed the chaperone a closed laptop and asked her to record the information from the physical exam and history in the patient medical record. He then turned to the fully clothed patient and began an examination of her spine from top to bottom. He asked her to reach down and touch her toes and when she did so, he put his hand in her underwear and inserted an ungloved finger into her anus. He did not explain why this was a necessary medical procedure, nor did he obtain informed consent prior to performing this action. When she turned her head to assess the physician's intent, she found him smiling at her with his finger still inserted. Quickly, he told her she could straighten up then turned to the sink and washed his hands, explaining that he did not believe she had a fracture in her spine. The chaperone who had had difficulty accessing the patient record was now entering information into the laptop as previously instructed. The patient objected verbally to what had just occurred. The chaperone had not observed the behavior.

1. What actions might the chaperone take? \_\_\_\_\_

2. What training is necessary for chaperones to perform their duties, and what is a physician's responsibility? \_\_\_\_\_

Discussion: The chaperone is there to act as a witness and should stand in a location where the examination can be observed. A chaperone has the right to stop a sensitive procedure or examination if they suspect the physician's behavior is inappropriate. In this case, the chaperone did not witness the behavior directly or stop the exam. But the patient complaint of unacceptable behavior means the chaperone should immediately report this incident to the appropriate manager, who should ask the patient if she would like to file a complaint and/or criminal charges. It is a physician's responsibility to know what constitutes appropriate training of a chaperone and to ensure that the presence of a chaperone provides protection to the patient through observation and reporting. More uniform expectations and clear education in regard to chaperones adopted throughout the medical profession can help ensure that they provide more than the illusion of safety and that harmful (or criminal) behaviors do not go unnoticed.

Considerations all physicians should weigh when online include the following:<sup>45</sup>

- Maintain patient privacy and confidentiality, refraining from posting identifiable patient information
- Follow ethics guidance regarding confidentiality, privacy, and informed consent when posting for educational purposes or to exchange information professionally with other physicians
- Use privacy settings to safeguard personal information and content while realizing privacy settings are not absolute and content on the internet is likely permanent
- Routinely monitor own internet presence to ensure that personal and professional information and (to the extent possible) content posted about oneself by others is accurate and appropriate
- Maintain same appropriate boundaries of the patient-physician relationship as in any other context if interacting with patients
- Consider separating personal and professional content online
- Bring unprofessional content posted by any colleague to the attention of the individual; if behavior significantly violates professional norms and the individual does not take appropriate action to resolve the situation, report the matter to appropriate authorities
- Recognize that actions online and content posted may harm reputations, have consequences for medical careers (particularly for physicians-in-training and medical students), and can undermine public trust in the medical profession

#### Trauma-Informed Care

Individual trauma results from an event, series of events, or set of circumstances experienced as physically or emotionally harmful or life threatening and that has lasting adverse effects on the individual's functioning and mental, physical, social, emotional, or spiritual well-being.<sup>1,46</sup>

Trauma-informed programs, organizations, or systems:<sup>1,46</sup>

- Realize the widespread impact of trauma
- Understand potential paths for recovery
- Recognize signs and symptoms of trauma in clients, families, staff, and others
- Respond by fully integrating knowledge about trauma into policies, procedures, and practices
- Seeks to actively resist re-traumatization

Physicians should also be familiar with how trauma can affect investigations. With a patient-complainant who has experienced trauma, the emotions may not appear to match circumstances of the complaint, the report of the event may not be linear, and seemingly salient details may be unreported or unknown to the complainant.<sup>1</sup>

The Ohio Alliance to End Sexual Violence maintains an online resource (<https://oaesv.org/what-we-do/resources-for-providers/advocates/>) for providers and advocates to facilitate the survivor's recovery process, from immediately following the crime to decades later.

The page contains information on underserved victims of sexual assault, including the elderly, culturally-specific communities and limited English-proficient speakers, people who are deaf or hard of hearing, American Indian and Alaskan Native women, children and youth, individuals who identify as LGBTQ, immigrant women, male survivors, and people who live in rural populations and communities of color.

Other resources for physicians are shown in Table 4.<sup>1</sup> This is not a comprehensive list but gives some guidance on preventing sexual misconduct and maintaining professional boundaries, providing trauma-informed care, and understanding and addressing implicit bias.

#### Resources and Education for Patients

It is essential that patients know how to file complaints about their physicians to state medical boards. But roughly half of Americans do not know that medical boards are responsible for licensing and regulating physician practice in the United States.<sup>15</sup> Only 3 in 10 Americans say they know how to find out if their physician's medical license has received a disciplinary action.<sup>15</sup> Some mistakenly believe the best resource to contact is the physician's office or hospital, the AMA, or a lawyer.

It must be reemphasized that responsibility of ensuring competent, professional care lies with physicians.<sup>30</sup> However, patients are empowered by information, and it is appropriate to provide them with written education (for example, ACOG's "Your First Gynecologic Visit").<sup>38</sup>



**Table 4. Resources for Physicians<sup>1</sup>**

<b>On Sexual Misconduct and Maintaining Professional Boundaries:</b>	
<b>Source</b>	<b>Title with links</b>
American Medical Association: Code of Medical Ethics	<a href="#">Sexual and Romantic Boundary Violations</a> <a href="#">Duties to Report Unprofessional Conduct: Physician Wellness and Professional Conduct</a> <a href="#">Political Matters, Contributions, Gifts, and Social Media</a>
American Academy of Orthopaedic Surgeons	<a href="#">Sexual Misconduct in the Physician-Patient Relationship</a>
Federation of State Medical Boards	<a href="#">Directory of Physician Assessment and Remedial Education Programs</a>
North Carolina Medical Board	<a href="#">Guidelines for Avoiding Misunderstandings During Patient Encounters and Physical Examinations</a>
University of Vermont	<a href="#">Mandatory Reporters and CSAs</a> (Sample Reporting Guidelines)
Vanderbilt University Medical Center Online	<a href="#">CME Course: Hazardous Affairs – Maintaining Professional Boundaries</a>
Vanderbilt University Medical Center	<a href="#">Boundary Violations Index</a> (questionnaire) <a href="#">The Sexual Boundary Violation Index: A Validation Study</a>
<b>On Trauma-Centered Care:</b>	
<b>Source</b>	<b>Title</b>
Substance Abuse and Mental Health Services Administration	<a href="#">Concept of Trauma and Guidance for a Trauma-Informed Approach</a>
National Institute for the Clinical Application of Behavioral Medicine	<a href="#">How Trauma Impacts Four Different Types of Memory</a>
Frontiers in Psychiatry	<a href="#">Memory Distortion for Traumatic Events: the Role of Mental Imagery</a>
Government of Canada, Department of Justice	<a href="#">The Impact of Trauma on Adult Sexual Assault Victims</a>
National Institutes of Health Public Access	<a href="#">Trauma-Informed Medical Care: A CME Communication Training for Primary Care Providers</a>
Western Massachusetts Training Consortium	<a href="#">Trauma Survivors in Medical and Dental Settings</a>
American Academy of Pediatrics	<a href="#">Adverse Childhood Experiences and the Lifelong Consequences of Trauma</a>
American Academy of Pediatrics	<a href="#">Protecting Physician Wellness: Working With Children Affected by Traumatic Events</a>
Public Health Agency of Canada	<a href="#">Handbook on Sensitive Practice for Health Care Practitioners</a>
Psychiatric Times	<a href="#">CME: Treating Complex Trauma Survivors</a>
NHS Lanarkshire (Scotland)	<a href="#">Trauma and the Brain (Video)</a>
London Trauma Specialists	<a href="#">Brain Model of PTSD - Psychoeducation Video</a>
<b>On Implicit Bias:</b>	
Association of American Medical Colleges	<a href="#">Unconscious Bias Resources for Health Professionals</a>
Association for the Study of Medical Education	<a href="#">Non-conscious bias in medical decision making: what can be done to reduce it?</a>
American Public Health Association	<a href="#">Patient Race/Ethnicity and Quality of Patient-Physician Communication During Medical Visits</a>
Institute for Healthcare Improvement	<a href="#">Achieving Health Equity: A Guide for Health Care Organizations</a>
BMC Medical Education	<a href="#">Training to reduce LGBTQ-related bias among medical, nursing, and dental students and providers: a systematic review</a>
American Psychological Association	<a href="#">CE: How does implicit bias by physicians affect patients' health care?</a>
Joint Commission	<a href="#">Implicit bias in health care</a>
Oregon Medical Board	<a href="#">Cultural Competency – A Practical Guide for Medical Professionals</a>
StratisHealth	<a href="#">Implicit Bias in Health Care</a> (Quiz)
1. Federation of State Medical Boards (FSMB). Report and Recommendations of the FSMB Workgroup on Physician Sexual Misconduct. 2020; <a href="http://www.fsmb.org/siteassets/advocacy/policies/report-of-workgroup-on-sexual-misconduct-adopted-version.pdf">http://www.fsmb.org/siteassets/advocacy/policies/report-of-workgroup-on-sexual-misconduct-adopted-version.pdf</a> . Accessed November 10, 2021.	

Educational resources help patients learn what to expect during intimate examinations and procedures (e.g., use of chaperones) and to know what is and is not normal practice.<sup>39</sup>

Patients should be encouraged to do the following:<sup>6</sup>

- Report sexual assaults to police
- Ask physicians for an explanation if unsure of

the medical necessity to undress or another portion of an intimate exam

- Never allow children to be examined alone
- Request the presence of a nurse or other chaperone if a minor requires a conversation or exam without parent present
- Trust their instincts if something does not look or feel right to them

Informed consent is key to shared decision making. Patients should be informed at minimum of the reason for the treatment, a discussion and comparison of treatment options, and risks involved with treatments or procedures.<sup>1</sup> The informed consent process should also encompass the patient's values and preferences and a documented record of this shared decision.<sup>1</sup>

With exceptions for urgent, emergency, or same-day care, one should obtain patient consent well in advance with the understanding that patients are disadvantaged by the requirement to give quick decisions at the point of care.<sup>1</sup> If anesthesia (or the possibility of anesthesia) is involved, informed consent should include information about the effects, including the possibility of amnesia, with a view to preventing particular dangers of sexual misconduct in these patients.<sup>1</sup> If any photograph or video is to be taken, the patient must give consent that is then documented in the medical record.<sup>13</sup>

All informed consent materials should be written in common language that is easily accessible to the lay public. If consent cannot be obtained (due to anesthesia or any other reason), only medically-necessary intimate examinations should be performed and never for purely educational reasons.<sup>1</sup> Patients capable of making decisions have the right to refuse any examination or procedure.<sup>13</sup>

### How State Medical Boards/ Professional Associations Can Facilitate Patient Reporting of Sexual Misconduct<sup>1</sup>

- » Provide multiple channels (e.g., writing, phone, email, online form)
- » Clearly post process of state medical board websites
- » Ensure translation of complaint materials for complainants who do not speak English
- » Educate as to types of physician behaviors to expect
- » Educate as to types of physician behaviors that warrant complaint
- » Educate on what to do if made uncomfortable by physician's actions
- » Educate on what actions would warrant direct report to law enforcement
- » Ensure public anonymity of complainant (anonymity to board may not be possible)

### Conclusions

The overwhelming majority of physicians who provide compassionate, competent care within professional boundaries risk compromise to the reputation of their profession from the “bad apples” within their ranks. Sexual misconduct by a physician is an abuse of power and is grounds for investigation, sanction, and, when warranted, criminal prosecution. Because offenders often repeat their misconduct, many patients can be affected over years or even decades.

Sexual misconduct by physicians is properly and effectively addressed through standards and expectations of professionalism, preventive education, meaningful disciplinary action, law enforcement when required, traditional self-regulation, and the modern concept of shared regulation.<sup>1</sup>

Best practices during intimate examinations include routine use of chaperones, obtaining patient consent, using the minimum amount of physical contact to inform diagnosis and treatment, and maintaining open, informative, and respectful communication. All physicians have a duty to report observed or credible suspicion of sexual misconduct by colleagues and superiors. Effectively addressing physician sexual misconduct will require widespread cultural and systemic changes and medical education across the practice continuum.<sup>1</sup>

### References

1. Federation of State Medical Boards (FSMB). Report and Recommendations of the FSMB Workgroup on Physician Sexual Misconduct. 2020; <http://www.fsmb.org/siteassets/advocacy/policies/report-of-workgroup-on-sexual-misconduct-adopted-version.pdf>. Accessed November 10, 2021.
2. Lewis J, Allan S. Physician-Patient Boundaries: Professionalism Training Using Video Vignettes. MedEdPORTAL: the journal of teaching and learning resources. 2016;12:10412-10412.
3. American Medical Association. Code of Medical Ethics: Patient-physician relationships. <https://www.ama-assn.org/delivering-care/ethics/code-medical-ethics-patient-physician-relationships>. Accessed December 17, 2019.
4. Hlavinka E. When Docs Sexually Violate Patients. January 24, 2019; <https://www.medpagetoday.com/publichealthpolicy/ethics/77605>. Accessed November 16, 2021.
5. Hulsman RL, Ros WJ, Winnubst JA, Bensing JM. Teaching clinically experienced physicians communication skills. A review of evaluation studies. Med Educ. 1999;33(9):655-668.
6. DuBois JM, Walsh HA, Chibnall JT, et al. Sexual Violation of Patients by Physicians: A Mixed-Methods, Exploratory Analysis of 101 Cases. Sex Abuse. 2019;31(5):503-523.
7. National Academies of Sciences E, Medicine, Policy, et al. The National Academies Collection: Reports funded by National Institutes of Health. In: Benya FF, Widnall SE, Johnson PA, eds. Sexual Harassment of Women: Climate, Culture, and Consequences in Academic Sciences, Engineering, and Medicine. 10.17226/24994 Washington (DC): National Academies Press (US). Copyright 2018 by the National Academy of Sciences. All rights reserved.; 2018.
8. AbuDagga A, Carome M, Wolfe SM. Time to End Physician Sexual Abuse of Patients: Calling the U.S. Medical Community to Action. J Gen Intern Med. 2019;34(7):1330-1333.
9. Sansone RA, Sansone LA. Crossing the line: sexual boundary violations by physicians. Psychiatry (Edgmont (Pa : Township)). 2009;6(6):45-48.
10. Arora KS, Douglas S, Dorr Gould S. What Brings Physicians to Disciplinary Review? A Further Subcategorization. AJOB Empirical Bioethics. 2014;5(4):53-60.
11. Dehlendorf CE, Wolfe SM. Physicians disciplined for sex-related offenses. JAMA. 1998;279(23):1883-1888.
12. Doctors & Sex Abuse. Atlanta Journal-Constitution 2016; [https://doctors.ajc.com/table\\_of\\_contents/](https://doctors.ajc.com/table_of_contents/) November 29, 2021.
13. Sexual Misconduct: ACOG Committee Opinion, Number 796. Obstet Gynecol. 2020;135(1):e43-e50.
14. American Academy of Orthopaedic Surgeons (AAOS). Opinion on Ethics and Professionalism: Sexual Misconduct in the Physician-Patient Relationship. Opinion 1208. Revised December 2014.
15. Federation of State Medical Boards (FSMB). National Survey Indicates Majority of Physician Misconduct Goes Unreported. <https://www.fsmb.org/advocacy/news-releases/national-survey-indicates-majority-of-physician-misconduct-goes-unreported/>. Accessed December 8, 2021.
16. Teegardin C, Robbins D, Ernsthausen J, Hart A. Doctors & Sex Abuse: License to Betray. Atlanta Journal-Constitution 2016; [https://doctors.ajc.com/doctors\\_sex\\_abuse/?ecmp=doctorssexabuse\\_microsite\\_nav](https://doctors.ajc.com/doctors_sex_abuse/?ecmp=doctorssexabuse_microsite_nav). Accessed November 29, 2021.
17. Carr GD. Professional sexual misconduct--an overview. J Miss State Med Assoc. 2003;44(9):283-300.
18. American Medical Association (AMA). Patient Rights: Code of Medical Ethics Opinion 1.1.3. <https://www.ama-assn.org/delivering-care/ethics/patient-rights>. Accessed December 7, 2021.
19. Morton CH, Henley MH, Seacrist M, Roth LM. Bearing witness: United States and Canadian maternity support workers' observations of disrespectful care in childbirth. Birth. 2018;45(3):263-274.
20. Enbom JA, Parsley P, Kollath J. A follow-up evaluation of sexual misconduct complaints: the Oregon Board of Medical Examiners, 1998 through 2002. Am J Obstet Gynecol. 2004;190(6):1642-1650; discussion 1650-1643, 1646A.
21. Brooks E, Gendel MH, Early SR, Gundersen DC, Shore JH. Physician boundary violations in a physician's health program: a 19-year review. J Am Acad Psychiatry Law. 2012;40(1):59-66.
22. Enbom JA, Thomas CD. Evaluation of sexual misconduct complaints: the Oregon Board of Medical Examiners, 1991 to 1995. Am J Obstet Gynecol. 1997;176(6):1340-1346; discussion 1346-1348.

23. d'Oronzio JC. Professional codes, public regulations, and the rebuilding of judgment following physicians' boundary violations. AMA J Ethics. 2015;17(5):448-455.
24. American Medical Association (AMA). Sexual Harassment in the Practice of Medicine: Code of Medical Ethics Opinion 9.1.3. <https://www.ama-assn.org/delivering-care/ethics/sexual-harassment-practice-medicine>. Accessed November 15, 2021.
25. Glass LL. Where the rubber meets the road: the challenge of reporting colleagues' boundary violations. AMA J Ethics. 2015;17(5):435-440.
26. Doctor Learns Why Not to Date a Patient. Posted under Risk Management on the NCMIC website. June 25, 2019; <https://www.ncmic.com/insurance/malpractice/risk-management/case-study-doctor-learns-why-not-to-date-a-patient/>. Accessed December 7, 2021.
27. American Psychiatric Association. The Principles of Medical Ethics with Annotations Especially Applicable to the Practice of Psychiatry. Arlington, VA: American Psychiatric Association; 2013:4.
28. AMA Code of Medical Ethics' Opinions on Observing Professional Boundaries and Meeting Professional Responsibilities. AMA J Ethics. 2015;17(5):432-434. doi: 10.1001/journalofethics.2015.17.5.coet1-1505.
29. Federation of State Medical Boards (FSMB). About Physician Discipline: How State Medical Boards Regulate Physicians after Licensing. <https://www.fsmb.org/us-medical-regulatory-trends-and-actions/guide-to-medical-regulation-in-the-united-states/about-physician-discipline/>. Accessed December 13, 2021.
30. Federation of State Physician Health Program Statement on Sexual Misconduct in the Medical Profession. May 2019; <https://www.fsphp.org/position-statements>. Accessed December 2, 2021.
31. Guthell TG, Gabbard GO. The concept of boundaries in clinical practice: theoretical and risk-management dimensions. Am J Psychiatry. 1993;150(2):188-196.
32. Vigilanti EM, Oliverio AL, Meeks LM. Sexual harassment and abuse: when the patient is the perpetrator. Lancet. 2018;392(10145):368-370.
33. American Medical Association (AMA). Reporting Incompetent or Unethical Behaviors by Colleagues: Code of Medical Ethics Opinion 9.4.2. <https://www.ama-assn.org/delivering-care/ethics/reporting-incompetent-or-unethical-behaviors-colleagues>. Accessed November 15, 2021.
34. Federation of State Medical Boards (FSMB). Position Statement on Duty to Report. 2016; <https://www.fsmb.org/siteassets/advocacy/policies/position-statement-on-duty-to-report.pdf>. Accessed November 30, 2021.
35. American Medical Association (AMA). The top 10 ethical issues medical students should be taught. February 14, 2020; <https://www.ama-assn.org/education/accelerating-change-medical-education/top-10-ethical-issues-medical-students-should-be>. Accessed November 15, 2021.
36. Caldicott CV, d'Oronzio JC. Ethics Remediation, Rehabilitation, and Commitment to Medical Professionalism: A Programmatic Approach. Ethics & Behavior. 2015;25(4):279-296.
37. Campbell EG, Regan S, Gruen RL, et al. Professionalism in medicine: results of a national survey of physicians. Ann Intern Med. 2007;147(11):795-802.
38. DuBois JM, Anderson EE, Chibnall JT, et al. Preventing Egregious Ethical Violations in Medical Practice: Evidence-Informed Recommendations from a Multidisciplinary Working Group. J Med Regul. 2018;104(4):23-31.
39. Protecting children from sexual abuse by health care providers. Pediatrics. 2011;128(2):407-426.
40. OSHA Education Center. The Complete Guide to Whistleblower Labor Laws. <https://www.oshaeducationcenter.com/articles/whistleblower-laws/>. Accessed December 14, 2021.
41. American Medical Association (AMA). Use of Chaperones: Code of Medical Ethics Opinion 1.2.4. <https://www.ama-assn.org/delivering-care/ethics/use-chaperones>. Accessed November 19, 2021.
42. Federation of State Medical Boards (FSMB). Social Media and Electronic Communications. 2019; <https://www.fsmb.org/siteassets/advocacy/policies/social-media-and-electronic-communications.pdf>. Accessed December 1, 2021.
43. Kind T. Professional guidelines for social media use: a starting point. AMA J Ethics. 2015;17(5):441-447.
44. Tettlebaum H, Meyers K. Part II--Sexual misconduct by professionals. Safeguarding yourself and your practice against allegations of sexual abuse or patient impropriety. Mo Med. 2012;109(3):187-188.
45. American Medical Association (AMA). Professionalism in the Use of Social Media: Code of Medical Ethics Opinion 2.3.2. <https://www.ama-assn.org/delivering-care/ethics/professionalism-use-social-media>. Accessed December 1, 2021.
46. Substance Abuse and Mental Health Services Administration. SAMHSA's Concept of Trauma and Guidance for a Trauma-Informed Approach. HHS Publication No. (SMA) 14-4884. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014.

# GUIDANCE ON PROFESSIONAL BOUNDARIES AND SEXUAL MISCONDUCT

## Self-Assessment

Choose the best possible answer for each question and mark your answers on the self-assessment answer sheet at the end of this book. There is a required score of 70% or better to receive a certificate of completion.

- 11. Percentage of people believed to report sexual misconduct by medical practitioners:**
  - A. Approximately 50%.
  - B. Approximately 15%.
  - C. Approximately 10%.
  - D. Approximately 5%.
- 12. Ways to increase reporting of incidents of physician sexual misconduct in the workplace include:**
  - A. Ensuring reports can be filed anonymously and free from fear of retaliation.
  - B. Expecting some frivolous claims of misconduct as a “cost of doing business”.
  - C. Protecting the anonymity of the institution involved from media representatives.
  - D. Requiring at least two reports of misconduct by colleagues of the physician.
- 13. During intimate examinations, the physician is advised to:**
  - A. Communicate with patients by clearly explaining each part of the exam.
  - B. Minimize privacy concerns by seeing the patient alone.
  - C. Instruct chaperones to document each physician action in the medical record.
  - D. Put the patient at ease by using distraction methods common to trauma-informed care.
- 14. To run a professional practice with appropriate patient boundaries, a physician-leader:**
  - A. Requires medical staff to report sexual misconduct to an immediate supervisor ahead of any outside agency.
  - B. Assumes patients with symptoms of post-traumatic stress disorder have experienced sexual trauma.
  - C. Strictly prohibits sexual harassment in the workplace.
  - D. Trains all medical staff to act as chaperones during intimate exams.
- 15. A trained chaperone is not necessary during a patient exam when:**
  - A. The physician and patient are the same gender.
  - B. The physician-patient relationship is established.
  - C. The patient has signed a release.
  - D. The patient refuses a chaperone.
- 16. Which of the following is an example of a physician sexual impropriety that does not rise to the level of a sexual violation, according to criteria of the Federation of State Medical Boards (FSMB)?**
  - A. Inserting a gloved finger into the anus during an intimate examination.
  - B. Asking a patient to meet for coffee outside of clinic hours to discuss medical care.
  - C. Commenting on the attractiveness of a patient’s breasts.
  - D. Kissing the patient on the mouth.
- 17. Which of the following is an example of a sexual violation that rises beyond the level of sexual impropriety?**
  - A. Rubbing an erect penis against the patient’s leg.
  - B. Inviting a medical student to watch an intimate examination without the patient’s consent.
  - C. Stopping the patient from leaving by placing both hands on the patient’s shoulders.
  - D. Reciprocating a hug initiated by the patient.
- 18. Which of the following statements is true of the lasting effects of trauma?**
  - A. Adults inevitably reenact the types of trauma learned in the childhood home.
  - B. A person who experienced trauma may exhibit emotions that do not appear to match the trauma.
  - C. Children rarely show effects of trauma until years after the traumatizing event.
  - D. A person who has experienced trauma can usually recall the exact time of a traumatizing event.
- 19. Accepting a brief hug from a patient who is expressing appreciation for medical care is:**
  - A. A cause for remediation.
  - B. An action for which a written report to a superior is advised.
  - C. An action that, if observed, might bring a warning letter from a state medical board.
  - D. An example of a boundary crossing that may offer therapeutic value in some circumstances.
- 20. Which of the following constitutes a reason a medical board might take disciplinary action?**
  - A. Failure to report observed sexual misconduct by a colleague.
  - B. Pattern of asking patients to coffee outside of clinic hours.
  - C. Rural physician who examines family friends, including for intimate exams as medically indicated.
  - D. A comment to a patient that could be judged as excessive self-disclosure.

# LEARNER RECORDS: SAMPLE

**InforMed**

PO Box 2595 | Ormond Beach, FL 32175

**2023 Utah Medical Licensure Program**

Learner Records: Answer Sheet and Payment Information

**To Receive Credit:** Please ensure information entered matches the information on file with the Utah Department of Commerce, Division of Occupational and Professional Licensing. Please write legibly, failure to accurately provide this information may result in your data being non-reportable. Using the spaces provided below, please PRINT the information below in CAPITAL LETTERS. Upon completion, please place this sheet in the envelope provided and mail to the address above. If paying by check or money order, please make payable to InforMed. For even faster service, we offer this test online with instant grading and certificate issuance online at **BOOK.CME.EDU**

Please PRINT NEATLY in the areas below using black or blue pen only:

First Name

MI.

Last Name

J	O	H	N							F	D	O	E												
---	---	---	---	--	--	--	--	--	--	---	---	---	---	--	--	--	--	--	--	--	--	--	--	--	--

Mailing Address

1	2	3		C	H	E	R	R	Y		S	T	R	E	E	T									
---	---	---	--	---	---	---	---	---	---	--	---	---	---	---	---	---	--	--	--	--	--	--	--	--	--

Suite / Floor / Apt. Number

City (do not abbreviate)

State

4	5	6								S	A	L	T		L	A	K	E		C	I	T	Y			U	T
---	---	---	--	--	--	--	--	--	--	---	---	---	---	--	---	---	---	---	--	---	---	---	---	--	--	---	---

Zip Code

Telephone Number

Utah Medical License #

8	4	1	1	1	8	0	1	-	4	5	6	-	7	8	9	0	1	0	1	5	5	9	2	-	8	9	0	5
---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---

E-mail address (Include to receive processing confirmation and instant certificate access)

J	O	H	N	D	O	E	@	E	M	A	I	L	.	C	O	M												
---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	--	--	--	--	--	--	--	--	--	--	--	--

Required Information for MOC Reporting (if desired)

Specialty Board

ID Number

License Type

Date of Birth (mm/dd/yyyy)

A	B	I	M					1	2	3	4	5	6					M	D			1	2	/	2	0	/	1	9	8	0
---	---	---	---	--	--	--	--	---	---	---	---	---	---	--	--	--	--	---	---	--	--	---	---	---	---	---	---	---	---	---	---

(ABA, ABIM, ABO, ABOHNS, ABPath, ABP)

(MD, DO, PA, etc.)

ALL UTAH LICENSES are made up of 6 or 7 numbers followed by a hyphen and a four (4) digit extension.

MDs	DOs	PAs	Dentists
- 8 9 0 5	- 8 9 0 4	- 8 9 0 6	- 8 9 0 3
Optometrists	Podiatrists	Ex: 101592-8905	
- 8 9 0 8	- 8 9 0 7		

**DATA REPORTING:** Federal, State, and Regulatory Agencies require disclosure of data reporting to all course participants. InforMed abides by each entity's requirements for data reporting to attest compliance on your behalf. Reported data is governed by each entity's confidentiality policy. To report compliance on your behalf, it's mandatory that you must achieve a passing score and accurately fill out the learner information, activity and program evaluation, and the 90-day follow up survey. Failure to accurately provide this information may result in your data being non-reportable and subject to actions by these entities.

**To Receive Credit:** Please ensure information entered matches the information on file with the Utah Department of Commerce, Division of Occupational and Professional Licensing. Please write legibly, failure to accurately provide this information may result in your data being non-reportable. Using the spaces provided below, please PRINT the information below in CAPITAL LETTERS. Upon completion, please place this sheet in the envelope provided and mail to the address above. If paying by check or money order, please make payable to InforMed. For even faster service, we offer this test online with instant grading and certificate issuance online at **BOOK.CME.EDU**

Please PRINT NEATLY in the areas below using black or blue pen only:

First Name

MI.

Last Name

Grid for First Name, MI., and Last Name

Mailing Address

Grid for Mailing Address

Suite / Floor / Apt. Number

City (do not abbreviate)

State

Grid for Suite/Floor/Apt. Number, City, and State

Zip Code

Telephone Number

Utah Medical License #

Grid for Zip Code, Telephone Number, and Utah Medical License #

E-mail address (Include to receive processing confirmation and instant certificate access)

Grid for E-mail address

**Required Information for MOC Reporting (if desired)**

Specialty Board

ID Number

License Type

Date of Birth (mm/dd/yyyy)

Grid for Specialty Board, ID Number, License Type, and Date of Birth

(ABA, ABIM, ABO, ABOHNS, ABPath, ABP)

(MD, DO, PA, etc.)

**Payment Method**

- Check / M.O. Enclosed
Entire Program \$55.00
Course 1 \$50.00
Credit Card

Visa / Mastercard / AMEX / Discover Number

Credit Card Expiration Date

Security Code

Grid for Payment Method, Card Number, Expiration Date, and Security Code

Cardholder Signature:

Shade circles like this: ● Final exam questions are located at the end of each chapter.

Effective Management of Acute and Chronic Pain with Opioid Analgesics

Guidance on Professionals Boundaries and Sexual Misconduct

Multiple choice options A, B, C, D for questions 1-10

Multiple choice options A, B, C, D for questions 11-20

For Internal Use Only - Do Not Mark In This Area

# LEARNER RECORDS: EVALUATION

You must complete the program evaluation and applicable activity evaluation(s) in order to earn *AMA PRA Category 1 Credits™*, MOC points, or participation in MIPS. For each of the objectives determine if the activity increased your:

**A Competence    B Performance    C Outcome    D No Change**

## COURSE 1 - EFFECTIVE MANAGEMENT OF ACUTE AND CHRONIC PAIN WITH OPIOID ANALGESICS:

- |  | A                     | B                     | C                     | D                     |
|--|-----------------------|-----------------------|-----------------------|-----------------------|
| 1. Assess non-pharmacological, non-opioid, and opioid analgesic therapies in comprehensive pain plans for patients with acute or chronic pain. . . . .     | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| 2. Identify and manage patients with opioid use disorder and recognize when to incorporate emergency opioid antagonists into prescribing practice. . . . . | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| 3. Please identify a specific change, if any, you will make in your practice related to safe prescribing of opioid analgesics.<br>_____<br>_____           |                       |                       |                       |                       |
| 4. What do you see as a barrier to making these changes?<br>_____<br>_____   |                       |                       |                       |                       |

## COURSE 2 - GUIDANCE ON PROFESSIONAL BOUNDARIES AND SEXUAL MISCONDUCT:

- |  | A                     | B                     | C                     | D                     |
|--|-----------------------|-----------------------|-----------------------|-----------------------|
| 5. Utilize best practices during intimate examinations, including use of chaperones and respectful communication with patient. . . . .                   | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| 6. Recognize and report suspected sexual misconduct or assault . . . . .   | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| 7. Please identify a specific change, if any, you will make in your practice related to professional boundaries and sexual misconduct.<br>_____<br>_____ |                       |                       |                       |                       |
| 8. What do you see as a barrier to making these changes?<br>_____<br>_____   |                       |                       |                       |                       |

## OVERALL PROGRAM:

- |  | Yes                   | No                    | If no, please explain: |
|--|-----------------------|-----------------------|------------------------|
| 9. The program was balanced, objective & scientifically valid . . . . .  | <input type="radio"/> | <input type="radio"/> | _____                  |
| 10. Do you feel the program was scientifically sound & free of commercial bias or influence? . . . . .   | <input type="radio"/> | <input type="radio"/> | _____                  |
| 11. How can this program be improved? _____<br>_____   |                       |                       |                        |
| 12. Based on your educational needs, please provide us with suggestions for future program topics & formats. _____<br>_____  |                       |                       |                        |
| 13. For which activities would you like to use your participation as a clinical practice improvement activity (CPIA) for MIPS?<br><input type="radio"/> Course 1 <input type="radio"/> Course 2 <input type="radio"/> None |                       |                       |                        |

# InforMed has joined the Elite Learning family

Two of the nation's top healthcare education providers have joined forces with one goal in mind: to offer physicians a state-of-the-art learning experience that fulfills your state requirements and empowers you with the knowledge you need to provide the best patient care.

Here's what you can expect from our new partnership:

- **COURSES:** In addition to the mandatory courses you need to renew your state license, you'll now have access to dozens of hours of elective courses and an expanded content library.
- **ACCOUNTS:** You'll also have access to a personalized learner account. In your account you can add, organize, and track your ongoing and completed courses. For instructions on how to set up your account, email us at [office@elitelearning.com](mailto:office@elitelearning.com).
- **BOOK CODES:** You may notice a book code on the back cover of the latest InforMed program you've received in the mail. When entered on our new site, this code will take you directly to the corresponding self-assessment. See more information below.



## How to complete


Please read these instructions before proceeding.

Read and study the enclosed courses and answer the self-assessment questions. To receive credit for your courses, you must provide your customer information and complete the mandatory evaluation. We offer three ways for you to complete. Choose an option below to receive credit and your certificate of completion.

### Fastest way to receive your certificate of completion

#### Online

- Go to **BOOK.CME.EDU**. Locate the book code **UT23CME** found on the back of your book and enter it in the box then click **GO**. If you would like to choose a different program option, use the table below and enter the corresponding code in the box.
- If you already have an account created, sign in to your account with your username and password. If you do not have an account already created, you will need to create one now.
- Follow the online instructions to complete your self-assessment. Complete the purchase process to receive course credit and your certificate of completion. Please remember to complete the online evaluation.



Program Options	Code	Credits	Price
Entire Program	UT23CME	5.5	\$55.00
Course 1	UT23CME-50	3.5	\$50.00

#### By mail

- Fill out the answer sheet and evaluation found in the back of this booklet. Please include a check or credit card information and e-mail address. Mail to **InforMed, PO Box 2595, Ormond Beach, FL 32175-2595**.
- Completions will be processed within 2 business days from the date it is received and certificates will be e-mailed to the address provided.
- Submissions without a valid e-mail will be mailed to the address provided.

#### By fax

- Fill out the answer sheet and evaluation found in the back of this booklet. Please include credit card information and e-mail address. Fax to **1-800-647-1356**.
- All completions will be processed within 2 business days of receipt and certificates will be e-mailed to the address provided.
- Submissions without a valid e-mail will be mailed to the address provided.

## 2023 Utah Medical Licensure Program

- **3.5 Hours**  
Approved Controlled  
Substance Course\*



**\*Mandatory CME Requirement Met by  
Approved Course Only: 3.5 Credit Hours on  
Controlled Substances for all Prescribers**

CME FOR: *AMA PRA CATEGORY 1 CREDITS™* MIPS MOC STATE LICENSURE

**UT.CME.EDU**



InforMed is Accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.